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Human Papillomavirus 16 (HPV16) is a double-stranded DNA virus known as a causative 
agent in almost all cervical cancers and an increasing number of oropharyngeal cancers. 
Variants of HPV16, such as the Asian-American (AA) and L83V, have been found to have 
increased abilities to promote carcinogenesis. Even though previous interactome studies 
identified which proteins interact with HPV16 E6, few have looked at interactions between 
variants of E6 in particular AAE6 and the European Prototype (EPE6). This thesis had two 
objectives: develop a method to co-immunoprecipitate host cellular proteins that interact 
with E6 variants; and identify potential differences between cellular host proteins and 
variant E6. We were successful in developing a method that not only could pull-down and 
identify E6 variant interacting proteins but the E6 variant proteins themselves. Using liquid 
chromatography-mass spectrometry (LC MS/MS), we identified 13 proteins that interact 
with both AAE6 and EPE6, along with six unique AAE6 interacting proteins and six unique 
EPE6 interacting proteins. Of the interactors we found, seven were of particular interest: 
TRIP12, GNL2, INO80B, CHMP4B, MX2, RPSK6K4A, and PROK2. These proteins 
affect a variety of cellular functions, including DNA replication and repair, telomere 
maintenance, cellular proliferation, ERK1/2 signaling, signal transduction, and immune 
response. Identification of different proteins using different bioinformatic analyses further 
provide evidence that AAE6 and EPE6 may have unique interactions with their host cells 
resulting in varied abilities to promote carcinogenesis. The identification of these proteins 
has furthered our understanding of potential mechanisms that allow AAE6 to promote 
carcinogenesis more than EPE6. More wet lab work is still required to confirm these 
interactions and determine their exact effects on the host cell.  
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Lay Summary 
Faculty and students in the Department of Biology are bound together by a common 
interest in explaining the diversity of life, the fit between form and function, and the 
distribution and abundance of organisms. Human papillomavirus 16 (HPV16) is a common 
virus that researchers have found to be the cause of almost all cervical cancers as well as 
the majority of head and neck cancers in both men and women. This thesis looks explicitly 
at two variants of the E6 protein in HPV16: the Asian-American (AA) and European 
Prototype (EP). Previous research conducted within our lab, along with other groups, found 
that AAE6 causes more invasive cancers compared to EPE6. This thesis aimed to develop 
a method to identify proteins that interact with E6 variants. This thesis also aimed to 
identify whether there is a difference in proteins that interact between AAE6 and EPE6 
such that it would uncover new and novel understandings for why AAE6 can better cause 
cancer. The information uncovered by this study can help improve our understanding of 









The most important individual throughout this entire journey has been my 
supervisor and mentor, Dr. Ingeborg Zehbe. You have spent countless hours with me, 
assisting me, and pushing me to become the best version of myself. You have helped me 
understand how to be humble and never give up when the going gets tough. I am always 
amazed by how you help me look at research with an open mind and helped me realize that 
there is a multitude of ways to approach a single task or problem. You have given me so 
many opportunities to connect and collaborate with researchers throughout Canada and the 
United States. For that, I am eternally grateful.  
To Dr. Guillem Dayer, my co-supervisor! You have spent countless hours helping 
me be successful. The countless laughs we had every day I have no words that can describe 
how thankful I am for all that you have done for me. When things became challenging you 
helped me to continue pushing forward. Not only were you a fantastic mentor and fellow 
scientist, but you are a fantastic life-long friend as well.
 To my committee members Dr. Heidi Schraft and Dr. Simon Lees, thank you for 
the time you have taken out of your busy lives to help guide me throughout this journey. I 
also would like to thank Dr. Michael Campbell, my external reviewer, for taking the time 
to evaluate my thesis. 
Dr. James Knockleby and Dr. Hoyun Lee from the Health Sciences North Research 
Institute, I cannot thank you enough for making me feel at home during my time in 
Sudbury, Ontario. Dr. Hoyun Lee, thank you once again for your hospitality and 
outstanding kindness. Dr. Knockleby, thank you for spending dozens of hours with me, 
 2 
from late nights to early mornings with the mass spectrometer! Dr. Melissa Togtema, Dr. 
Robert Jackson, I cannot thank you two enough for all of your support. From getting me 
settled in the lab and supporting me. You both taught me so many skills and spent so many 
hours reviewing my work and helping me improve every day. I hope you both know that I 
always remember the moments where you helped me. From learning how to culture cells 
to designing figures and reviewing my experiment designs. You both are brilliant and 
excellent scholars! I would also like to thank my fellow lab members and friends, Meagan, 
and Yuri. For amazing memories and helping me throughout my early days at the Thunder 
Bay Regional Health Research Institute. 
Personal 
I am so grateful to have my mother (Lucja) and father (Shoaa) in my life. You keep 
me striving to be the best I can be every day. Matthew, I don’t know how you haven’t 
gotten tired of me talking about my thesis, but I’m glad you are there to listen and 
encourage me. Adrian, I appreciate every time you check up on me to see how things are 
going. I don’t always express that I am thankful, but please know every day I knew you 
were making sure I was making progress. 
 
 1 
Table of Contents 
Abstract .............................................................................................................................................. ii 
Lay Summary .................................................................................................................................. iii 
Dedication ......................................................................................................................................... iv 
Acknowledgements .......................................................................................................................... v 
Table of Contents ............................................................................................................................. 1 
Table of Figures ............................................................................................................................... 4 
Table of Tables ................................................................................................................................. 5 
1 Introduction ............................................................................................................................. 6 
1.1 Historical Overview of Human Papillomavirus ............................................................ 6 
1.2 HPV16 Genome and Functions of Early Genes ............................................................ 8 
1.3 E6 Oncoprotein ...................................................................................................................... 9 
1.4 HPV16 E6 Variants ............................................................................................................. 11 
1.5 Current Discoveries of HPV16 E6 Variant Studies ................................................... 13 
1.6 Protein-Protein Interaction Methodology .................................................................... 16 
1.7 Bioinformatic Interactome Analysis Software ............................................................. 27 
1.8 Rationale ................................................................................................................................ 28 
2 Materials and Methods ....................................................................................................... 30 
2.1 Cell Lines ............................................................................................................................... 30 
2.2 Cell Culture ........................................................................................................................... 31 
2.3 Contamination Tests ........................................................................................................... 33 
2.4 PCR .......................................................................................................................................... 33 
2.5 Cell Lysis ................................................................................................................................ 37 
2.6 Bradford Assay ..................................................................................................................... 38 
 2 
2.7 Western Blotting ................................................................................................................... 40 
2.8 MS1 Protocol ........................................................................................................................ 42 
2.8.1 Cell culture ........................................................................................................................ 42 
2.8.2 Cell Lysis ........................................................................................................................... 43 
2.8.3 Co-IP ................................................................................................................................... 44 
2.8.4 2-D electrophoresis ......................................................................................................... 45 
2.8.5 1-D SDS-PAGE Electrophoresis ................................................................................ 47 
2.8.6 MALDI MS ...................................................................................................................... 48 
2.9 LC MS/MS .............................................................................................................................. 50 
2.9.1 Cell Culture ....................................................................................................................... 50 
2.9.3 Cell Lysis ........................................................................................................................... 51 
2.9.4 Co-IP ................................................................................................................................... 51 
2.9.5 LC MS/MS by Harvard Mass Spectrometry and Proteomics Facility 
(HMSPF) .......................................................................................................................................... 53 
2.10 Identification of Proteins for MALDI MS/MS ............................................................. 54 
2.10.1 MALDI MS/MS proteins using Peptide Mass Fingerprinting ........................... 54 
2.10.2 Filtering of protein and peptide results from Mascot ........................................... 54 
2.10.3 Biological process of unique proteins in Panther DB ........................................... 55 
2.10.4 Reactome Pathway Analysis ........................................................................................ 55 
2.11 Protein Filtering for LC MS/MS .......................................................................................... 57 
2.11.1 Protein Filtering “Peptide Method” ............................................................................ 58 
2.11.2 Protein Filtering “Protein-Pathway Method” .......................................................... 58 
2.11.3 Bioinformatic analysis of filtered proteins ................................................................ 59 
 3 
3 Results ...................................................................................................................................... 61 
3.1 MALDI MS/MS at HSNRI .................................................................................................. 61 
3.1.1 2-D Electrophoresis ........................................................................................................ 61 
3.1.2 Presence of Protein of Interest ..................................................................................... 62 
3.1.3 Identified Proteins ........................................................................................................... 63 
3.2 Optimization of Co-IP for LC MS/MS trials ................................................................ 64 
3.2.1 Lysis of Mammalian PHFK ......................................................................................... 64 
3.2.2 Antibody Selection for Western Blotting/Co-IP .................................................... 66 
3.2.3 Incubation and Wash of Input Protein ...................................................................... 67 
3.2.4 Elution of Protein ............................................................................................................ 69 
3.2.5 Stability of Protein Within Elution Buffer ............................................................... 71 
3.2.6 Quality Control of IP Methodology ........................................................................... 73 
3.2.7 Effect of Proteasome Inhibitor MG132 on HPV16 E6 ........................................ 74 
3.2.8 Increasing Quantity of Protein Input ......................................................................... 75 
3.3 LC MS/MS ..................................................................................................................................... 76 
3.3.1 Detection of HPV16E6 and Known Interacting Proteins .................................... 76 
3.3.2 Identification of Significant Proteins ......................................................................... 77 
4 Discussion ................................................................................................................................ 98 
5 References ............................................................................................................................. 102 




Table of Figures 
Figure 1 – Schematic representation of the circular HPV16 genome developed using the 
Pathogen Host Analysis Tool (PHAT) (Gibb et al. 2019). ......................................... 9 
Figure 2  – To scale depiction of HPV16 E6 SNPs between AAE6 and EPE6. ............... 15 
Figure 3 – Near-diploid immortalized keratinocytes (NIKS) grown on top of a dermal 
equivalent .................................................................................................................. 16 
Figure 4 – Phase contrast images of AAE6 and EPE6 late passage samples and non-
transduced PHFK cell samples (PHFK and PHFK-HA). ......................................... 31 
Figure 5 – Fluorescence microscopy image of E6 variant nuclei stained with 4’,6-
diamidino-2-phenylindole (DAPI). ........................................................................... 35 
Figure 6 – Overview of main steps in MS1 protocol. ....................................................... 49 
Figure 7 – Overview of main steps in MS2 protocol. ....................................................... 54 
Figure 8 – Screenshot of the Mascot Peptide Mass Fingerprint input screen. .................. 56 
Figure 9 – Equation used to filter repeated proteins from unique proteins ...................... 57 
Figure 10 – Summary of both Peptide (yellow) and Protein-Pathway (blue) filtering 
methods for LC MS/MS Trials. ................................................................................ 59 
Figure 11 – Western blot of PHFK, PHFK HA, AA and EP for three biological replicates
................................................................................................................................... 62 
Figure 12 – DAPI stained nuclei of PHFK cells transduced with the L83V HPV16 E6 
oncogene ................................................................................................................... 65 
Figure 13 –Western blot of L83V transduced PHFK’s lysed with Tris-HCl lysis buffer 
[pH 7.5] (Column 1), MPER with 150 mM NaCl (Column 2), and MPER (Column 
3). .............................................................................................................................. 66 
Figure 14 – Comparison between incubating 600 µg of lysed PHFK’s transduced with 
L83V input protein on 25 µg of anti-HA magnetic beads for 30 minutes or 
overnight. .................................................................................................................. 68 
Figure 15 – Elution comparison between HEPES buffer and SDS elution ...................... 71 
Figure 16 – Stability of protein eluted using 0.2 M glycine [pH 2.5] from Co-IP’d L83V 
cellular proteins.. ....................................................................................................... 72 
Figure 17 – Confirming the selective pull-down ability of the Co-IP .............................. 73 
Figure 18 – Comparison of co-immunoprecipitated L83V and PHFK proteins treated for 
4 hours with either 30 µM MG132 proteasome inhibitor or DMSO ........................ 74 
















Table of Tables 
 
Table 1 – Reported cellular targets of the human papillomavirus type 16 E6 protein (1991 
to 2018) ..................................................................................................................... 22 
Table 2 – Procedure for Touchdown PCR for the identification of SNPs for all HPV16 E6 
variants. ..................................................................................................................... 36 
Table 3 – Steps used during IEF of eluted samples. ......................................................... 46 
Table 4 – Heat map of Peptide Method depicting potential candidates for AAE6-targeted 
proteins (greater than three peptides) ........................................................................ 78 
Table 5  – Heat map of Peptide Method depicting potential candidates for EPE6-targeted 
proteins (greater than three peptides). ....................................................................... 78 
Table 6 – Heat map of Protein-Pathway Method showing AAE6-targeted proteins unique 
to PHFK-HA. ............................................................................................................ 86 
Table 7 – Heat map Protein-Pathway Method showing EPE6-targeted proteins unique to 
PHFK-HA proteins/pathways ................................................................................... 87 
Table 8 – Proteins targeted by both AAE6 and EPE6 identified using the Protein-Pathway 
method. ...................................................................................................................... 87 
Table 9 – Most significant pathways found in AAE6 targeted proteins using Reactome. 91 




1.1 Historical Overview of Human Papillomavirus 
Since the late seventies, human papillomavirus (HPV) is known to be responsible 
for almost all (99.7 %) worldwide cases of cervical cancer (Walboomers et al. 1999; zur 
Hausen 1977). Recently, approximately 1 350 women in Canada and 569 800 women 
across the globe were diagnosed with cervical cancer, making it the fourth most common 
female cancer worldwide (Smith et al. 2019; Ferlay et al. 2019). Primarily, HPV affects 
intraepithelial cells of the cervix and other squamous cells within the ano-genital region of 
males and females causing a substantial number of cervical and ano-genital lesions. 
However, HPV also has the potential to infect squamous cells of the pharynx in both males 
and females causing oropharyngeal squamous cell carcinomas (OPSCCs) (Burk et al. 2003; 
Chaturvedi et al. 2011; Wakeham et al. 2014). From 1989 to 2004, worldwide HPV 
prevalence in OPSCCs increased drastically from 16 % to over 70 %. In Canada alone, the 
annual incidence of HPV related OPSCCs has risen on average by 3.4 % and 1.1 % per 
year for males and females respectively (Nuttall et al. 2016). Researchers believed that the 
number of HPV positive OPSCC’s would outnumber HPV positive cervical cancers by 
2020 (Chaturvedi et al. 2011). In 2019 their hypotheses were confirmed when the number 
of HPV positive OPSCC’s in the United States (n=13 300) was greater than the number of 
HPV positive cervical cancers (n=10 933) (OPSCC incidence (n=19 000) and 70.1% HPV 
positive incidence of OPSCC’s obtained from the United States Cancer Statistics and 
Saraiya et al. 2016). 
As of 2019, researchers have annotated 225 HPV types while, over 240 are awaiting 
classification as oncogenic “high-risk” (HR) and “low-risk” (LR), making this virus a 
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global burden for humans (Papillomavirus Episteme (PaVE) from Van Doorslaer et al. 
2016; Pastrana et al. 2019). HR HPV types such as 16 and to a lesser extent 18, are 
responsible for over half of all HPV positive cervical carcinomas (reviewed in zur Hausen 
2009). In 2007, Australia initiated the first government-funded National HPV Vaccination 
Program (NHVP), to reduce the incidence of HPV infections in youth (Tabrizi et al. 2012). 
The program was aimed at observing genotype-specific HPV infections in females aged 18 
- 24 over a span of four years prior to and after the vaccination period (2005 – 2007 and 
2010-2011 respectively). The study concluded that the introduction of an HPV vaccination 
program reduced HPV 6, 11, 16, 18 infections by over 20 %. The Australian NHVP is so 
successful that researchers believe cervical cancers will no longer be a public health 
concern (less than 4 new cases per 100 000 females) in Australia within the next 20 years 
(Hall et al. 2019). Surprisingly, with HPV vaccines such as Gardasil9 and Cervarix 
available to the public, less than 2 % of the global female population have completed 
vaccinations (Harper and DeMars 2017). Although studies suggest one dose of HPV 
bivalent vaccines is enough to develop long-lasting immunity to HPV16 and 18 types, 
uptake rate and availability is low and next to none in developing countries (Kreimer et al. 
2018). In Canada, HPV vaccine uptake is far below the average compared to other 
developed countries such as Australia (Tabrizi et al. 2012; Bird et al. 2017). Canada has 
set a goal of 85 % vaccine uptake for all female populations but as of 2017 only managed 





1.2 HPV16 Genome and Functions of Early Genes 
HPV16 is a 7.9 kb double-stranded DNA virus that exists as circular episomes or 
integrated within the host genome (Smith et al. 2011; Cheung et al. 2013). There are four 
unique regions within the HPV16 genome: a long control region (LCR), an early region, a 
late region and a non-coding region (NCR) (Smith et al. 2011) (Figure 1). There are six 
early genes present within the early genome region. Early genes are numerically numbered 
and denoted by the letter ‘E’ (E1, E2, E4, E5, E6, E7). E1 is a helicase/ATPase while E2 
behaves as a transcriptional regulator of E6 and E7 via binding to one of four binding sites 
in the LCR (McBride et al. 1991; Hughes et al. 1993; Bouvard et al. 1994). HPV16 
transfected keratinocytes possess a E8^E2 spliced mRNA that is found to repress E1 
replicase expression limiting early gene expression (Lace et al. 2008). E4 is present within 
the open reading frame (ORF) of E2. Transcription can initiate through the ORF within E2 
or by an E1^E4 spliced mRNA that originates within the E1 ORF (Doorbar 2013). E4 plays 
a vital role in releasing the virus from the host environment as well as disrupting cellular 
keratin networks within cells (Doorbar 2013). E5 reduces tumour suppressor proteins p21 
and p27 expression in HPV16 infected cells, increasing cellular proliferation (Venuti et al. 
2011). E5 was recently discovered to be heavily involved in reducing miRNA-196a 
expression in HPV16 infected cells aiding in cellular transformation (Liu et al. 2015). E6 
and E7 are of particular interest in HPV research. These genes are responsible for 
production of their respective proteins E6 and E7. These proteins are extensively studied 
because of their ability to transform and immortalize host cells in the absence of other early 
or late genes (reviewed in Vande Pol et al. 2013). E6 is involved with a multitude of 
functions including degradation of cellular proteins such as tumour suppressor protein P53 
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via the E6 protein binding to an E6 associated protein (E6AP) causing cellular 
immortalization. E7 most notably inhibits the retinoblastoma tumour suppressor protein 
(pRB) leading to loss of cell cycle regulation and increased cellular proliferation (reviewed 
in zur Hausen 2009).  
 
1.3 E6 Oncoprotein 
For over 40 years, researchers extensively studied and described the functions of 
E6 (zur Hausen et al. 1977; Scheffner et al. 1990; Huibregtse et al. 1991; Kiyono et al. 
1997; Zhang et al. 2005). There are several biological functions regulated by the E6 protein, 
most notably as described above in Section 1.2 the degradation of P53 through E6AP 
(reviewed in Vande Pol et al. 2013). Transcription is also affected by the expression of the 
E6 protein by interacting with histone acetyltransferases (HAT) such as human 
alteration/deficiency in activation protein (hAda3) (Neveu et al. 2012, reviewed in Vande 
Pol et al. 2013). 
 
Figure 1 – Schematic representation of the circular HPV16 genome developed using the 
Pathogen Host Analysis Tool (PHAT) (Gibb et al. 2019). Green regions are early genes 
expressed during initial stages of HPV16 viral infection. Pink regions are late genes which 
are expressed in later stages of HPV16 infection. E6 is the oncogene of interest because of 
its ability to promote cell immortalization, immune evasion and malignancy (reviewed in 
Vande Pol et al. 2013).  
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This interaction is dependent on the interaction between E6 and E6AP whereas E6’s 
ability to target another HAT, tat-interacting protein 60 kDa (TIP60) is independent of the 
formation of the E6-E6AP-P53 protein complex (Jha et al. 2010; reviewed in Vande Pol et 
al. 2013). Interestingly E6’s ability to interact with E6AP is required to activate human 
telomerase reverse transcriptase (hTERT). Therefore, E6 is capable of immortalizing cells 
through maintaining telomeres within the genome (Liu et al. 2005).  
Within the carboxy-terminus of high-risk E6 oncoproteins, a PDZ binding domain 
(PBM) is present (contains amino acid motif ETQL) allowing for the interaction of E6 with 
proteins containing a PDZ domain. These interactions result in the degradation or inhibition 
of PDZ-containing partners involved in cellular adhesion and polarity control such as: 
human homologue of Drosophila discs large (hDlg), human homologue of Drosophila 
scribble (hScrib), membrane-associated guanylate kinase with an inverted arrangement of 
protein-protein interaction domains (MAGI-1) and multi-PDZ-containing protein 
(MUPP1) (Nguyen et al. 2003). It should be noted that there is no PBM present within low-
risk HPV E6 proteins suggesting that the PBM is integral for promoting epithelial 
hyperplasia (Nyugen et al. 2003; reviewed in Vande Pol et al. 2013). Interestingly, E6 in 
HPV16 contains a bimodal half-life with one segment having a half-life of approximately 
4 hours, the other less than 30 minutes (Androphy et al. 1987). It is worth noting that E6 is 
stabilized in the presence of E6AP (Tomaić et al. 2009).  
Recently, HPV16 E6 has been found to target the toll like receptor (TLR) pathway 
(Oliveira et al. 2018). E6 is capable of targeting six different proteins involved in this 
pathway: Inhibitor of nuclear factor kappa-B kinase subunits beta and epsilon, Interleukin-
1 receptor-associated kinase-like 2, myeloid differentiation primary response protein 
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MyD88, TIR domain containing adapter molecule 1, and, TNF receptor associated factor 
6. The result of E6’s interactions with these TLR pathway proteins is an increase in NF-
!B activation (Oliveira et al. 2018) It is important to note that many of these experiments 
were conducted using mutants of the prototype HPV16 E6 (Table 1 Refs Within). These 
proteins do not contain all of the mutations observed in naturally occurring variants, 
whereas our research aims to fill in this gap by using the full genome of HPV16 E6 variants 
AAE6 and EPE6. Even though so much is known about E6, many mechanisms underlying 
its ability to promote carcinogenesis remain unknown.  
 
1.4 HPV16 E6 Variants 
 There are nucleotide variations within HPV16 E6 genes known as single nucleotide 
polymorphisms (SNPs). Analysis of SNPs within intratypes of HPV16 E6 has led to more 
specific classifications called variants. Many intratype SNPs are used to define variants of 
HPV16 E6 and initially were thought to be geographically distributed (Zuna et al. 2009). 
Since the first HPV16 genome sequenced was from a woman of European descent, the 
term “European Prototype” (EP) was used to define this variant (Seedorf et al. 1985; Zuna 
et al. 2009). The number of HPV16 E6 variants have increased steadily since the 1980s. In 
1993, Ho et al. identified five distinct HPV16 geographical variants from cervical cancer 
biopsies named: European (EP-1 and EP-2), Asian (As), African-1 (Af-1), African-2 (Af-
2) and Asian American (AA-1, AA-2, North-American (NA)) (Ho et al. 1993). Each of the 
geographical variants was thought to have evolved over 200 000 years through genetic drift 
likely originating in Africa. Variant nomenclature has largely remained the same (except 
for the Asian variant which sometimes is included as a European sub-variant) until 2013 
 12 
(Ho et al. 1993; Smith et al. 2011; Burk et al. 2013). Unfortunately, geographical variant 
nomenclature is misleading due to factors such as breeding between humans, and increased 
migration rates (Clifford et al. 2019). The introduction of lineage variants in 2013 was a 
significant shift in HPV nomenclature moving away from geographic variants and using 
four alphabetic lineages from ‘A’ to ‘D’ and four numeric sub-lineages from ‘1 - 4’ to 
classify and categorize intratype HPV SNPs (Burk et al. 2013). Current lineage 
classification of HPV16 is as follows: Lineage A is the most common worldwide with sub-
lineages A1 - 2 being the most prevalent. Sub-lineages A3 and 4 are localized to East Asia 
and pose increased cancer risks to East Asia and South American Populations. Lineages B 
and C are localized to populations within Africa with sub-lineages B1 and C1 being the 
most common in Sub Saharan and Northern Africa respectively. Interestingly although 
sub-lineages B1 - 3 are primarily located in Sub-Saharan Africa, sub-lineage B4 is most 
common within Northern Africa. Lineage D HPVs are most commonly found in 
individuals from South/Central America. D4 is a unique sub-lineage that is almost 
exclusively found within Northern Africa.  (PaVE from Van Doorslaer et al. 2016; Clifford 
et al. 2019).  
HPV16 E6 variants have been reported to vary in their ability to produce malignant 
lesions within intraepithelial cells of the cervix and squamous cells of the head and neck 
(Zuna et al. 2009). Specifically, the Asian American variant (DNA sequence: sub-lineage 
D2 from GenBank ID AY686579.1; Amino acid sequence: sub-lineage D2 and D3 from 
GenBank ID: AAV91644.1 and AAO85408.1) of HPV16 E6 (AAE6) has been shown to 
possess significantly greater abilities to produce malignant lesions of the cervix compared 
to their European counterpart (EPE6) (DNA sequence: sub-lineage A1 from GenBank ID: 
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K02718.1; Amino acid sequence: A1 from GenBank ID: AAA46939.1) (Sichero et al. 
2007; Zehbe et al. 2009 refs within). AAE6 and EPE6 genes differ by only six SNPs, half 
of which are non-synonymous (Zehbe et al. 1998). These SNPs result in AAE6 differing 
by three amino acids from EP to AA beginning form the second start codon of the 151-
residue E6: Q14H, H78Y, and L83V (Figure 2) (Zehbe et al. 1998; Zehbe et al. 2009, 
Jackson et al. 2014).  
This research shall focus on only the Prototype (A1) and Asian-American (D2/D3) 
sub-lineages because of their varied abilities to promote tumourigenesis (Richard et al. 
2010; Niccoli et al. 2012). Research from the late 1990’s has demonstrated that although 
the Prototype sub-lineage is equally present in Cervical intraepithelial neoplasia grade I – 
III (CIN I – III), the majority (94%) of invasive cervical carcinomas (ICC) were variants 
such as AAE6 (Zehbe et al. 1998). AAE6 has increased invasive and transforming potential 
resulting in increased carcinogenic abilities (Richard et al. 2010; Niccoli et al. 2012; 
Jackson et al. 2016).    
 
1.5 Current Discoveries of HPV16 E6 Variant Studies 
AAE6 possesses greater abilities to produce malignant lesions of the cervix 
compared to EPE6. The AAE6 variant of E6 is associated with increased viral persistence 
and increased cervical intraepithelial neoplasia (CIN) grade II to III development since 
2000 (Villa et al. 2000; Berumen et al. 2001). Recently, Jackson et al. (2014) found that 
within three-dimensional keratinocyte raft models AAE6 produced moderate hyperplasia 
compared to EPE6 epithelium which only developed a mild dysplasia within epithelium 
(Figure 3). Researchers also found the Asian-American variant of HPV16 E6 to increase 
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PI3K/AKT and MAPK pathway expression through increased activation of MEK1, ERK2 
and AKT2 proteins (Hochmann et al. 2016; Cuninghame et al. 2017). To further explain 
the mechanisms behind such functional observations, Zacapala-Gomez et al. completed a 
global transcriptome study of five E6 variants (AA-a, AA-c, E-A176/G350, E-C188/G350 
and E-G350 (L83V)) expressed in C33A cells and found 387 differently expressed genes 
compared to cells transfected with the European Prototype (Zacapala-Gomez et al. 2016). 
Zacapala-Gomez et al. identified that Asian-American variants and the L83V (E-G350) 
variant of E6 upregulate cell-cell adhesion, protein and tyrosine kinase activity. As 
described in the section above, many of the proteins E6 interacts with are involved with 
adhesion and kinase activities. Another important finding was L83V’s upregulation of N-
cadherin (cadherin 2), AA-a’s upregulation of cadherins 18 and 6, as well as AA-c’s 
upregulation of cadherin 9. Furthermore, recent clinical studies confirm that the D sub-
lineage (including AA) is most associated with cervical carcinomas in the Americas (Ortiz-
Ortiz et al. 2015; Clifford et al. 2019). 
In recent years, our lab has made significant strides to unravel physiological, 
epidemiological and molecular differences further in AAE6 and EPE6 transduced cell lines 
(Zehbe et al. 2009; Richard et al. 2010; Niccoli et al. 2012; Togtema et al. 2015; Jackson 
et al. 2016; Cuninghame et al. 2017). Our group previously found signaling pathway 
differences between variant E6 cell lines such as increased hypoxia inducing factor 1-alpha 
(HIF-1a) expression within Asian-American E6 cells resulting in dysregulation of cellular 
metabolism similar to the Warburg effect. Increased HIF-1a levels were caused by the 
activation of MAPK/ERK1/2 signaling pathway (Richard et al. 2010; Cuninghame et al. 
2017). Our research has also found that AAE6 possesses more effective migration ability 
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compared to EPE6 (Niccoli et al. 2012). Such abilities could further explain increased viral 
persistence and increased CIN grade II to III development as described previously. Our lab 
also identified that AAE6 was capable of immortalizing and transforming PHFKs in the 
absence of E7 whereas EPE6 could immortalize but not transform PHFKs without E7 
(Togtema et al. 2015). 
 
Figure 2  – To scale depiction of HPV16 E6 SNPs between AAE6 and EPE6. Lines in blue 
indicate a SNP that results in an amino acid change (missense mutation), whereas lines in 
red indicate no amino acid changes at that particular site (nonsense mutation). SNPs 
resulting in amino acid changes from EPE6 to AAE6 (Q14H, H78Y, and L83V) are found 
at nucleotide (NT) positions G145T, C335T, and T350G. SNPs that do not result in any 
change in amino acids are found at NT positions: T286A, A289G, and G532A. This 
correlates with SNPs that are found in Zehbe et al. 1998. Developed using InkscapeTM 





Figure 3 – Near-diploid immortalized keratinocytes (NIKS) grown on top of a dermal 
equivalent (consists of a collagen matrix and embedded fibroblasts) demonstrating 
differences in cellular dysplasia due to 16 E6 variant expression. AAE6 (right) shows 
increased dysplasia compared to raft culture of EPE6 (centre). Adapted from Jackson et al. 
2016, originally published in BMC Genomics, and free-to-use with attribution (CC BY 
4.0). 
 
At the transcriptome level, our lab has identified a unique transcriptional profile for 
the AAE6 variant of HPV16 E6 allowing for a proliferating phenotype to be exhibited 
within the epithelium. From this, our group identified increased levels of proliferation, 
resulting in a significant reduction in chromosomal stability within the AAE6 variant, a 
common characteristic of cancer (Jackson et al. 2016).  
 
1.6 Protein-Protein Interaction Methodology 
The most common methods used to experimentally identify potential protein-
protein interactions are through binary (direct) and co-complex (direct and indirect) 
interactions (BI and CCI respectively) (De Las Rivas, 2010). Binary interactome methods 
detect physical and direct protein-protein interactions (PPI). Examples of Binary 
techniques are: yeast two hybrid (Y2H) or membrane yeast two hybrid (MYTH), 
Luminescence-based mammalian interactome mapping (LUMIER), mammalian protein-
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protein interaction trap (MAPPIT) and mammalian membrane two hybrid (MaMTH, 
Snider et al. 2015). The most common binary method used in E6 interactome studies is the 
Y2H assay. The Y2H assay works by developing a bait (target) protein fused to a 
transcriptional activating domain (AD) and a library of complementary DNA (cDNA) 
fused to a DNA binding domain (BD).  If a protein containing a BD comes in contact with 
a bait protein bearing the AD, expression of a reporter gene will occur, and the interaction 
is detected (Snider et al. 2015). Unfortunately, the Y2H method may cause a significant 
number of false positives and negatives. One reason for this is posttranslational 
modifications for specific proteins required to be functional which does not occur in an 
environment where Y2H are conducted (Rao et al. 2014). A reason for false negative 
findings is due to the requirement that both proteins must have access to the nucleus. Since 
many proteins can only be found in cellular organelles such as the mitochondria it is 
unlikely that any expression of a reporter gene will be observed (Snider et al. 2015). As 
such, co-complex approaches are progressively becoming preferred over binary methods 
to conduct interactome studies (Ronco et al. 1997, White et al. 2012; Oliveira et al. 2018).  
Co-complex methods consist of tandem affinity purification-mass spectrometry 
(TAP-MS), and affinity purification mass spectrometry (AP-MS) (Howie et al. 2011, 
White et al. 2012, Rao et al. 2014). TAP-MS is an affinity purification method consisting 
of protein complex interaction with a TAP-tagged protein and two purification steps. TAP-
tagged proteins initially are bound to an IgG coated support via Staphylococcus aureus 
protein A (ProtA) and washed before cleavage of the TEV protease cleavage site. A 
subsequent purification step of the eluate is completed via binding to calmodulin coated 
supports in the presence of calcium (Ca2+). A final elution is done using ethylene glycol-
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bis(ß-aminoethyl ether)-N,N,N’,N’-tetraacetic acid (EGTA) and the resultant eluate can be 
analyzed by MS (Puig et al. 2001).  
One of the most common affinity purification methods is co-immunoprecipitation 
(Co-IP). Co-IP is a common in vitro protein interaction method between protein complexes 
and an antibody. The protein complex contains an antigen enabling the binding of a target 
protein to a solid support such as magnetic or agarose beads (Yaciuk 2007). The collection 
of agarose beads is done by centrifugation while collection of magnetic beads is done by 
using a strong magnetic stand. Subsequent washes remove any nonspecific protein 
interactions. Finally, protein complexes (containing bait and prey) are eluted from the solid 
support by different elution methods. Harsh elutions such as SDS buffer can strip beads of 
all bound proteins but suffer from antibody contamination as those are also released from 
the beads. Milder elutions such as synthetic peptide, or mild acidic (0.2 M Glycine pH 
<3.0) elutions can reduce antibody contamination while removing protein complexes from 
the beads (ThermoFisher Sci. Overview of the Immunoprecipitation (IP) Technique). 
Eluting with mild solutions does have downsides however, as stronger bait/prey 
interactions may not release from the beads leading to loss of interacting protein. One 
advantage of the Co-IP method is that interactions can be identified from proteins present 
in their native form or allow for posttranslational modifications (PTM). However, one 
should acknowledge the potential for non-specific binding between proteins and the 
antibody, or solid support. Therefore, a control such as non-transduced cell lysate 
preferably is used (Yaciuk 2007, Rao et al. 2014). Once Co-IP is complete, pulled-down 
proteins can be identified by mass spectrometric methods. 
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 In this thesis, the interactome of HPV16 E6 will be studied. To do this, a co-
complex method known as co-immunoprecipitation was used to identify potential PPIs. A 
list of all known interactors to HPV16 E6 can be found in Table 1. This table also mentions 
the methods used to identify and confirm each interactor that will be discussed in further 
detail below. 
 MS is a rapid, highly sensitive method to identify complex protein samples 
(Aebersold and Mann 2003). The most common approach to mass spectrometric protein 
identification is “bottom-up”. Bottom-up proteomic approaches first digest the protein into 
small oligopeptide fragments by proteases. The most common protease is trypsin which 
cleaves the carboxy terminus of lysine or arginine. Depending on the proteins being 
analyzed, it may be favourable to use another protease such as: ArgC, chymotrypsin, LysC 
or LysN. Each protease has a unique specificity for a particular cleavage site within an 
amino acid sequence (Rogers and Bomgarden 2016). The resulting oligopeptides can then 
be separated and analyzed by two common methods explored in this thesis: liquid 
chromatography electrospray ionization (LC MS/MS) and matrix assisted laser desorption 
ionization mass spectrometry (MALDI MS/MS).  
 The principle of both MS methods is similar. That is “to measure the mass-to-
charge (m/z) ratio of ionized peptides and identify the number of peptides that possess this 
m/z value” (Aebersold and Mann 2003). The way how each technique accomplishes this, 
is different. MALDI MS/MS utilizes a high-powered laser to ionize peptide samples. 
Samples must be dried and placed in a crystalline matrix to allow for proper analysis. The 
samples will then travel through a single or multiple time of flight mass separators (TOF) 
to calculate the mass of the ion produced. This is accomplished by separating ionized 
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peptides based on their differences in kinetic energies. Heavier ionized peptides will travel 
slower than ionized peptides with a low molecular weight (Aebersold and Mann 2003). the 
charge of the ionized sample is calculated by the detector and analyzer producing a m/z 
ratio (Aebersold and Mann 2003). LC MS/MS first separates proteins within a mobile 
liquid phase using liquid chromatography (LC) or high-performance liquid 
chromatography (HPLC). Separated proteins are converted into ions using electrospray 
ionization. Electrospray ionization is the process of ionizing the samples using a high 
voltage source to convert the solution of proteins into ions (Abersold and Mann 2003). For 
greater sensitivity, a nanoelectrospray can be used (Maziarz et al. 2000; Michalski et al. 
2011). The ions then travel to a mass detector which can be a TOF sensor or an orbitrap 
analyzer (Aebersold and Mann 2003; Michalski et al. 2011). The benefit of an orbitrap 
analyzer is that it is capable of accurately analyzing most peptides large or small. Finally. 
the samples continue to a detector which will calculate the final m/z ratio (Aebersold and 
Mann 2003; Michalski et al. 2011).   
 Both MS methods have advantages and some drawbacks. For example, MALDI 
MS/MS is excellent for analyzing simple samples with high resolution and accuracy, while 
LC MS/MS can better handle complex protein mixtures (Aebersold and Mann 2003). One 
problem that all mass spectrometers face and continuously attempt to overcome is under 
sampling. Under sampling occurs when not every peptide injected into the mass 
spectrometer is detected and analyzed. This causes many proteins (~30 %) to be missed 
and fail to be identified (Pagala et al. 2015). Many experiments perform analyses with 
multiple replicates to reduce under sampling (Pagala et al. 2015). Biological replicates are 
commonly used for analysis of proteomic datasets. Many groups use at least two biological 
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replicates to produce accurate mass spectrometric datasets (White et al. 2012; 





Table 1 – Reported cellular targets of the human papillomavirus type 16 E6 protein (1991 to 2018) 
Protein Name Accession ID Binding Mechanism Identification Method Mass Spectrometry Outcome of Interaction HPV16 E6 Sub-lineage Reference 
(1) Transcriptional 
adapter 3 (TADA3) alias 
hADA3  
O75528 
Targets hADA3 to prevent co-activation of 
P53 
Yeast two-hybrid; confirmed with GST pull-
down None 
Inactivated by high risk E6; coactivator 
for P53-mediated transactivation of 
target promoters and P53 stabilization 
Not specified; most likely EP/A1 following publications back to 
Halbert et al. 1992; used E6 mutants F2V, 8S9, A10T, Y54H Kumar et al. 2002 
(2) Bcl-2 homologous 
antagonist/killer (BAK1)  
Q16611 
Targets BAK1 through E6AP (UBE3A) 
known to interact with it; has zinc-binding 
properties 
GST pull-down; originally described in 
Thomas and Banks, 1998 
None 
Part of the pro-apoptotic Bcl-2 family; 
degraded by E6 thereby preventing 
BAK-induced apoptosis.  
Not specified  Thomas and Banks 
1999 
(3) BRCA1-associated 
RING domain protein 1 
(BARD1)  
Q99728 
BARD1 binds to E6 through E6’s two zinc 
finger motifs with zinc finger 1 (AA 30-66) 
being the most important region for binding; 
has zinc finger, and metal ion-binding 
properties 
Yeast two-hybrid; confirmed with 
immunoprecipitation  None 
Tumour suppressor through apoptotic 
signaling; inhibits E6, and stabilizes 
P53 
Not specified; mutants Δ9-13, Δ101-105, Δ111-115, Δ138-142, 
45Y/47Y/49H, R39G, L50G, D120G, K115E, C66G, C136G, 
C66G/C136G 
Yim et al. 2007 




Targeted via zinc finger domains of E6; has 
zinc finger, and zinc ion-binding properties GST pull-down  None 
Inhibits telomerase activity; inactivated 
by E6  
Not specified; most likely EP/A1 based on BLAST comparison; gift 
from Peter Howley; they used mutants at both zinc finger domains: 
C66, 136G 
Zhang et al. 2005 
(5) Golgi-associated PDZ 
and coiled-coil motif-
containing protein 
(GOPC) alias CAL  
Q9HD26 
The PDZ domain of CAL interacts with the 
PDZ-binding motif of E6; interacts with the 
E6/E6AP complex enhancing proteasome 
degradation 
GST pull-down  MALDI-TOF 
Involved in the vesicular trafficking 
pathway between membranous 
organelles; E6 mediates proteasome 
degradation of CAL through E6AP 
Not specified; most likely EP/A1 based on BLAST comparison; gift 
from Peter Howley; used “wildtype and mutants E6 T149I, L151V, 
ΔC1, ΔC4, L50G, C66G/C136G, D120G 




Q86X55 Not acquired In vitro methyltransferase assay None 
Activates P53 downstream genes by 
histone methylation; inhibited by E6; 
results in prevention of P53-responsive 
promotors and downregulation of P53 
downstream gene expression 
Not specified; His-tagged E6 and mutants E66C/6S F47R Hsu et al. 2012 
(7) CREB-binding Protein 
(CREBBP) alias CBP Q92793 
E6 binds to 3 regions on CBP and p300: 
C/H1, C/H3 and C-terminus. Binding is 
independent of P53; has zinc-binding 
properties 
Co-immunoprecipitation  None 
Acts as a co-activator for cell cycle 
regulation and differentiation; E6 
inhibits the activation of P53 and NF-
kB by CBP/p300 
Not specified; E6 “wildtype and mutants Δ106-110 ∆133-137, 
45Y/47H/49H, ∆123-127, ∆128-132, C66G/C136G  Patel et al. 1999 
(8) Ubiquitin carboxyl-
terminal hydrolase CYLD 
(CYLD)  
Q9NQC7 Not acquired; has zinc-binding properties 
Determined effect based on Electrophoretic 
mobility shift assay (EMSA) and NF-kB 
reporter gene assay 
None 
Tumour suppressor through negative 
regulation of the NF-kB pathway; E6 
mediated ubiquitination and 
proteasomal degradation of CYLD 
resulting in hypoxia-induced NF-kB 
activation 
Not specified; E6 nucleotide positions 32-617 based on Halbert et al. 
1991 An et al. 2008 
(9) Discs large 
homologue 1 (DLG1) Q12959 
E6 binds to second PDZ domain via C-
terminal XS/TXV/L motif Maltose-binding protein and GST pull-down  None 
Involved in cell junctions and tumour 
suppression; E6 binds to hDLG 
promoting the transformation of cells 
Not specified; “prototype” and mutants: E6L151del, E6L151V, 
E6L151I, E6L151P, E6L151LP, E6L151ETQV  Kiyono et al. 1997  
(10) Discs large 
homologue 4 (DLG4) P78352 
Binds to C-terminus of E6 mainly through its 
second PDZ motif. Last amino acid change 
from leucine to valine changes affinity 
Maltose-binding protein and GST pull-down None 
Suggested tumour suppressor function; 
E6 binds induces proteolytic 
degradation of DLG4 
Not specified; “prototype” and mutants E6SD∆151, E6-151V, E6-
151, E6SAT (8S9A10T unable to target P53 but can bind E6AP), 
E6SAT-∆151, E6SAT-∆151V 
Handa et al. 2007 
(11) Ubiquitin-protein 
ligase E3A (UBE3A) 
alias E6AP  
Q05086 
Not stated in original paper; has zinc finger, 
and metal ion-binding properties Co-immunoprecipitation and GST pulldown  None 
E6 forms a stable complex with E6AP 
and mediates numerous downstream 
interactions such as proteolytic 
degradation of P53 






Protein Name Accession ID Binding Mechanism Identification Method Mass Spectrometry Outcome of Interaction HPV16 E6 Sub-lineage Reference 
(12) Reticulocalbin-2 
(RCN2) alias E6BP, 
ERC55 
Q14257 
Chen et al. 1998 determined that E6BP 
residues 18 – 29 (AA Sequence: 
VSLEEFLGDY) is the binding site for E6 
Yeast two-hybrid; confirmed with GST pull-
down None 
A truncated form of ERC55; a putative 
calcium-binding protein; interacts with 
E6 to form a complex and is thought to 
be involved with E6 induced 
transformation and degradation of 
cellular proteins 
Not specified  Chen et al. 1995 
(13) Signal-induced 
proliferation-associated 1-




Binds to E6TP1’s C-terminus at residue 194; 
PDZ domain within E6TP1 has little effect 
on binding with E6 
Yeast two-hybrid; confirmed with GST pull-
down None 
Possible tumour suppressor protein; 
degradation by E6 potentially alters G-
associated protein signaling pathways 
Not specified Gao et al. 1999 
(14) FAS-associated death 
domain protein (FADD)  
Q13158 
Targets the N-terminus with major binding 
contributions at Serine residue 10, 14, 16 and 
18 and Glutamic acid residue 19; site-
directed mutants enabled localization of E6-
binding to N-terminal end of FADD 
Mammalian two-hybrid to identify E6 binding to 
FADD and in vitro GST pull-down to confirm 
interaction deletion 
None 
Triggers apoptotic pathway and cell 
death; E6 accelerates depredation of 
FADD preventing transmission of 
apoptotic signals through FAS pathway 
Not specified Filippova et al. 
2004 
(15) Fibulin-1 (FBLN1) P23142 No consensus binding motif identified; has 
calcium-binding properties 
Yeast two-hybrid; confirmed with GST pull-
down None 
Hypothesized E6 binds to and inhibits 
Fibulin-1 allowing for invasion and 
metastasis  
Not specified; same plasmids as Chen et al. 1995 Du et al. 2002 
(16) E3 ubiquitin-protein 
ligase HERC2 (HERC2)  
O95714 
Interaction with E6 is E6AP dependent; has 
zinc finger, and zinc ion-binding properties 
Liquid chromatography with tandem mass 
spectrometry (LC-MS/MS) and confirmed using 
co-immunoprecipitation with anti-HA magnetic 
beads 
LC MS/MS 
Can only interact with E6 through 
formation of complex with E6AP to 
result in degradation of HERC2 
Not specified; E6 “wild type” and mutants E6 8S9A10S (AA 
changes at position 8, 9, and 10 (R-P-R to S-A-T)); E6 I128T (AA 
change at position 128 (I to T)); E6 ∆146-151 (deletion of final 5 
AA in 151 residue sequence)  
White et al. 2012 
(17) Protein scribble 
homolog (SCRIB) alias 
hScrib  
Q14160 
Interacts with E6AP in the presence of E6, 
C-terminus of E6 recognizes PDZ domain of 
hScrib 
GST pull-down  MALDI  
MS/MS 
Tumour suppressor protein; 
ubiquitinated in the presence of both E6 
and E6AP resulting in degradation and 
reducing integrity of tight junctions 
Not specified; N-terminal FLAG tagged E6 described in Tong et al. 
1997, E6 SAT (8-10) mutants used  
Nakagawa et al. 
2000 
(18) Telomerase reverse 
transcriptase (hTERT)  
O94807 
Proximal promotor/regulatory regions (nt 
position -251 to -88 and +5 to +40) involved 
with 60% of E6-induced hTERT activity; has 
DNA-binding properties 
Identified E6 as potential up-regulator for 
hTERT using telomerase activity assay; 
confirmed E6 upregulates hTERT mRNA using 
mRNA protection assay 
None 
E6 induces increased hTERT activity 
resulting in maintenance of telomere 
length 
Not specified Veldman et al. 2001 
(19) Inhibitor of nuclear 
factor kappa-B kinase 
subunit beta (IKKB) 
 
O14920 Not acquired; has nucleotide (ATP)-binding properties 
Identified and confirmed by co-
immunoprecipitation assay  None 
E6 binding potentially intervenes with 
NF-kB activation during bacterial or 
viral infection or DNA damage 
CaSki cells and plasmids containing HPV16 E6 however sub-
lineage and mutants not specified Oliveira et al. 2018 
(20) Inhibitor of nuclear 
factor kappa-B kinase 
subunit epsilon (IKKE) 
 
Q14164 
E6 binds to a location within the first 160 
residues of IKKε; 	has		nucleotide (ATP)-
binding properties 
Identified and confirmed by co-
immunoprecipitation assay  None 
E6 binding potentially intervenes with 
type I IFN, NF-kB and STAT signaling 
CaSki cells and plasmids containing HPV16 E6 however sub-
lineage and mutants not specified Oliveira et al. 2018 
(21) Interleukin-1 
receptor-associated 
kinase-like 2 (IRAK2) 
 
O43187 Not specified, has nucleotide (ATP)-binding properties 
Identified and confirmed by co-
immunoprecipitation assay  None 
E6 binding potentially intervenes with 
NF-kB activation during TLR9 
signaling 
CaSki cells and plasmids containing HPV16 E6 however sub-
lineage and mutants not specified Oliveira et al. 2018 
(22) Interferon regulatory 
factor 3 (IRF3) alias IRF-
3  
Q14653 
IRF-3 residues 109-149 contain the ELLG 
sequence most likely attributing to 
interaction with E6; ELLG is also present in 
the E6 binding domain of E6AP; has DNA-
binding properties 
Yeast two-hybrid; confirmed with GST pull-
down None 
Transcriptional activator; interacts with 
E6 inhibiting transactivation of IFN-ß Not specified Ronco et al. 1998 
(23) Membrane-
associated guanylate 
kinase, WW and PDZ 
domain-containing 
protein 1 (MAGI1) alias 
MAGI-1  
Q96QZ7 
E6 PBM interacts with PDZ1 of MAGI-1; 
has nucleotide (ATP)-binding properties GST pull-down  None 
Functions in signal transduction and 
likely a tumour suppressor protein; E6 
targets MAGI-1 for proteasomal 
degradation 






Protein Name Accession ID Binding Mechanism Identification Method Mass Spectrometry Outcome of Interaction HPV16 E6 Sub-lineage Reference 
(24) Membrane-
associated guanylate 
kinase, WW and PDZ 
domain-containing 
protein 2 (MAGI2) alias 
MAGI-2  
Q86UL8 
PDZ1 domain interacts with E6 most likely 
through the PDZ Binding Motif (PBM) 
In vitro degradation assay used varying 
concentrations to observe degradation of MAGI-
2 
None 
Functions in signal transduction; E6 
targets MAGI-2 for proteasomal 
degradation 
Not specified Thomas et al. 2002 
(25) Membrane-
associated guanylate 
kinase, WW and PDZ 
domain-containing 
protein 3 (MAGI3) alias 
MAGI-3  
Q5TCQ9 
PDZ1 domain interacts with E6 most likely 
through the PBM. PDZ1 domain of MAGI-3 
alone is capable of inhibiting the interaction 
between E6 and MAGI-3; has nucleotide 
(ATP)-binding properties 
In vitro degradation assay used varying 
concentrations to observe degradation of MAGI-
3 
None 
Functions in signal transduction; E6 
targets MAGI-3 for proteasomal 
degradation  
Not specified Thomas et al. 2002 
(26) Mastermind-like 
protein 1 (MAML1) Q92585 
E6 interacts through acidic carboxy terminal 
LXXLL motif on MAML1 Yeast two-hybrid  None 
Transcriptional co-activator; E6 
represses transcriptional activity and 
downstream Notch signaling pathways 
Not specified Brimer et al. 2012 
(27) DNA replication 
licensing factor MCM7 
(MCM7) alias hMCM7 
P33993 
Deletion analysis found E6’s N-terminal 
residues 1-91 bind to hMCM7 C-terminal 
residues 572-719; has nucleotide (ATP)-
binding properties 
Yeast two-hybrid  None 
Component of replication licensing 
factors; E6 potentially interferes with its 
ability to associate with chromatin 
avoiding G1-phase arrest point 







MGMT interacts with E6AP through L2G 
box sequence LLGXXXS/T; PDZ domain 
present shows potential binding with E6; has 
zinc-binding properties 
GST pull-down; confirmed with 
immunoprecipitation and immunodepletion  None 
DNA repair protein that protects against 
mutations; E6 promotes ubiquitination-
dependent degradation 
Not specified Srivenugopal et al. 
2002 
(29) Myc proto-oncogene 
protein (MYC)  
P01106 
Binds to E6 in an E6AP dependent manner 
along with E2F1 transcription factor; has 
DNA-binding properties 
GST pull-down  None 
Transcription factor involved in cellular 
regulatory processes; binding of E6 
results in shortening of MYC’s half-life 
and accelerated degradation 
Not specified Mesilaty et al. 1998 
(30) Myeloid 
differentiation primary 
response protein MyD88 
(MYD88) 
 
Q99836 Not acquired Identified and confirmed by co-immunoprecipitation  None 
E6 binding potentially prevents innate 
immune receptor signaling 
CaSki cells and plasmids containing HPV16 E6 however sub-
lineage and mutants not specified Oliveira et al. 2018 
(31) Nuclear factor kappa 





Not acquired; has DNA-binding properties Immortalization assays and dual luciferase assays None 
E6 increased NF-kB levels for baseline 
and TNF-a by 2- to 3-fold Not specified 
Vandermark et al. 
2012 
(32a) Transcriptional 





NFX1-91 is destabilized by the E6/E6AP 
complex at NFX-91’s C-terminus; has zinc-
finger and DNA-binding properties 
Yeast two-hybrid; confirmed with co-
immunoprecipitation and RT-qPCR None 
Transcriptional repressor of hTERT 
promoter; E6/E6AP complex 
destabilizes NFX1-91 through 
ubiquitination 
Not specified; E6 mutants F2V, 8S/9A/10T Gewin et al. 2004 
(32b) Transcriptional 





NFX1-123 is stabilized in the presence of 
E6; Gewin et al. 2004 demonstrated its 
interaction with E6 in vitro using a yeast 
two-hybrid screen and in vitro binding 
assays; has zinc-finger and DNA-binding 
properties 
Yeast two-hybrid; confirmed with co-
immunoprecipitation and GST pull-down  LC MS/MS 
Transcriptional activator of hTERT 
promoter; E6 may bring NFX1-123 to 
the hTERT promoter allowing for 
increased hTERT activation and 
overexpression 
Not specified Katzenellenbogen 
et al. 2007 
(33) InaD-like protein 
(PATJ) Q8NI35 
E6 binds to the PDZ domain of PATJ (ETQL 
AA sequence) 
Yeast two-hybrid; confirmed with co-
immunoprecipitation None 
E6 binds to and targets PATJ for 
degradation independently of E6AP 
preventing the formation of a TJ- 
associated complex Par6-aPKC-PAR3 
responsible for regulation of kinase 
activity and formation of tight junctions 
in polarized cells 
Not specified Storrs and 
Silverstein 2007  
(34) Paxillin (PAXI) P49023 
Not acquired; E6 effect likely occurs 
downstream of paxillin tyrosine 
phosphorylation and is sensitive to status of 
actin polymerization; has zinc-binding 
properties 
GST pull-down  None 
Transduces signals from plasma 
membrane to focal adhesions and the 
actin cytoskeleton; E6 disrupts paxillin-
mediated actin fibre formation 
Not specified; E6 “wildtype” and mutants 141T, C128T, C17P, 
C20S, C53R, C90S, C93H, C93S, H105D, R116S, C124V, Δ127-
137, Δ134-137 





Protein Name Accession ID Binding Mechanism Identification Method Mass Spectrometry Outcome of Interaction HPV16 E6 Sub-lineage Reference 
(35) E3 ubiquitin-protein 
ligase PDZRN3 
(PDZRN3) 
Q9UPQ7 PDZRN3 interacts with E6 within the PBM; 
zinc finger, and has zinc-binding properties Yeast two-hybrid  None 
When interacting with E6, PDZRN3 is 
targeted for degradation increasing 
STAT5-ß activation 
Not specified Thomas and Banks 
2014  
(36) Serine/threonine-
protein kinase N1 (PKN1) 
alias PKN 
Q16512 
E6 binds to C-terminal region of PKN; has 
nucleotide (ATP)-binding properties 
Yeast two-hybrid; confirmed with GST pull-
down None 
Protein kinase that contributes to 
oncogenic transformation signal 
transduction pathways; PKN 
phosphorylates E6, which may allow 
for E6 to influence Rho-mediated 
signaling 
Not specified; E6 “wildtype” and mutants F2L/Y43C, K34E, Q35R, 
I101V, Y84C, C103R/D120G/I128M/R131P, 
C111Y/Q116H/R117K/R124STOP, R124G/H126R, C63S 
Gao et al. 2000 




Not acquired; has amino acid-binding 
properties In vitro methyltransferase assay None 
Coactivates and methylates proteins; E6 
reduces PRMT1-induced methylation of 
histone H4 at R3; resulted in reduced 
P53 transactivation 
Not specified; His-tagged E6; used mutants E66C/6S F47R Hsu et al. 2012 
(38) Caspase-8 (CASP8) 
alias Procaspase-8 Q14790 
Not acquired; both E6 full-length and 
truncated E6* can bind to procaspase 8 
Mammalian two-hybrid; confirmed with GST 
pull-down, immunoprecipitation and co-
immunoprecipitation  
None 
Initiator caspase in several apoptotic 
pathways; full-length E6 targets 
procaspase 8 for degradation and also 
decreases caspase 8 interaction with 
FADD and procaspase 8 dimerization; a 
truncated form of E6 was found to 
stabilize procaspase 8 




type 3 (PTPN3) 
P26045 
Interaction between C-terminus of E6 and 
the PDZ domain of PTPN3; has substrate-
binding properties 
GST pull-down  None 
Membrane-associated phosphatase; 
degraded by E6 which prevents tyrosine 
phosphorylation of growth factor 
receptors 
Not specified; E6 “wildtype” and mutants E6∆C, E6F2V Jing et al. 2007 
(40) Cellular tumour 
antigen P53 (P53) P04637 
Not acquired; has zinc- and DNA-binding 
properties Immunoprecipitation  None 
Tumour suppressor protein and 
negative regulator of proliferation; E6 
binds to and degrades P53 





Binding domain on E6 between residues 
100-147. Binds to 3 regions on CBP/p300: 
C/H1, C/H3 and C-terminus; has zinc-
binding properties 
Co-immunoprecipitation  None 
Coactivator important for cell 
differentiation and cell cycle 
progression; E6 prevents the activation 
of P53 and NF-kB by CBP/p300 
Not specified; E6 “wildtype” and mutants ∆133-137, 45Y/47H/49H, 





Not acquired; has substrate-binding 
properties In vitro methyltransferase assay None 
Methylation of histones and non-
histone substrates such as P53; 
inhibition by E6 results in the decrease 
of P53 stability and activity 
Not specified; His-tagged E6 and mutants E66C/6S F47R Hsu et al. 2012 
(43) Telomerase reverse 
transcriptase (TERT) O14746 
Not acquired; has magnesium-binding 
properties 
Modified telomere repeat amplification protocol 
assay (TRAP) None 
Synthesizes telomere repeat sequences; 
E6 causes ubiquitin-mediated 
degradation of a telomerase repressing 
protein; most likely E6 interaction with 
hTERT causes telomerase activation 
Not specified; E6 “wildtype” and mutants ∆146-151, ∆118-122, and 
8S/9A/10T 
Klingelhutz et al. 
1996 
(44) Tax-1 binding 




TIP-1 interacts with E6 by binding to the 
PDZ binding region at E6’s terminus 
Yeast two-hybrid; confirmed with co-
immunoprecipitation None 
TIP-1 interacts with E6 but rather than 
being degraded, it results in increased 
activation of RhoA kinase 






Protein Name Accession ID Binding Mechanism Identification Method Mass Spectrometry Outcome of Interaction HPV16 E6 Sub-lineage Reference 
(45) Histone 
acetyltransferase KAT5 
(KAT5) alias TIP60  
Q92993 
Charged residues of the N-terminus of E6; 
has zinc finger, and metal ion-binding 
properties 
GST pull-down None 
Tumour suppressor protein; E6 
destabilizes and degrades TIP60 
promoting cell proliferation and cell 
survival 
Not specified; mutant C33G Jha et al. 2010 
(46) Tumor necrosis 
factor receptor 




E6 binds to the C-terminal cytoplasmic tail 
of TNF R1 
Immunoprecipitation; confirmed with 
mammalian two-hybrid  None 
Involved in apoptotic signaling; E6 
inhibits TNF induced apoptosis and 
formation of the death induced 
signaling complex (DISC) 
Not specified Filippova et al. 
2002 
(47) TNF receptor-
associated factor 6 
(TRAF6) 
Q9Y4K3 Not acquired; has zinc-finger, and zinc-binding properties 
Identified and confirmed by co-
immunoprecipitation  None 
E6 binding potentially de-regulates 
DNA damage response and host 
immunity 
 
CaSki cells and plasmids containing HPV16 E6 however sub-
lineage and mutants not specified Oliveira et al. 2018 
(48) TIR domain-
containing adapter 
molecule 1 (TICAM1) 
alias TRIF 
 
Q8IUC6 Not acquired Identified and confirmed by co-immunoprecipitation  None 
E6 binding potentially inhibits innate 
immune functions and antiviral 
responses 
CaSki cells and plasmids containing HPV16 E6 however sub-
lineage and mutants not specified Oliveira et al. 2018 
(49a) Tuberin (TSC2) P49815 
Residues 1-175 and 1251-1807 of TSC2 are 
required for binding to residues of 260-316 
and 428-500 of E6AP 
GST pull-down; confirmed with co-
immunoprecipitation  None 
Tumour suppressor; E6 binds to 
E6AP/TSC2 complex and targets TSC2 
for degradation  
Not specified; most likely EP/A1 based on BLAST comparison; gift 
from Peter Howley  Zheng et al. 2008 
(49b) Tuberin alias TSC2 P49815 DILG and ELVG domains of Tuberin bind to E6 residues 78-104 
Yeast two hybrid; confirmed with GST pull-
down None 
Tumour suppressor protein; negatively 
controls proliferation; E6 binding 
causes ubiquitin mediated degradation 
of Tuberin 
Not specified Lu et al. 2004 
(50) Ubiquitin carboxyl-
terminal hydrolase 15 
(UBP15) alias USP15 
Q9Y4E8 Not acquired Targeted mass spectrometry Targeted MS 
Interaction of E6 with active form of 
USP15 results in increased stability and 
increased E6 half-life 
Not specified Vos et al. 2009 
(51) DNA repair protein 
XRCC1 (XRCC1) P18887 
E6 interacts with the N-terminus of XRCC1 
(residues 107-170) 
Yeast-two hybrid; confirmed with co-
immunoprecipitation  None 
Required for DNA repair and genetic 
stability; E6 inhibits XRCC1. and 
prevents ability to maintain genetic 
integrity and utilize DNA strand break 
repair mechanisms 







1.7 Bioinformatic Interactome Analysis Software 
 Once proteins have been identified by MS, relationships between samples must be 
made. There are numerous tools available for researchers to analyse relationships between 
identified proteins. For instance, Reactome is an online database that can allow researchers 
to build biological process maps with identified proteins within the human genome. This 
database is constantly updated and monitored to provide users with the most up to date 
information possible (Fabregat et al. 2018). Mapped proteins can be analyzed using a 
graphical user interface enabling easy identification of what role a protein may play in the 
biological system (Fabregat et al. 2018). Such a tool can be used to make sense of 
differences in PPI between a viral protein and a host cell. Another useful database that 
helps visualize interacting proteins is the STRING database (Szklarczyk et al. 2017). 
 The STRING database enables researchers to identify PPIs that may exist within a 
particular dataset. These PPIs can be classified as direct or indirect based on a variety of 
experimental databases such as: the IMEx consortium and BioGRID. This database can 
provide insight into experimental, or interlog (similarity between orthologs) evidence as 
well as curated databases citing existence of an interaction between two proteins 
(Szklarczyk et al. 2017). Such a database can simplify the process of pathway building and 
PPI identification. Finally, the Protein Analysis Through Evolutionary Relationships 
(PANTHER) database builds functional relationships between proteins based on over 900 








1.8 Hypothesis, Aims and Rationale  
Hypothesis: It is hypothesized that the Asian American (D2/D3) variant will 
possess several different virus-host PPIs resulting in increased activity of carcinogenic 
molecular pathways.  
Specific Aims: To identify differential PPIs, the pull-down of E6 binding partners 
using co-immunoprecipitation (Co-IP) was optimized and LC MS/MS was used to identify 
pulled-down proteins. Next, literature searches and bioinformatic methods were used to 
identify potential differing interactors between each variant through a combination of mass 
spectrometric and bioinformatic processes. Once differences between variant E6 
interacting host proteins were identified, the potential effects of E6 on each interactor was 
investigated.  
Decades of research helped unravel what makes E6 capable of immortalizing 
primary human foreskin keratinocytes (PHFKs) without the presence of other HPV16 early 
or late genes. We have a better understanding of E6’s ability to activate and alter numerous 
molecular pathways such as: phosphatidylinositol-3-kinase (PI3K) and extracellular 
signal-regulated kinase/ mitogen-activated protein kinase (ERK/MAPK) (Reviewed in 
Vande Pol et al. 2013). However, the mechanisms underlying AAE6’s efficiency at the 
protein level to promote carcinogenesis compared to EPE6 continues to elude researchers. 
This thesis attempted to develop a method to effectively pull down HPV16 E6 oncoproteins 
along with interacting host proteins regardless of variant type. This method will be 
optimized to perform the pulldown, sample preparation (lysis, inhibitors etc.), MS analysis 
(MALDI vs. LC MS/MS) and utilization of bioinformatic systems to identify novel binders 





new PPIs, and significant advances in MS technologies ensured that data produced was 
accurate and meaningful (Berggård et al. 2007). Co-IP was conducted on retrovirally 
transduced primary human foreskin keratinocytes (PKFKs) possessing E6 protein linked 
to a HA tag developed by a previous member of our lab (Niccoli et al. 2012). PHFKs were 
appropriate because as the host keratinocyte differentiates, upregulation of viral genes 
increases, and production of viral and capsid proteins occurred. Eventually, the cell cycle 
in non-dividing cells restarts and dysregulated growth begins, resulting in cellular 
immortalization, a hallmark of cancer (Stanley 2010; Hanahan et al. 2011). HA-tagged E6 
proteins and their interacting protein partners were eluted using anti-HA tagged magnetic 
beads. SDS-PAGE electrophoresis and western blotting were used to visually confirm the 
presence of E6. As a control, the Co-IP was completed in tandem with PHFKs retrovirally 
transduced with only the HA tag.  
To identify the binding partners of the different E6 variants, our group collaborated 
with Dr. Hoyun Lee (Health Sciences North, Sudbury, ON) whom we have worked 
extensively with in the past to conduct the peptide mass fingerprinting analysis (Richard et 
al. 2010; Niccoli et al. 2012) and purchased LC MS/MS services from Harvard University 
because of their outstanding work on White et al. 2012. By developing this method, I was 
be able to identify potential differences in E6 host protein interactions. Identifying 
differences in PPI between each variant, it will be possible to unravel potential 
tumourigenic mechanisms between AAE6 (D2/D3) and EPE6 (A1) variants resulting in 






2 Materials and Methods 
As mentioned in Section 1.8. numerous methods were added, altered or removed 
throughout the duration of this thesis to optimize the pull-down of E6 along with associated 
binding partners by Co-IP. Section 2.1 discusses the methods for cell culture to prepare 
samples for downstream applications. The initial cell culture protocol (Section 2.8.1) was 
used for MALDI MS/MS trials at the Health Sciences North Research Institute (HSNRI) 
while the optimized cell culture protocol (Section 2.9.2) was used for optimization and LC 
MS/MS trials at Harvard University. The protocol for Co-immunoprecipitation varied 
based on three main characteristics: Lysis, IP and Elution. Initial protocols for the 
immunoprecipitation, 2-D electrophoresis, 1-D electrophoresis and Tryptic in-gel digestion 
were conducted for all trials at HSNRI using MALDI MS/MS while all optimized protocols 
for immunoprecipitation were conducted at the Thunder Bay Regional Health Research 
Institute (TBRHRI) for all LC MS/MS trials at Harvard University.   
 
2.1 Cell Lines 
As described in Niccoli et al. 2012, PHFKs from the same donor were used for all 
experiments. All PHFKs were transduced with one of the following: AAE6 (variant 
D2/D3) or EPE6 (variant A1). To successfully observe differences in virus host interactions 
between HPV16 E6 variants, PHFKs were retrovirally transduced with one of the 
following: hemagglutinin (HA) tag (PHFK-HA), PHFK’s transduced with carboxy 
terminus (C-terminus) HA-AAE6 (AAE6) and PHFK’s transduced with C-terminus HA-
EPE6 (EPE6). Transducing cells expressing the HA-tag, allows for specific 





the target protein was E6 and was tagged at the carboxy terminus with HA. The affinity 
tag was placed at the C-terminus because we wanted to reduce any disruption in 
interactions present at or near SNP sites for both AAE6 and EPE6. The consequence of 
placing an affinity tag at the carboxy terminus is the potential to disrupt PDZ interacting 
proteins (Personal communications with Dr. Elizabeth White). PHFK cells containing 
AAE6 or EPE6 vary in appearance from their primary cell counterparts (Figure 4). 
However, PHFK’s transduced with C-terminus HA-L83VE6 (L83V) were initially used 
for troubleshooting experiments as they express constant levels of E6. 
 
Figure 4 – Phase contrast images of AAE6 and EPE6 late passage samples and non-
transduced PHFK cell samples (PHFK and PHFK-HA). All cell samples are at 75-80 % 
confluency and as mentioned on the previous page. There is a visual difference between 
HPV16 E6 transduced cell lines and PHFK/PHFK-HA primary cells. E6 transduced cell 
lines are smaller and have little variation in their shape and size compared to non-HPV16 
E6 transduced PHFKs. Cells were imaged using an Axiovert 200 inverted phase-contrast 
microscope with halogen bulb on. Objective magnification was set to 10 X, photon of 1,0,4, 
and clear top filter. Exposure time for each image was 5 ms. Contrast of images were edited 
using Photoshop CC 2017 (Adobe, San Jose CA).  
 
2.2 Cell Culture 
All cells used in this thesis were cryogenically preserved in liquid nitrogen. To 
begin culturing cells for Co-IP and MS experiments, samples were removed from liquid 
nitrogen, thawed and placed in tissue culture flasks containing completed keratinocytes 
growth media (KGM, EpiLife medium completed with 60 µM calcium (EpiLife, Fisher 





Fisher Sci., Cat# SV3007901); and 1 X Human Keratinocyte Growth Hormone (HKGS, 
Fisher Sci., Cat# S0015)). Depending on the number of cells seeded, different flasks were 
used. For < 4 X 105 cells a sterile 25 cm2 FalconTM Tissue culture flasks (T25, Fisher Sci., 
Waltham MA, Cat# 10-126-10) containing 5 mL KGM was used. For 400 000 – 1 X 106 
cells, a sterile 75 cm2 FalconTM Tissue culture flasks (T75, Fisher Sci., Cat# 1368065) 
containing 11 mL of KGM was used. When seeding 1 million or more cells, a sterile 
NuncTM EasYFlaskTM 225 cm2 culture flasks (T225, Fisher Sci., Cat# 12-565-221) 
containing 33 mL of complete KGM was used. Cells were incubated at 37.0 °C in an 
atmosphere containing 5.0 % CO2 and monitored daily to ensure constant growth and 
samples were free of any possible contamination (Section 2.3). Every 48 hours, growth 
media was removed and replaced with fresh room temperature KGM. Once cells reached 
75-80 % confluency (Figure 4), KGM was removed and cells were treated with trypsin 
(Trypsin, Fisher Sci., Cat# SH3023602) and incubated for 10 minutes to allow all cells to 
detach from the flask. Trypsin neutralizing solution (TNS) (Cedarlane, Burlington ON, 
Cat# 080-100) was then added and cells were collected and centrifuged at 750 rpm for 5 
minutes to pellet cells. Cells were either collected to be cryopreserved for future 
experiments or reseeded into new flasks for subsequent pull-down experiments. Although 
cells typically proliferate better when reseeded into their original flasks, the seeding of cells 









2.3 Contamination Tests 
As mentioned in Section 2.2, cells were observed daily for potential contamination. 
Mycoplasma sp. unfortunately, is a common contaminant in cell cultures. Mycoplasma 
contamination could alter the physical and physiological characteristics of cells as well as 
reduce accuracy and reproducibility of MS results (Nikfarjam et al. 2012). It was of utmost 
importance to ensure no such contamination occurred. Since mycoplasma cannot be seen 
with typical light microscopes, 100 000 cells were seeded every second passage into a 
sterile 35 mm FalconTM tissue culture dish (Fisher Sci., Cat# CA25382-064) with 3 mL of 
complete KGM and one autoclaved cover slip (Fisher Sci., Cat# 12-550-15). Cells were 
cultured as described in Section 2.2 and once 75-80 % confluent, were incubated in 
Carnoy’s fixative (3 : 1 methanol to glacial acetic acid) twice (1st incubation – 5 minutes, 
2nd incubation – 10 minutes) and allowed to air dry. Cover slips were gently removed from 
the culture dish and placed cell side down on a clean microscope slide with 25 µL mounting 
medium containing 4’,6-diamidino-2-phenylindole (DAPI, Cedarlane, Burlington ON, 
Cat# H-1200). Slides were visualized and imaged (Figure 5) to confirm the presence or 
absence of mycoplasma.  
 
2.4 PCR 
Variants required confirmation of SNPs prior to use in any Co-IP or MS procedure 
to ensure no cross-contamination occurred across cell lines. As mentioned in Section 1.4 
there are six SNPs between the EP and AA variants. To confirm the presence of SNPs, 
polymerase chain reaction (PCR) was utilized similarly for all experiments. DNA 





Germany, Cat# 69504) 1 X 106 cells were thawed from -80 °C and resuspended in 200 µL 
sterile Dulbecco’s PBS (dPBS, Fisher Sci., Cat# SH3002802) with 20 µL proteinase K. 
Addition of proteinase K was used to remove proteins which may result in degradation of 
DNA. RNase A (4 µL of 100 mg/mL) was added to the suspension of cells followed by 
addition of 200 µL Buffer AL (contains guanidine hydrochloride). Samples were vortexed 
thoroughly for 1 minute and incubated at 56 °C for 10 minutes. Following incubation, 200 
µL of anhydrous ethyl alcohol was added to each sample and vortexed again for 1 minute. 
The solution containing DNA was pipetted into a DNeasy spin column and centrifuged for 
1 minute at 6 000 X g. Two wash solutions resuspended in anhydrous ethanol labelled 
AW1 and AW2 were prepared. Next, 500 µL of wash buffer AW1 was added to the spin 
column and centrifuged for 1 minute at 6 000 X g. The flow-through was discarded, 500 
µL of wash buffer AW2 was added to each sample and centrifuged for 3 minutes at 20 000 
X g. To remove any residual flow-through, the spin column was placed into a new 
collection tube and centrifuged once more for 1 minute at 20 000 X g. The spin column 
was placed into a new 1.5 mL microcentrifuge tube prior to the addition of 100 µL buffer 
AE. After addition of buffer AE, the sample was incubated at room temperature for 2 
minutes and centrifuged for 1 minute at 6000 X g. This elution step was done twice. Eluted 
DNA samples were pooled together and stored at 4 °C overnight labelled ‘template DNA’. 
DNA concentration and purity were measured using BioTek® Gen5TM software 
version 2.06. Master mixes for PCR contained the following: 1 U of Platinum Taq, 1 X 
PCR buffer, 1 mM MgCl2 (Taq, PCR buffer and MgCl2 came from same package, Fisher 





of both forward and reverse primers (Millipore Sigma). The sequences for the forward and 
reverse primers are shown beneath figure 5.  
 
Figure 5 – Fluorescence microscopy image of E6 variant nuclei stained with 4’,6-
diamidino-2-phenylindole (DAPI). Cell samples in a) are AAE6 transduced PHFK cells 
that are mycoplasma free and no other signs of contamination are present. The absence of 
granular debris that is stained blue with DAPI indicates no mycoplasma contamination. In 
image b), a previous example from our laboratory shows EPE6 transduced cells with 
significant mycoplasma contamination surrounding most nuclei. Mycoplasma appears as 
small granular sized particles at 40 X magnification. Images visualized with an Axiovert 
200 fluorescence inverted microscope at 40 X with an exposure of 10 ms. 
 
Forward Primer (Initial Concentration 100 µM): 5’ – CAATGTTTCAGGACCCACA	–	3’	
Reverse	Primer	(Initial Concentration 100 µM): 5’ – GTTTCTCTACGTGTTCTTGA	–	3’	
 
Into the master mix was added 100 ng of template DNA and filled to a final volume 
of 25 µL using nuclease free dH2O (General Electric Healthcare Life Sciences, Mississauga 
ON, Cat# SH3053802). Samples were run using an Applied Biosciences 2720 Thermal 
Cycler (ThermoFisher Sci., Cat# 4359659) using the cycles outlined in Table 2. Once the 
thermocycler entered the ‘hold’ step, 10 µL of post-PCR product was immediately run on 
a 2 % PCR certified agarose gel (BioRad, Cat# 161-3104) containing 0.01 % (v/v) 10 000 
X  GelRed Nucleic Acid gel stain (Biotium, Fremont CA, Cat# 41003) at a constant voltage 





Post electrophoresis, the gel was imaged using UVP imager for 0.1 seconds, and 0.15 
seconds with 1 X 1 binning. 
Table 2 – Procedure for Touchdown PCR for the identification of SNPs for all HPV16 E6 
variants. The protocol was developed by a previous member of the lab and serves as a 
general template for touchdown PCR protocols. This protocol contains the same steps as a 
traditional PCR; however, the annealing step occurs at a higher temperature than the 
greatest melting point of the primer and slowly decreases until several degrees below the 
lowest melting point of the primers. 
Number of Cycles Cycle Temperature (°C) Duration (Minutes) 
1 Polymerization 94 4 
40 - (* Annealing 
temperature of 64 °C 
(cycle 1) decreased by 1 
°C per cycle until 48 °C) 
Denaturation 94 1 
Annealing* 64 1 
Extension 72 2 
1 Final Extension 72 7 
1 Hold 4 ∞ 
  
Once the identified bands were in detected by electrophoresis (Supplemental Figure 
S1) purification of post-PCR product could take place. This was done using a QIAquick 
PCR Purification Kit (Qiagen, Cat# 28104). The remaining 15 µL of PCR product was 
combined with 75 µL of buffer PB and mixed by pulse vortexing sample before placing 
into a QIAquick spin column. The Spin column was inserted into a 2 mL collection tube 
and incubated at room temperature for 1 minute before centrifuging at 17 900 X g for 1 
minute. Once flow-through was discarded, 750 µL of buffer PE containing anhydrous 
ethanol was added to the spin column and centrifuged at 17 900 X g for 1 minute. To 
remove any residual ethanol, a subsequent centrifugation was done for 1 minute. The spin 
column was then placed into a new 1.5 mL microcentrifuge tube and incubated for 2 
minutes at room temperature with 30 µL of elution buffer (Buffer EB) added onto the 
membrane. After incubation, the DNA was eluted by centrifuging for 1 minute at 17 900 





15 minutes at a constant voltage of 100 V. The image was taken using the same methods 
as the unpurified post-PCR product. An image of the gel can be seen in supplemental data 
(Figure S2). The purified samples were then sent to the Lakehead University Paleo DNA 
laboratory for sequencing and SNPs were confirmed using MEGA7 (Kumar et al. 2016) 
 
2.5 Cell Lysis 
After collected cells were stored at -80 °C for up to 24 hours, the samples underwent 
protein extraction. Protein extraction begins with cell lysis using Mammalian Protein 
Extract Reagent (MPER, Thermo Sci., Waltham MA, Cat# 78501),  supplemented with 1 
X HALTTM phosphatase inhibitor cocktail (ThermoFisher Sci., Cat# 78428), 1 X cOmplete 
EDTA free protease inhibitor (Millipore Sigma., Cat# 4693159001), 1 mM 
phenylmethylsulfonyl fluoride (PMSF, ThermoFisher Sci., Cat# 36978) and 150 mM NaCl 
(Fisher Sci., Cat# BP358212). To each pellet, 3 mL of ice-cold supplemented lysis buffer 
was added. Gently using a pipette, the frozen cell pellet was resuspended in the lysis buffer 
and immediately placed on a tilting table on ice for 30 minutes. After incubation, the lysed 
cells were centrifuged twice at 14 000 X g for 15 minutes at a temperature of 4 °C. In 
between each centrifugation, the supernatant was carefully removed ensuring to not disturb 
the pellet and placed in two new clean low protein binding micro centrifuge tube (Fisher 
Sci., Cat# PI88379). After centrifugation, 5 µL of the resulting supernatant was diluted in 
45 µL of ultrapure ddH2O for quantification of protein (Section 2.6). The remaining 







2.6 Bradford Assay 
Magnetic beads have a limited capacity to bind target proteins which varies from 
product to product. The PierceTM Anti HA-Magnetic Beads (Fisher Sci., Cat# PI88836) 
have a working range from 500 µg to 1 mg of input protein per 25 µL of beads. For this 
reason, prior to incubating lysed cells on anti-HA magnetic beads, the concentrations and 
protein quantity of samples needed to be determined. This was done using either the 
PierceTM bicinchoninic acid (BCA) Protein Assay (Fisher Sci., Cat# PI23225) or the 
Detergent Compatible Protein Assay (DC Protein Assay Reagents Package, Bio-Rad 
Laboratories Inc., Hercules CA. Cat# 5000116). The BCA assay is a highly sensitive 
method for quantifying protein concentrations through the reduction of Cu2+ to Cu1+ within 
an alkaline medium (Smith et. al. 1985). Bovine serum albumin (BSA) standards were 
prepared with ratios according to the manufacturer’s protocol. A total volume of 6 mL 
working reagent (WR) was prepared using 50 : 1 ratio of Reagent A (sodium carbonate, 
sodium bicarbonate, bicinchroninic acid and sodium tartrate in a 0.1 M sodium hydroxide 
solution) and B (4 % (v/v) cupric sulfate solution). Into a 96 well plate, 25 µL of protein 
extract and BCA standard was added to each well and immediately after, 200 µL of 
working reagent was added to each well and incubated for 30 minutes at 37 °C. The colour 
change is caused by the chelation of one Cu2+ to two molecules of BCA (Smith et. al. 1985). 
The assay was done with 1 : 10 diluted samples in MPER. Once again 25 µL of samples 
and standards were combined with 200 µL of WR and incubated for 30 minutes at 37 °C. 
Incubated samples were placed in a Synergy HTX Multi-Mode Reader (BioTek 





at 562 nm using BioTek Gen5 (BioTek Instruments, Inc., Cat# S1LFTA-1340001) 
software.  
Gen 5 is a microplate reading software developed by BioTek Instruments Inc.TM 
that permits the analysis of nucleic acids, and quantification of protein samples. Gen 5 
software was used to generate a linear curve of protein standards based on their absorbances 
from the BCA assay. A linear slope equation was calculated by protein standard absorbance 
values and presented in the form “Y=mX+B”. The values for each variable were as follows: 
Y – sample/standard absorbance, X – Protein concentration (µg/mL), A – slope of curve 
generated, B – Y-intercept. By inserting the calculated absorbances (‘Y’) for each sample, 
the concentration was determined. This method of protein quantification was used for 
initial pull-down attempts at the Health Sciences North Research Institute. 
The DC Assay is an alternative method to quantify proteins using a reaction similar 
to the Lowry assay. The Lowry assay is based on a two-step reaction where proteins 
tyrosine, tryptophan as well as cystine, cysteine and histidine initially react with copper in 
an alkaline (pH >7.0) solution (Lowry et al. 1951). The DC assay uses a proprietary 
alkaline copper tartate solution (Reagent A) to treat proteins with copper. In protein 
solutions containing detergents such as Tween 20, sodium dodecyl sulphate (SDS) or 
nonidet P-40, 10 µL of surfactant solution containing SDS must be added to every 500 µL 
of reagent A to create reagent A’. Copper-treated proteins obtain their maximum colour 
through via reduction of copper bound to proteins (Lowry et al. 1951). The DC assay 
utilizes a proprietary folin reagent (reagent B) to perform this reducing step. In a 96-well 
plate, 5 µL of dilute extracted protein and known bovine serum albumin protein standards 





A’ was prepared by combining 10 µL of reagent S and 500 µL of reagent A in a separate 
1.5 mL microcentrifuge tube. For each well containing either protein extract or standard, 
25 µL of reagent A’ was added. Finally, 200 µL of reagent B was added to each well and 
the samples were incubated at room temperature for 15 minutes. After incubating, the 96-
well plate was placed into a PowerWaveXSTM absorbance reader (BioTek Instruments, 
Inc.) The final protocol utilized the DC Assay as it was accurate and easily accessible 
within our laboratory. 
KC Junior is a legacy software provided by BioTek upon purchase of the 
PowerWaveXSTM. This software automatically calculates the concentration of proteins by 
analyzing the absorbance at a wavelength of 750 nm. Similarly, to Gen5 software, a linear 
concentration curve is generated by known protein standards and any outliers were 
removed. Unlike the Gen5 software, there was no need to calculate the equation of the 
curve because the concentration of protein was automatically determined.   
 
2.7 Western Blotting 
The following antibodies: anti-HA 1 : 1000 (monoclonal mouse (mAB), Abcam [HA, 
C5], Cat# ab181818, 1 mg/mL), anti-E6AP 1 : 1000 (polyclonal rabbit (pAB) [H-182], 
Santa Cruz Antibodies, Dallas TX, Cat# SC-25509, 200 µg/mL), anti-P53 1 : 500 and 1 : 
1000 (monoclonal rabbit (RabmAB) [E26], Abcam, Cambridge UK, Cat# ab32389), anti-
HA conjugated to horseradish peroxidase (HRP) 1 : 1000 (HA-HRP, rat mAB [3F10], 
Roche, Cat# 12013819001, 25 U/mL), anti-actin 1 : 1000 (goat polyclonal (pAB) [I-19], 
Santa Cruz Antibodies, Dallas TX, Cat# SC-1616, 100 µg/mL), anti-AIP2 (WWP2) 1 : 





antibodies: anti-mouse conjugated to HRP 1 : 2000 (Jackson Immunoresearch Laboratories 
Inc., West Grove, PA, Cat# 115-035-062), anti-rabbit conjugated to HRP 1 : 1000 
(ThermoFisher Sci., Cat# SA1-200, 40 µg/mL), anti-goat to HRP 1 : 1000 (Jackson 
Immunoresearch Laboratories Inc., Cat# 705-035-147) were used. 
To each sample, 6 X SDS loading was added until a final concentration of 1 X SDS 
was reached. Samples were boiled for 10 minutes to complete protein reduction. Reduced 
samples were run on a mini 4-12% gradient gel (Bio-Rad, Cat# 4561094) for 1 hour and 
15 minutes at a constant voltage of 120 V. Fifteen minutes prior to the completion of 
electrophoresis, a polyvinyl difluoride membrane (PVDF, Fisher Sci., Cat# PI88518) was 
cut to similar dimensions as the mini gel. Once the gel completed the run, it was carefully 
removed from the casing and immediately placed in ice-cold 1 X transfer buffer (100 mL 
10 X transfer buffer (14.41 g glycine, 3.03 g Tris base, 200 mL methanol (Fisher Sci., Cat# 
A454-4), 700 dH2O). At the same time, the PVDF membrane was transferred into ice-cold 
1 X transfer buffer in a separate container and both the gel and membrane were incubated 
for 10 minutes. After incubation in transfer buffer, the gel and membrane were placed 
together in between blotting paper to assemble a transfer sandwich and inserted into an ice-
cold tank containing 1 X transfer buffer continuously mixed with a magnetic stir bar. The 
protein was transferred to the membrane for 1 hour at a constant voltage of 100 V and 
maximum amperage of 0.35 A.  
After the transfer, the membrane was removed from the sandwich and incubated for 
10 minutes with 0.05% TBS-T at room temperature. During the incubation, blocking buffer 
was prepared (5% (w/v) powdered skim milk (Safeway Pleasanton CA) in 0.05% TBS-T). 





containing 15 mL of prepared blocking buffer. The sample was incubated on a rotating 
rack for 1 hour at room temperature before being transferred into another 50 mL conical 
cube containing primary antibody in 5 mL of blocking buffer. Once placed in primary 
antibody, the sample was stored on a rotating rack overnight at 4 °C.  
The next day, samples were removed from primary antibody and washed three times 
for 5 minutes with 0.05% TBS-T at room temperature. If the primary antibody was not 
conjugated to HRP, the sample was placed in another 50 mL tube containing secondary 
antibody in 5 mL of blocking buffer for 1 hour at room temperature. After the final 
incubation in secondary antibody, the samples were washed once again three times in 
0.05% TBS-T for 5 minutes. Immediately after the final wash, excess TBS-T was removed 
by gently placing on a dry paper towel and then placing on plastic wrap. To produce 
chemiluminescence, samples were incubated in equal volumes of peroxide reagent and 
luminol/enhancer reagent (Clarity Western ECL Substrate, BioRad, Cat# 1705061) for 1 
minute. Immediately following incubation, the samples were imaged at 1 X 1 binning for 
0.1 seconds, 1, 5, and 20-minute intervals. 
 
2.8 MS1 Protocol 
2.8.1 Cell culture 
All primary cells (PHFK, PHFK-HA) and cell lines (AAE6-Late, EPE6-Late) were 
thawed from liquid nitrogen and seeded (600 000 cells) into sterile T75 flasks containing 
11 mL of complete KGM. Cells were incubated in the same manner as described in Section 
2.2.  Once cells reached 75-80 % confluency (Figure 4), KGM was removed and cells were 





from the base of the flask, trypsin was neutralized with TNS and centrifuged for 5 minutes 
at a speed of 750 rpm and temperature of 4 °C. Post centrifugation, cells were resuspended 
in 2 mL of complete KGM and 500 000 cells were collected for storage in liquid nitrogen 
while 1 800 000 cells were seeded equally (600 000 cells per flask) into three new T75 
flasks containing 11 mL of complete KGM. Reseeded cells were cultured in the same 
manner as above and centrifuged at the same speed for the same duration. However, instead 
of resuspending cells in complete KGM, 2 mL of dPBS was used to resuspend cells and 
600 000 cells were reseeded in one new T75 while remaining cells were centrifuged again 
as described above. After centrifugation, cells had dPBS removed using suction and flash 
frozen using liquid nitrogen and stored at -80 °C for up to one month for subsequent Co-
IP experiments.   
2.8.2 Cell Lysis 
Collected cells for co-immunoprecipitation (Co-IP) were stored at -80 °C prior to 
use. Immediately after cells were removed from -80 °C, mammalian protein extract reagent 
(MPER, Thermo Sci., Waltham MA, Cat# 78501) supplemented with protease inhibitors 
(1 X protease inhibitor cocktail (PIC, Millipore Sigma, Burlington MA, Cat# P8340-1 ml)), 
phosphatase inhibitors (2 mM Na3VO4 (Millipore Sigma, Cat# 22,059-0), 50 mM NaF 
(Millipore Sigma, Cat# S-7920), and 1 mM phenylmethylsulfonyl fluoride (PMSF, 
ThermoFisher Sci., Cat# 36978)) was added and gently mixed to increase cell lysis 
efficiency. Samples were incubated on ice with constant mixing on an orbital platform (The 
Belly Dancer, IBI Scientific, Dubuque IA, Cat# BDRAA115S) for 10 minutes and 





stored at 4 °C for 30 minutes during quantification of protein concentration (Section 2.6) 
prior to incubation on magnetic beads.  
2.8.3 Co-IP 
Co-immunoprecipitation of beads will allow E6 to be selectively pulled down along 
with interacting proteins by binding of HA tag to the antibodies on a solid support (Section 
1.6). Prior to binding of E6 and associated binding partners to Pierce anti-HA magnetic 
beads (Anti-HA magnetic bead, Fisher Sci., Cat# PI88836L), 25 µL of beads were pre-
rinsed by incubating once in 125 µL of room temperature tris buffered saline with 0.05 % 
Tween - 20 (0.05% TBS-T, 3.03 g Tris base (Fisher Sci., Cat# BP1521), 8.76 g NaCl 
(Fisher Sci., Cat# BP358212), pH 7.5 in 1 L of dH2O and 0.05 % Tween - 20 (Fisher Sci., 
Cat# BP337500)) for 30-seconds followed by a 1-minute incubation at room temperature 
using 1 mL of 0.05 % TBS-T. Following cleaning of beads, 600 μg of cell lysate was added 
to anti-HA magnetic beads, resuspended and incubated overnight on a rotating rack at 4 
°C. Beads were gently washed with room temperature 0.05 % TBS-T 3 times for 30 
seconds then eluted by incubation at 95 °C for 10 minutes in 1 X SDS loading dye with 
dithiothreitol (DTT, Fisher Sci., Cat# BP172-25) for trials using 1-D electrophoresis or in 
8 M urea (BioRad, Cat# 161-0730) containing 400 µL Triton X-100 (4 % (v/v), United 
States Biological, Salem MA, Cat# T8655) 50 mM DTT and 0.0002 % bromophenol blue 
(Fisher Sci., Cat# FLB3925) for trials attempting to use 2-D electrophoresis. Eluted 








2.8.4 2-D electrophoresis 
Isoelectric focusing (IEF) has the potential to increase separation of pulled down 
proteins. This is done by first separating samples by their isoelectric point (PI) and then by 
their molecular weight. To prepare immobilized protein gradient (IPG) strips, six 
Immobiline DryStrip pH 3-10, 13 cm strips (General Electric Healthcare Life Sciences, 
Cat# 17600114) were trimmed to fit within the Protean IEF System cell (Bio-Rad 
Laboratories Inc., Cat# 165-4000). Prior to placement of IPG strips on IEF trays, eluted 
Co-IP samples were thawed from -80 °C and spread evenly into each IEF tray well. 25 µL 
of all eluted samples were added into individual wells. Rehydration solution containing 
275 µL of 2D elution buffer, and 15 µL of Bio-Lyte 3/10 40 % (Bio-Rad Laboratories Inc., 
Cat# 165-1112) was applied on top of each well. IPG strips were carefully placed agarose 
side down such that the anode and cathode touched both sides of the sample. Any air 
bubbles underneath IPD strips were removed by applying gentle pressure to the plastic side 
of the gel. Finally, each strip within the wells was covered with 2 mL of mineral oil (Plus 
One dry strip cover fluid, General Electric Healthcare Life Sciences, Cat# 17-1335-01). 
The plastic tray cover was placed on the IEF tray and samples were left to incubate at room 
temperature overnight.  
The following day, the IEF tray containing now rehydrated IPG strips with samples 
were placed onto the Protean IEF System. Sterile absorbent paper strips were dipped in 
MilliQ water and placed onto each anode and cathode that was in contact with an IPG strip. 
The paper was used to absorb salts that may accumulate at the electrodes. IEF was 
completed in several steps as instructed by the manufacturer (Table 3). The stepwise 





denaturing of target proteins caused by minute concentrations of salts and ampholytes 
within the strip (Rabilloud et al. 2011). The extended voltage at 8 000 V was done to ensure 
finite focusing of all proteins within the sample containing an isoelectric point (PI) between 
3 and 10. The final hold at 50 V was used to maintain pH gradient. Blot paper was changed 
every hour to maximize salt removal and improve protein migration.  
Table 3 – Steps used during IEF of eluted samples. Gradual steps to increase the voltage 
were used to ensure that minimal heat was generated. Total runtime was 7 hours and 40 
minutes. 
Step Voltage (V) Increase method Time (hours) 
1 500 Step and Hold 1 
2 1 000 Gradient 1 
3 8 000 Gradient 3 
4 8 000 Step and Hold 2 & 40 minutes 
5 50 (hold) Hold 99 
  
SDS-PAGE gels (10 %) were cast and stored at 4 °C overnight until ready for use. 
1 % Overlay agarose was produced using 25 mL dH2O, 0.25 g agarose (Fisher Sci., Cat# 
BP161-100) and 0.01 g of Pierce Coomassie Brilliant Blue R-250 (Fisher Sci., Cat# 
PI20278). IPG strips were placed on the top of each gel and run for 2 hours at 300 V. Gels 
were subsequently stained using Thermo Scientific PierceTM Silver Stain Kit (Fisher Sci., 
Cat# PI24612). To silver stain PAGE gels, they first were washed twice in 100 mL of 
MilliQ water for 5 minutes. Next, gels were fixed in a 30 : 10 ethanol to acetic acid solution 
with two 15-minute incubations. Post fixation, gels were washed in 10 % ethanol twice for 
5 minutes and twice for 5 minutes using MilliQ water to remove any residual ethanol or 
fixative. A sensitizing working solution containing 1 : 500 silver stain sensitizer to 
autoclaved water was incubated on gels for exactly 1 minute. The sensitizing solution 
increases the proteins ability to bind silver ions (Steinberg, 2009). Proteins were 





The development of silver stained gels is completed through the reduction of silver ions 
bound to proteins to metallic silver that is insoluble (Steinberg, 2009). Gels were developed 
by incubating in working developer solution (500 µL enhancer with 25 mL developer) 
using extended times as needed until desired bands appeared. To prevent over developing 
of silver stained proteins, samples were placed in a 5 % (v/v) acetic acid stop solution. Gels 
were imaged using a charge coupled device (CCD) camera as needed (FluorChemQ, 
Proteinsimple, San Jose CA, Cat# 92-14095-00). It should be noted that the process of 2-
D electrophoresis was not continued following initial attempt as it was not an optimal 
method for downstream proteomic applications.  
2.8.5 1-D SDS-PAGE Electrophoresis 
Since 2-D electrophoresis did not successfully allow for efficient protein 
separation, 1-D electrophoresis was attempted. Eluted proteins were loaded into mini 12 % 
polyacrylamide gels with Precision Plus Protein Standard Dual Colour Ladder (Bio-Rad 
Laboratories Inc., Cat# 161-0374) and ran for 1 hour and 15 minutes at a constant voltage 
of 120 V. Gels were incubated twice for 30 minutes at room temperature with gentle mixing 
using a fixing solution (50 % (v/v) methanol and 7 % (v/v) acetic acid). Immediately 
following protein fixation, gels were stained overnight using InvitrogenTM Molecular 
ProbesTM SYPROTM Ruby Protein Gel Stain (Fisher Sci., Cat# S12000). SYPRO Ruby is 
a fluorescent stain with similar sensitivity to silver staining methods that provides increased 
downstream compatibility for MS analysis. Similarly, to coomassie colourimetric stains, 
the proteins non-covalently interact with chelate ruthenium (II) resulting in a luminescent 
stain that can be excited with ultraviolet (UV) light (Lauber et al. 2001; Steinberg 2009). 





15 minutes. The gels were then imaged using the FluorChemQ imager (Proteinsimple, San 
Jose CA, Cat# 92-14095-00) in the auto exposure and contrast setting with an excitation 
wavelength of 280 nm. Gel bands were cut using sterile Graham Field Single-Use Scalpels 
(Fisher Sci., Cat# 08-927-5A) on an ultraviolet (UV) transilluminator table and placed into 
autoclaved 1.5 mL microcentrifuge tubes. 1-D electrophoresis was utilized only for 
MALDI MS attempts since we could get improved identification of proteins by keeping 
the entire protein sample in elution buffer and not be limited by well size.  
2.8.6 MALDI MS 
Samples were digested using the PierceTM In-Gel Tryptic Digestion Kit 
(ThermoFisher Sci., Waltham MA, Cat# PI89871). Before digestion, SYPRO stain was 
removed from gel slices by adding 200 µL of destaining solution (80 mg of ammonium 
bicarbonate in 40 mL 50 : 50 mixture of acetonitrile and ultrapure water) to each 1.5 mL tube 
and incubating twice for 30 minutes at 37 °C. As digestion solution (25 mM ammonium 
bicarbonate in ultrapure water) was able to be stored at 4 °C for up to two months, 15 mL 
was prepared. Next, gel slices were reduced in 30 µL of reducing buffer (3.3 µL tris[2-
carboxyethyl]phosphine (TCEP) in 30 µL of digestion buffer per sample) and incubated 
for 10 minutes at 60 °C. The purpose of the reducing step by TCEP is to break disulfide 
bonds originally formed when cysteine is oxidized to form cystine (Muskal et al. 1990; 
Gundry et al. 2010). A 5 X alkylation solution (500 mM Iodoacetamide) was prepared and 
combined with digestion buffer at a 4 : 1 ratio immediately prior to the alkylation of 
reduced gel slices. To the cooled slices, 30 µL of alkylation buffer was added and incubated 
in the dark at room temperature for 1 hour. Alkylation of proteins prevents free sulfhydryl 





(Gundry et al. 2010). Post alkylation of samples, slices were washed two times with 200 
µL of destaining buffer for 15 minutes at 37 °C. Gel slices were dehydrated by incubating 
in 50 µL of acetonitrile for 15 minutes at room temperature and air dried for 10 minutes. 
Trypsin working solution was prepared by ten-fold dilution in ultrapure water. Immediately 
prior to digestion, trypsin working solution was added to digestion buffer to create a 10 
ng/µL activated trypsin solution. Gel pieces were swelled by submerging in activated 
trypsin and incubated at room temperature for 15 minutes. An additional 25 µL of digestion 
buffer was added to each sample and incubated at 30 °C overnight. The resulting digestion 
mixtures were placed in a clean 1.5 mL tube and prepared for analysis with MALDI MS.   
Each spot on the MALDI plate had 1 µL of PierceTM 0.1 % Trifluoroacetic acid 
(v/v) (ThermoFisher Sci., Waltham MA, Cat# PI85172) added as the matrix for samples. 
1 µL of digested sample was added to each well ensuring to record which band was present 
at each spot on the metal plate. Plates were allowed to air dry prior to placement in the 
mass spectrometer. Metal plates were inserted into the vacuum chamber of a MicroMx 
MALDI TOF mass spectrometer (Waters, Milford MA, Cat# 201000178). Samples were 
run by Dr. James Knockleby and each sample had a minimum of 100 tandem MS/MS 
spectra obtained prior to continuing to the next sample. Raw spectra files were saved to a 
USB drive. Peak lists along with their respective intensities were saved in the form of a 
Microsoft Office word document.  
 






2.9 LC MS/MS 
2.9.1 Cell Culture 
Similarly, to Section 2.8.1, PHFK cells with or without transduced viral DNA 
genomes were used for LC MS/MS analysis. The following changes were made to 
accommodate increased cell production. 1.5 X 106 cells of each of the following: PHFK-
HA, AAE6, EPE6 were seeded into sterile NuncTM EasYFlaskTM 225 cm2 culture flasks 
containing 33 mL KGM. Media changes occurred every 48 hours as described previously 
while trypsinizing, pelleting and resuspension of pellets were done in the same manner as 
Section 2.8.1 for each flask with a volume increase by a factor of 3 for KGM and a factor 
of two for trypsin and TNS (33 mL KGM, 6 mL trypsin and 18 mL TNS). After neutralizing 
trypsin activity, the cells were centrifuged in the same manner as Section 2.8.1, 
resuspended in 2 mL of complete KGM and seeded 50 % of each sample into two new 
T225 flasks. By expanding from one to 2 confluent T225 flasks, we had enough cells to 
seed 1.5 million cells into 9 new T225’s (13.5 X 106 cells total). Cells would be once again 
grown until 75-80 % confluent as previously described and harvested using the methods 
described above. Once cells were centrifuged, they were resuspended in 2 mL of complete 
KGM.  For each sample, 1.5 X 106 cells were seeded into nine sterile T225 containing 33 
mL of fresh KGM. Since continued cell growth for subsequent pull-downs was necessary, 
one of the 9 T225 flasks were used for another expansion into two T225’s then further 
expanded into 9 T225 flasks. Once cells seeded for pull-downs were 75-80 % confluent, 
four flasks from each sample were treated for 4 hours with 10 mL of fresh KGM containing 
30 µM MG132 proteasome inhibitor in DMSO (MG132, Millipore Sigma., Cat# 474791-





(vehicle) in 10 mL of KGM. Following treatment, cells were collected as described above 
and stored in -80 °C overnight. 
2.9.3 Cell Lysis 
After collected cells were stored at -80 °C for up to 24 hours, the samples were 
lysed with the following changes. The composition of the lysis buffer changed to include 
MPER supplemented with 1 X HALTTM phosphatase inhibitor cocktail (ThermoFisher 
Sci., Cat# 78428), 1 X cOmplete EDTA free protease inhibitor (Millipore Sigma., Cat# 
4693159001), 1 mM PMSF and 150 mM NaCl (Fisher Sci., Cat# BP358212).  Each frozen 
pellet had 3 mL of ice-cold supplemented lysis buffer added. Gently using a pipette, the 
cell pellet was resuspended in lysis buffer and immediately placed on a tilting table on ice 
for 30 minutes. After incubation, the lysed cells were separated into two 2 mL low protein 
binding microcentrifuge tubes (Fisher Sci., Cat# PI88379). Samples were centrifuged twice 
at 14 000 X g for 15 minutes at a temperature of 4 °C. In between each centrifugation, the 
supernatant was carefully removed ensuring to not disturb the pellet and placed in new 
clean low protein binding microcentrifuge tubes. After centrifugation, 5 µL of the resulting 
supernatant was diluted in 45 µL of ultrapure ddH2O for quantification (Section 2.6). The 
remaining extracted protein was stored at 4 °C for 30 minutes during quantification to 
reduce any protein degradation.  
2.9.4 Co-IP 
Co-IP was adjusted to allow samples to be eluted in a MS-compatible buffer at a 
high enough concentration to allow for identification, reduce leeching of antibodies from 
solid supports and maintain stability of proteins post elution. anti-HA magnetic beads were 





in Section 2.9.3) in sterile 15 mL conical tubes (Fisher Sci., Cat# 1495949B) followed by 
incubation on magnetic stands for 2 minutes and subsequent removal of supernatant. For 
each MG132 sample after beads were washed, 4 mg of extracted protein was loaded onto 
80 µL of anti-HA magnetic beads and incubated on a rotating rack overnight at 4 °C. As 
the volume required to load 4 mg of protein onto the beads exceeded the volume capacity 
of the tubes, two aliquots containing 2 mg of protein and 20 µL of beads were used instead. 
Post-overnight incubation, the unbound protein was removed by incubating the sample on 
a magnetic stand for 4 minutes on ice and then carefully pipetting the supernatant. Using 1 
mL ice cold supplemented lysis buffer without inhibitors, beads were washed three times 
for 5 minutes on a rotating rack at 4 °C. To remove all detergents and inhibitors, samples 
were subsequently washed with 1 mL sterile filtered 1 X PBS three times for 5 minutes on 
a rotating rack at 4 °C. In between all washes, samples were incubated on a magnetic stand 
for 2 minutes prior to removal of supernatant. This prevented aspiration of beads from 
tubes resulting in loss of sample. To elute proteins, samples were pooled together and 
incubated for 10 minutes in 100 µL 0.2 M glycine (Fisher Sci., Cat# BP3815) pH buffered 
to 2.5 at room temperature. After incubation in elution buffer, samples were placed on 
magnetic stands for 4 minutes and eluate was placed into a new 2 mL microcentrifuge tube. 
Immediately after elution, samples were neutralized using 12 µL of 1 M Tris-HCl (pH 7.5). 
Thirty µL of eluted samples were reduced using 7.5 µL 6 X SDS loading dye with DTT 
and heated at 95 °C for 10 minutes. All samples were then stored at -80 °C prior to western 







2.9.5 LC MS/MS by Harvard Mass Spectrometry and Proteomics Facility (HMSPF) 
Upon arrival at HMSPF, samples were reduced, alkylated and digested in 
preparation of LC MS/MS analysis. Similarly, to MALDI MS/MS sample preparation 
(Section 2.8.6) TCEP was used to reduce samples. To reduce samples using TCEP, 20 µL 
of each sample, 2.0 µL of 20 mM TCEP (Millipore Sigma., Cat# 75259-1G) in 50 mM 
triethylammonium bicarbonate [pH 8.0] (TEAB, Millipore Sigma., Cat# T7408) buffer was 
added. Samples were incubated at 37 °C for 1 hour and subsequently cooled to room 
temperature vortexed and pulse centrifuged to ensure samples remained at the bottom of 
each tube. Next, 2.2 µL of freshly prepared 40 mM iodoacetamide (Millipore Sigma., Cat# 
I1149-5G) in 50 mM TEAB was added to each sample for alkylation. Samples with added 
iodoacetamide were covered with tin foil and incubated at room temperature for 1 hour. 
Trypsin (1 : 50-1 : 100 [w/w], Promega Corp., Madison WI, Cat# V5111) was then added 
and incubated at 37 °C for 16 hours overnight. After incubation, samples had 1 µL of 
formic acid (Millipore Sigma., Cat# 56302-50ML) thoroughly vortexed and placed into a 
nanoACQUITY ultra performance liquid chromatography (UPLC) system (Waters, Cat# 
WTF-ARC-2998) to begin LC MS/MS protein identification. The mass spectrometer used 
for all LC MS/MS tests was an Orbitrap EliteTM Hybrid Ion Trap Orbitrap Mass 
Spectrometer (ThermoFisher Sci., Cat# IQLAAEGAAPFADBMAZQ).  
After each sample was placed into the mass spectrometer the spectra obtained were 
input into Proteome Discoverer version: 2.4.0.292. A complete description of the workflow 
used at HMSPF can be found in Supplemental Data S3 and S4. Three databases were used 
for identification of proteins: Uniprot Human Proteome Database; a custom curated 





for HPV16 E6 (AAE6 and EPE6). Proteins were identified and emailed in the form of a 
heatmap within Microsoft Excel.  
 
Figure 7 – Overview of main steps in MS2 protocol. 
 
2.10 Identification of Proteins for MALDI MS/MS 
2.10.1 MALDI MS/MS proteins using Peptide Mass Fingerprinting 
Generated spectra peak lists from all MALDI MS/MS trials were entered into the 
Mascot peptide Mass Fingerprinting search (Matric Science Inc. Boston MA). Search 
parameters can be seen in Figure 8. Peak lists were entered into the query entry location 
(Figure 8) and searched for matching proteins within the contaminant database. All 
proteins found were downloaded as a .CSV file and added to the list of proteins found for 
the respective samples. All unmatched peptides were then searched once again for further 
contaminants in the cRAP database curated by the Global Proteome Machine using 
UNIPROT protein sequences. Once again, all proteins found were placed into the same 
.CSV file and unmatched peptides were searched for a third time in the NCBI database. All 
peak lists were analyzed in this manner and compiled into three separate trials for all six 
samples.  
2.10.2 Filtering of protein and peptide results from Mascot 
Using Microsoft Excel, Repeated proteins were removed for each sample using the 
“IF(COUNTIF)” function (Figure 9). Once repeated peptides were removed from each 
sample, all samples were compiled together, and ascension numbers were compared to 





using the “IF(COUNTIF)” function. All proteins unique to PHFK in each sample 
proceeded to undergo several comparisons. First Individual trials for late passages of AAE6 
and EPE6 were compared for unique and common proteins using the “IF(COUNTIF)” 
function. Unique proteins for all trials for each comparison (i.e. unique proteins from trial 
1,2 and 3, for late AAE6 and late EPE6 comparison) were compiled and used for analysis 
in several databases.  
2.10.3 Biological process of unique proteins in Panther DB 
The Protein Analysis Through Evolutionary Relationships (PANTHER) is a 
database containing evolution of gene function and pathway relationships (Mi et al. 2013). 
Ascension numbers of identified proteins post filtering were entered into the manual search 
section separated by a space and analyzed for Homo sapiens gene functional classifications. 
This search was conducted for all three replicates of: AAE6 Late, EPE6 Late during 
MALDI MS/MS analysis and the first replicate of LC MS/MS identified proteins (Section 
2.9.6).  
2.10.4 Reactome Pathway Analysis 
Reactome is a public database that enables researchers to cellular processes at the 
molecular level for over 50 % of human protein-coding genes. Unlike PANTHER (Section 
2.5.3), which analyzes evolutionary relationships for gene functions and pathway 
relationships, Reactome generates systematically described molecular pathways allowing 
for a deeper understanding of mechanisms behind signal transductions, metabolism, DNA 
replication and more (Fabregat et al. 2018). By importing the ascension numbers of 
discovered proteins for all three replicates of: AAE6 Late and EPE6 Late, pathway analysis 





for similarities. Results were compiled in a PDF file consisting of detailed pathway analysis 
and likelihood of any false positives. Detected pathways were exported as a .CSV file and 
filtered using ‘IF(COUNTIF)’ function described in Section 2.10.2. 
 
Figure 8 – Screenshot of the Mascot Peptide Mass Fingerprint input screen. The four 
arrows from top to bottom depict the following: Database selection(s), Fixed modifications, 










Figure 9 – Equation used to filter repeated proteins from unique proteins. All values for 
“COLUMN”, “ROW”, “COLUMNROW” could be modified to fit the user’s needs. For 
example, if column ‘A’ from rows 1 to 1000 were to be checked to see if any cells contained 
the same value as cell “G3” the cells checked would be written as “$A$1: $A$1000, G3”. 
If this value is equal to the number specified by ‘x’ the number ‘0’ will be the output and 
if the value is not equal to ‘x’ the number ‘1’ will be the output. 
 
2.11 Protein Filtering for LC MS/MS 
As HMSPF used Proteome Discoverer to identify proteins prior to delivery of the 
data, no identification of MS/MS spectra data was required. Proteins from each sample 
needed to be sorted and filtered for contaminants. The filtering of LC MS/MS data was 
done by first removing all proteins in AAE6 and EPE6 samples containing the names: 
ribosomal, ribosomal protein, or *CON* (n=50). The Contaminant Repository for Affinity 
Purification MS Data (CRAPome, Mellacheruvu D, et al. 2013) allowed for the removal 
of commonly found proteins in LC MS/MS experiments. Commonly identified proteins 
returned a score of at least 200 out of 411 experiments resulting in removal from further 
analysis (n=44). Finally, any remaining proteins had their respective UniProt Identifiers 
imported into Reactome, and removed any proteins involved with Metabolism of RNA 
from analysis (n=89). With all remaining proteins unique from common contaminants and 
ribosomal proteins, they were filtered in one of two ways: Peptide Method and Protein-





2.11.1 Protein Filtering “Peptide Method”  
As proteins present within any PHFK sample most likely is a contaminant, they needed 
to be removed (n=586). Now that the remaining proteins were also unique to all negative 
control samples potential candidates needed to be selected.  The criteria for shortlisting a 
protein by the Peptide Method was the following:  
1. Any EPE6- or AAE6-targeted protein must have a sum of 2 or more peptides in 
either trial independent of treatment. 
OR 
2. Any EPE6- or AAE6-targeted protein must have at least one peptide in both trials 
independent of treatment. 
Using this “peptide method” we identified 19 proteins as AAE6 binders and 19 proteins 
as EPE6 binders of which 13 proteins are found in both AAE6 and EPE6 (Table S2). Figure 
10 shows a flow chart depicting how proteins were filtered using the “peptide method”. 
2.11.2 Protein Filtering “Protein-Pathway Method”  
An alternative and more inclusive filtering process was conducted due to a loss of 
known E6 interacting proteins using the stringent Peptide Method. This method reduces 
any reliance on the number of peptides present in a given sample but emphasizes the protein 
differences between two groups: AA and PHFK-HA as well as EP and PHFK-HA. First 
proteins from AA, EP and PHFK samples were filtered similarly to Section 2.11.1 All 
AAE6 targeted proteins that appeared in PHFK-HA samples were removed. The same was 
done for EPE6 targeted proteins and PHFK-HA samples and. The final filtering step in the 
protein-pathway method was to import once again all remaining AA, EP and PHFK-HA 





then all PHFK-HA proteins). All proteins in AA or EP samples involved in a similar 
pathway to that of PHFK-HA proteins were removed from further analysis.  
 
Figure 10 – Summary of both Peptide (yellow) and Protein-Pathway (blue) filtering 
methods for LC MS/MS Trials. Steps in green are part of both methods. PHFK=Primary 
Human Foreskin Keratinocytes; *CON*=technical contaminants (e.g. Trypsin). 
 
2.11.3 Bioinformatic analysis of filtered proteins 
Proteins filtered by the Peptide method were of greatest interest and remained the 
focus of bioinformatic analyses. All analyses began through investigation of each protein’s 





Reactome database using their respective UniProt identifiers. By importing each protein 
separately into Reactome, we simplified the output result of which pathway they were 
involved in. Once all proteins were analyzed through Reactome and their involvement in 
biological pathways were recorded, a short list of potential intriguing proteins was 
developed. For a protein to be included within the short-list, they needed to be involved in 
pathways involving hallmarks of cancer such as: angiogenesis, inflammation, DNA 
repair/destabilization, energy dysregulation; HPV; cervical cancer; or relationships with 
previously published literature within our lab group. For proteins filtered by the Protein-
Pathway Method, the list of proteins identified for AAE6 and EPE6 were run through 
Reactome. The level and significance of enrichment in each pathway was identified and 
this information was used to compare the effects of AAE6 and EPE6.  
Next, for Peptide Method selected proteins, they were imported into The BioGrid 
(Oughtred et al. 2019) using their UniProt Identifier. One of the benefits to BioGrid is that 
it lists all published interactions with any particular protein. The list of unique interactors 
for each protein were searched for their presence in the final Peptide Method table. Each 
unique interacting protein present within our datasets were noted and investigated for their 









The results are presented in three parts. The first section discusses the approaches 
conducted at the Health Sciences North Research Institute (HSNRI) in Sudbury Ontario 
with the generous assistance and hospitality of Dr. Hoyun Lee and Dr. James Knockleby 
but which had to be abandoned as discussed below. The second section discusses the 
conditions for each optimization done to the Co-IP protocol. All of the tests done for the 
second part of the thesis were conducted at the Thunder Bay Regional Health Research 
Institute (TBRHRI). The final part of the thesis results discusses the proteins identified by 
LC MS/MS through Harvard University’s Center for Mass Spectrometry Proteomics, 
Cambridge Massachusetts, United States.  
 
3.1 MALDI MS/MS at HSNRI 
3.1.1 2-D Electrophoresis 
 HPV16 E6 interacts with a variety of cellular host proteins that vary in size. Some 
interacting proteins have similar masses. An example of two proteins are hDLG and E6AP. 
Both of these proteins have a mass around 100 KDa (hDLG and E6AP have masses of 
100.4 KDa and 100.68 KDa respectively). Proteins with such similar masses may be 
difficult to differentiate on an SDS PAGE gel through conventional 1-D methods. 
Therefore, an attempt was made to separate pulled down proteins as much as possible 
through 2-D electrophoresis. Sample proteins were separated first by pI and then by their 
molecular weight. The added separation by pI should prove beneficial for proteins with 
similar masses. Due to the potential of low amounts of protein pulled down from the co-





electrophoresis was not an efficient method to increase protein separation and overall 
detectability for downstream applications.  
3.1.2 Presence of Protein of Interest 
 To prevent unnecessary use of the mass spectrometer, western blotting was done to 
confirm the presence of the target protein E6. Samples were incubated as described 
(Section 2.2.5 and 2.2.6) and eluted with 20 µL 1 X SDS reducing buffer. From the total 
eluted sample, 4 µL was set aside for transfer to a PVDF membrane. Post transfer, samples 
were incubated overnight in anti-HA mouse mAb and a subsequent 1-hour incubation with 
goat anti-mouse Ab conjugated with HRP. As expected, samples transduced with any 
variant of HPV16 E6 showed an additional band at 18 KDa (Figure 11). This additional 
band was absent in all PHFK and PHFK-HA samples. Therefore, E6 positive samples 
analyzed for MALDI MS/MS contained E6 but our negative controls did not. 
 
Figure 11 – Western blot of PHFK, PHFK HA, AA and EP for three biological replicates 
(E denotes early passage samples whereas L denotes late passage samples). Each sample 
was incubated overnight with 1°Ab and for 1 hour with 2°Ab. The lowest band (18 KDa) 
present in all AAE6 and EPE6 samples is E6. As expected, this band was absent for all 
PHFK and PHFK-HA samples. Images were taken with 2-minute exposure, automatic 






3.1.3 Identified Proteins 
 Three biological replicates for each of AAE6, EPE6, PHFK and PHFK-HA were 
analyzed after in gel tryptic digestion with a MALDI MS/MS. Spectra from each sample 
were uploaded for Mass peptide fingerprinting analysis and compiled into an Excel 
spreadsheet. Samples were first organized based on sample type (i.e. AAE6 or EPE6), then 
filtered for the following: repeating peptides (within sample type) and repeating peptides 
and accession numbers (between sample type and negative controls (PHFK and PHFK-
HA)). Once samples were filtered and sorted, AAE6 and EPE6 samples were compared for 
unique accession numbers, and unique peptides. The criteria to determine whether an 
identified protein was significant, a threshold of three or more peptides was chosen. 
Interestingly, there was no significant protein that appeared in all three biological replicates 
for a given sample (i.e. AAE6, EPE6 or PHFK-HA).  When looking at the proteins present 
in both AAE6 and EPE6 samples, several proteins were involved in the cellular immune 
system (Table 4). Partial MHC class II antigens as well as interleukin 11 and 17 were 
identified as unique to AAE6. Therefore, there is the possibility that AAE6 can alter 
immune functions within the cell. Two ubiquitin protein ligases NEDD4-like E3 ubiquitin 
protein ligase WWP2 (WWP2) and E3 ubiquitin protein ligase NEURL3 were identified 
in only the AAE6 cells. The presence of WWP2 was of interest as there has not been data 
published of its interaction with E6. This protein not only was identified in AAE6 but was 
absent in all samples of EPE6 and the negative controls PHFK, PHFK-HA. Therefore, there 
is the possibility that E6 interacts with another E3 ligase in vitro.  
 Proteins unique to EPE6 samples obtained from the MS data generated other 





Table 5) was identified in only EPE6. There was also a CASP8 associated protein 
indicating there may be more to the E6-CASP8 interaction than previously thought and 
will require more investigation. Another known interacting protein to E6 was c-MYC 
(Table 1). Unique to EPE6 samples was a c-MYC binding protein present in only one 
replicate. Interestingly, the tumour suppressor protein breast cancer type 2 susceptibility 
protein was identified as unique to only EPE6-transduced PHFKs. Unfortunately, the 
processed MS data failed to identify several key proteins known to bind to E6 such as 
E6AP, P53, and most importantly failed to identify E6 itself for both AAE6 and EPE6 
samples. Therefore, another approach was required to allow for straight-forward 
bioinformatics analysis. In order to create such an approach, laboratory techniques were 
revisited and optimized such that the total quantity of protein extracted from each sample 
was maximized; minimize antibody leeching during Co-IP elutions; and optimize retention 
of E6 variants and their interacting proteins. The first technique revisited was lysing variant 
E6 transduced mammalian PHFK cells. 
 
3.2 Optimization of Co-IP for LC MS/MS trials 
3.2.1 Lysis of Mammalian PHFK 
 PHFK’s transduced with HPV16 L83VE6 were lysed using several buffers. Buffers 
were cooled to 4 °C prior to lysis of cells. After incubation of cells in lysis buffer, protein 
concentration was determined for total protein amount obtained and cells were air dried 
onto a clean glass microscope slide and imaged (Figure 12).  To have a baseline for lysis 
efficiency, a control lysis was conducted using 1 X PBS. The use of MPER has no effect 





increasing the volume of lysis buffer from 10 : 1 (10 µL buffer to 1 µg of cells) to 20 : 1 
there was no visual difference in lysis efficiency. The nuclei lysed with MPER have sharp 
edges and little nuclear debris throughout the sample. Interestingly, the addition of 150 
mM NaCl to MPER resulted in increased nuclear disruption indicating improved lysis 
efficiency. Similarly, to the lysis of MPER with 150 mM NaCl, nuclear disruption 
efficiency increased when lysing with a Tris-HCl lysis buffer developed by Elizabeth 
White et al. 2012. Once again there is visual disruption of the nuclear membrane. However, 
some cells lysed with this buffer demonstrated improved lysis efficiency as nuclear debris 
is present in regions distant from lysed nuclei. Overall, we determined that the most 
efficient lysis method was using the Tris-HCl buffer. As, there were several steps to 
completing a Co-IP, I continued to test the incubation and washing efficiency of all three 
buffers. 
   
Figure 12 – DAPI stained nuclei of PHFK cells transduced with the L83V HPV16 E6 
oncogene. Image was taken in greyscale. All lysis buffers show varying disruption of the 
nuclear membrane. Cells lysed with MPER alone experienced poor nuclear disruption and 
visually did not vary from the control. The addition of 150 mM NaCl to MPER resulted in 
a clear increase in nuclear membrane disruption. This can be identified by increased 
nuclear debris surrounding each nucleus. Finally, cells lysed with Tris-HCl/nonidet P-40 
buffer seemed to have the greatest levels of nuclear membrane disruption. 
 
Lysis efficiency was quantitatively and qualitatively compared via western blot 
using actin as a normalizer for densitometry (Figure 13). Since the original method used 





efficiency increased the most (28.0 %, n=1) when Tris-HCl was used as a buffer. When 
adding 150 mM of NaCl to MPER, the efficiency of lysing PHFK’s increased by 2.82 % 
(n=1) compared to the benchmark. Overall, the buffer with the greatest lysis efficiency was 
Tris-HCl. Surprisingly, when a complete Co-IP using the same number and duration of 
washes with different lysis buffers, there visually appeared to be more E6 eluted using the 
MPER + NaCl lysis buffer (Figure 13 C). Therefore, going forward, the lysis buffer used 
was MPER with 150 mM NaCl.  
 
 
Figure 13 – A) Western blot of L83V transduced PHFK’s lysed with Tris-HCl lysis buffer 
[pH 7.5] (Column 1), MPER with 150 mM NaCl (Column 2), and MPER (Column 3). In 
this figure, actin was used as a normalizer and the blotting of E6AP was done to confirm 
the ability of the antibody to bind to E6AP effectively. B) Densitometry of E6 post lysis 
using Tris-HCl [pH 7.5] (Column 1), MPER with 150 mM NaCl (Column 2), and MPER 
(Column 3). Data was plotted using R Studio Version 1.1.383 and densitometry completed 
using Image Lab Version 6.0.1. C) Comparison between total E6 and E6AP eluted from 
L83V cells lysed with either Tris-HCl (Column 1), MPER with 150 mM NaCl (Column 2) 
or MPER (Column 3). Western Blot images were taken at 20-minute exposure and 1 X 1 
binning with gamma adjusted to 0.4 using PhotoshopTM. 
 
3.2.2 Antibody Selection for Western Blotting/Co-IP  
 Proper choice of antibodies used for western blotting is important when trying to 





PHFK’s, two anti-HA antibodies were used. The first was a monoclonal antibody that 
requires the use of a secondary antibody such as anti-mouse conjugated to an HRP tag. The 
other option is to use a primary anti-HA antibody with a conjugated HRP tag already on 
the antibody. Figures 14 – 19 show differences between the results of the western blots. 
When using the monoclonal anti-HA antibody with no HRP conjugated tag (Figures 14-
17), a secondary antibody that interacts with IgG proteins that may leech from the beads 
can allow for dual detection of IgG and E6. Pierce anti-HA magnetic beads use mouse IgG 
and therefore it is possible to use the combination of mouse monoclonal anti-HA primary 
with anti-mouse conjugated to an HRP tag so E6 can be visualized at the same time as any 
leeched antibodies from beads. If E6 is solely to be detected, it is possible to use anti-HA 
antibody conjugated to HRP as shown in Figures 18 and 19.   
3.2.3 Incubation and Wash of Input Protein 
 To determine the optimal time required to sufficiently bind E6 to our anti-HA 
magnetic beads, equal amounts of lysed proteins recovered post lysis of MPER were used. 
Most literature stated that they used an overnight incubation (4-16 h) however, due to the 
instability of E6 post-lysis, there was reason to believe a shorter incubation time would be 
beneficial. For each sample we used 600 µg of input protein with 25 µL of magnetic beads 
and incubated at 4 °C for 30 minutes and overnight (Figure 14 A and B respectively). 
Washes were concentrated using a 3K concentrator (Fisher Sci., Cat# 88512) until the 
volume was low enough for the entire sample to be loaded into each well. Western blotting 
was completed and imaged to identify how much E6 was lost while incubating and washing 
(Figure 14). Samples that were incubated for 30 minutes could not sufficiently bind all 





incubating our input protein overnight, there appeared to be no E6 within the flow-through 
and no E6 in any washes. Therefore, incubating input protein overnight resulted in 
increased binding of E6 to the magnetic beads and overall reduced loss of E6 during 
washes. Most likely an increased incubation time will result in increased retention of 
binding partners to E6. 
 
Figure 14 – Comparison between incubating 600 µg of lysed PHFK’s transduced with 
L83V input protein on 25 µg of anti-HA magnetic beads for 30 minutes or overnight. A) 
Shows the effect washing samples with TBS containing 0.05 % tween 20 after 30 minutes 
of incubation. B) Shows the effect washing samples with TBS containing 0.05 % tween 20 
after incubating samples on beads overnight. Images were taken with the same CCD 
camera with 4 X 4 binning, 10-minute exposure and gamma adjusted to 0.5 using 
PhotoshopTM; LC=light chain 
 
As shown in Supplemental Table 1, a comprehensive literature search was done for 
all known interactome studies done for HPV16 E6. The results from this search provided 
a standard for how previous studies washed their samples to remove nonspecific binders 
and potential contaminants. White et al. 2012 demonstrated an efficient method to co-
immunoprecipitate E6 along with known binders that consisted of three 5-minute washes 
in cold lysis buffer, and three 5-minute washes in cold 1 X PBS. Their positive results, 
other papers and the manufacturer’s suggestion to use three washes provided enough 
rationale to wash our samples with three 5-minute washes with cold lysis buffer and three 





3.2.4 Elution of Protein 
 To determine the efficiency of elution buffers on our samples of interest, several 
buffers were used and compared to our original method using SDS loading dye. As a 
baseline, equal volumes of SDS elution’s were done on each sample post alternative elution 
buffer. A method to determine elution efficiency is either by decreased presence of E6 
within the SDS elution buffer or increased presence of E6 in the alternative elution buffer. 
Initial elution methods used SDS reducing buffer as this would strip all proteins from the 
beads. However as seen in Figure 15. the elution is too harsh causing large quantities of 
antibody to leech from the beads. This left only two buffers available for elution. The first 
was HEPES Buffer (25 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) 
[pH 8.0], 8 M urea, 0.02 % (v/v) Triton X-100 and 5 % (v/v) glycerol, and the second was 
RIPA buffer (25 mM Tris-HCl [pH 7.6], 150 mM NaCl, 1 % sodium deoxycholate, 0.1% 
SDS and 8 M urea). When eluting protein using HEPES buffer (Figure 15), E6 failed to be 
detected on the western blot at any exposure time. It is worth noting that increasing the 
temperature of incubation to 37 °C or time of incubation did not result in any noticeable 
improvement of elution efficiency. When using RIPA buffer, elution efficiency improved 
compared to HEPES buffer. E6 was detected at a moderate (5-minute) exposure time with 
4 X 4 binning. Unfortunately, the majority of E6 present within the sample remained on 
the beads as can be seen in the SDS lanes for Figure 15 B. A trial run of variant samples 
(AA and EP) using RIPA buffer to elute the protein was done (Figure 15 A and B) and sent 
for MS identification. Unfortunately, with poor results, once again troubleshooting was 





As a result of the literature search, the most popular elution method was using 
synthetic HA peptide to out compete the interaction between E6 with HA tag, associated 
binding partners and magnetic bead antibodies. As shown in Figure 15 C eluting protein 
with HA peptide failed to successfully elute E6 and associated binding partners. Changing 
the concentration of HA peptide (used 125 µg/mL to 1 mg/mL) as well as altering 
incubating temperature and duration failed to improve elution efficiency. Finally, two 
acidic elution buffers were used: Glycine-HCl [pH 2.5] and a commercial elution buffer 
from ThermoFisher Scientific (Acid EB, Cat# 1858606). Upon first glance there does not 
appear to be a significant difference between the two buffers ability to elute proteins. 
However, when analyzing the SDS elutions for both acidic buffers, it appears the Glycine 
buffer had removed all E6 from the beads while keeping the majority of antibody on the 
solid substrate. The commercial elution buffer did remove a substantial amount of E6 from 
the beads but there remained a detectable amount of target protein on the magnetic beads. 
Therefore, we continued to optimize elution buffers using Glycine-HCl. To determine the 
optimal pH of Glycine-HCl to elute our protein without leeching antibody off of the beads. 
Three pH levels were tested: 2.2, 2.5 and 2.8 (Figure 15 D). There did not appear to be a 
noticeable difference between the three samples for the amount of E6 eluted. Visually there 
appears to be more antibody leeched from the beads when comparing the pH 2.2 versus the 
2.5 elution. As a result, further troubleshooting continued with 0.2 M Glycine-HCl pH 2.5. 
While determining which buffer would be best suited for elution of target proteins and MS 
analysis, an attempt was made to scale up the experiment. This was done by performing a 





(Figure 15 D). Elution conditions were the same as other acidic elution’s and resulted in 
increased target protein elution with a moderate increase in antibody leeching.  
 
Figure 15 – Elution comparison between HEPES buffer and SDS elution A). Image was 
taken with 5-minute exposure, 4 X 4 binning, and gamma adjusted to 0.2. Elution of 
proteins using RIPA buffer was done and because there was improved elution, a shorter 
exposure time was used (1-minute) with 4 X 4 binning B). Gentle elution attempts were 
done on L83V cell lines as troubleshooting needed to be conducted once again C). Images 
were obtained using a 10-minute exposure due to decreased binning (1 X 1) and 0.2 
gamma. Decreased binning was used to make it easier to identify E6 in the presence of 
substantial antibody when eluting with SDS loading buffer. Elution of samples using 0.2 
M Glycine-HCl with varying pH. Images were taken with 20-minute exposure and 1 X 1 
binning with 0.5 gamma correction. 
 
3.2.5 Stability of Protein Within Elution Buffer 
 Once determining the most efficient elution buffer compatible with MS 
applications, another challenge was presented. As described in section 1.3.0, E6 has a short 
half-life (less than30 minutes) and the samples must be stable for at least a week to ensure 
accurate identification of proteins within the eluted sample. As such, the stability of E6 
was tested with protein eluted by 0.2 M glycine [pH 2.5] and immediately neutralized. This 
was done by performing two identical pull-downs with equal amounts of protein (1.2 mg). 
To simulate immediate denaturation of protein, one sample was incubated in 6 X SDS 





stored at -80 °C for one week while the other sample was immediately stored at -80 °C 
without denaturing.  Storage at -80 °C simulated shipping conditions on dry ice and 
handling conditions both in our lab and at the proteomic facility. Once one week had 
passed, both samples were thawed, the nondenatured sample was reduced with 6 X SDS 
loading dye containing DTT and 30 µL of both samples were run on a 15 % SDS PAGE 
gel. Subsequent western blotting was conducted as shown below (Figure 16 A). Samples 
were analyzed in triplicate (n=3) by comparing the ratio of E6 to the light chain antibody. 
Figure 16 B shows that there was no significant difference between the ratio of E6 to light 
chain antibody. Therefore, storage of Co-IP’d samples in neutralized 0.2 M Glycine [pH 
2.5] provides a stable environment for E6. 
 
Figure 16 – Stability of protein eluted using 0.2 M glycine [pH 2.5] from Co-IP’d L83V 
cellular proteins. a) Western Blot of E6 and E6AP for samples with varying time between 
elution and denaturing using DTT. Denaturing samples immediately compared to 7 days 
post elution resulted in no significant difference in the total amount of E6 and E6AP pulled-
down. b) Ratio of E6 to light chain antibody (n=3) also shows little difference between 
denaturing samples immediately or 7 days post elution (standard deviation (SD) bars 
overlap). Western Blotting image was taken with 1 X 1 binning, 20-minute exposure and 








3.2.6 Quality Control of IP Methodology 
 To ensure the IP methodology worked, a comparison was done between a 
transduced cell line containing E6 (L83V) and non-transduced control (PHFK) cells. 
Western blotting on eluted IP samples for both PHFK, and L83V samples was conducted 
to identify specificity of interactions with HA antibodies. A positive result would show 
differences between pulled down proteins for each sample (no protein should be pulled 
down for PHFK). A known interactor E6AP was used to determine if our IP could 
selectively pull-down proteins interacting with E6 (Figure 17). The figure shows a clear 
band representing E6 and E6AP in the lane containing L83V eluted proteins while there is 
an absence of E6 and E6AP in the control lane containing PHFK input protein. This 
indicates the Co-IP is able to selectively pull-down proteins bound to E6. Another example 
can be found in Figure 18.  
 
Figure 17 – Confirming the selective pull-down ability of the Co-IP. A positive cell line 
(L83V) and negative control (PHFK) were used. L83V cellular proteins were capable of 
pulling-down both E6 and E6AP while PHFK was unable to pull-down any known E6 
binders as expected. This confirmed the method is able to selectively pull-down proteins 
that only interact with HPV16 E6. Image was taken with 1 X 1 binning, 20-minute exposure 








3.2.7 Effect of Proteasome Inhibitor MG132 on HPV16 E6 
 To determine the effect of pulled-down proteins treated with proteasome inhibitor, 
AAE6 and EPE6 transduced cells were treated for 4 hours with either 30 µM MG132 in 
DMSO, or an equivalent volume of DMSO as a control. Samples were harvested and equal 
amounts of input protein were pulled down using the method discussed in Section 2.1.2. 
The ideal effect of the proteasome inhibitor would be to prevent the degradation of P53 a 
known target of E6. To confirm the presence of P53, a western blot using 35 µL (31.3 % 
of total elution volume) of eluted protein was done. For quality control the membrane was 
also blotted to detect E6 and E6AP in the samples. Figure 18 clearly demonstrates 
successful increase in P53 for not only the input which was expected but in the elution of 
MG132 treated proteins. As expected, P53 was absent in the controls (DMSO treatment 
and PHFK). Therefore, the use of MG132 is beneficial to detect interacting proteins that 
may be degraded or present in low quantities. 
 
Figure 18 – Comparison of co-immunoprecipitated E6 variants and PHFK proteins treated 
for 4 hours with either 30 µM MG132 proteasome inhibitor or DMSO. As expected in the 
negative control (PHFK) there was no E6AP, P53, or E6 present within the elution. The 
DMSO control provided no detectable band for P53 while the MG132 treated sample 
contained a detectable level of P53 in E6 transduced cells. Image was taken with 1 X 1 










3.2.8 Increasing Quantity of Protein Input 
 Although the Co-IP can selectively pull-down E6, E6AP and P53 (with MG132 
treatment (Section 3.2.7)), the bands appear faint increasing the possibility that these 
proteins along with other interacting proteins will fail to be detected during MS analysis. 
Therefore, as briefly trialed in Section 3.2.4 (Figure 15 D) pull-downs were attempted with 
increasing the quantity of both anti-HA magnetic beads and input protein from lysed 
samples. The Pierce Anti-HA magnetic beads have a capacity to bind at least 100 µg of 
protein and a few trials were required to identify a point in which we could saturate the 
binding of E6 and associated binding partners to the beads. The maximum capacity for our 
laboratory to grow cells for all three trials at the same time is eight T225 flasks used as 
described in Section 2.1.2. This level of cell culture allowed for 8 mg of input protein to be 
loaded for each sample. Since the volume required to input 8 mg of protein was greater 
than 2 mL, the sample was split in half and loaded with equal amounts of beads, as 
described in Section 2.2.6. We found the maximum volume of beads to sufficiently be 
saturated by 8 mg of input protein was 80 µL or 10 µL of beads per 1 mg of input protein. 
Figure 19 demonstrates the difference in total E6 and binding partners pulled-down 
between 1.2 mg of input protein with 50 µL of magnetic beads and our optimized 8 mg of 
input protein and 80 µL of magnetic beads. Both western blots used equal volumes of 
eluted samples (35 µL or 31.5 % of total elution volume). In conclusion, 8.0 mg input 
protein and 80 µL of anti-HA magnetic beads allows for maximum pull-down of E6 and 








Figure 19 – Effectiveness of saturating input protein on Pierce Anti-HA Magnetic Beads. 
Using 1.2 mg of input protein with 50 µL of magnetic beads we were able to detect a single 
binding partner E6AP with preliminary LC MS/MS attempts. There are faint bands present 
for E6 and E6AP for samples treated with DMSO while slightly stronger bands are present 
for E6 and E6AP with MG132 treatment. As expected with treatment of MG132, P53 is 
present in low quantities for the MG132 treated sample with 1.2 mg of input protein. 
Increasing the quantity of input protein and beads to 8 mg and 80 µL respectively there is 
a noticeable increase in the amount of pulled-down proteins. All bands are present in large 
quantities for MG132 treated cells while there is an extremely faint band present for P53 
with DMSO treated cells. Images were taken with 1 X 1 binning, 20-minute exposure and 
0.2 gamma correction using PhotoshopTM. 
 
3.3 LC MS/MS  
3.3.1 Detection of HPV16 E6 and Known Interacting Proteins 
By optimizing the Co-IP protocol and using a more sensitive mass spectrometer 
(LC MS/MS) successful AAE6 pull-down from AAE6 cell lines treated by both DMSO 
and MG132 was demonstrated. Two peptides were identified in AAE6 treated with DMSO 
while only one peptide was identified in AAE6 treated with MG132. Not only did the Mass 
spectrometer identify AAE6, it also identified five known E6 binding proteins in at least 





The most important known binder E6AP was identified in all E6 samples and absent in all 
PHFK-HA control samples. P53 was identified in only MG132 treated AAE6 and EPE6 
samples. BCL2 was identified only in MG132 treated EPE6. Interestingly both MAGI2 
and MAGI3 were detected in DMSO treated AAE6 while being absent in all EPE6 samples. 
It is worth noting that E6TP1 was identified in PHFK-HA MG132 treated cells and as this 
was a control sample the protein was excluded from subsequent analysis. Interestingly I 
still could not detect EPE6 in any of the treatment samples.  
3.3.2 Identification of Significant Proteins  
Many proteins within each MS sample were present with only identification of one 
or two peptides. Therefore, multiple approaches were used to look into possible unique 
interactions. The Peptide Method (Section 2.11.1) used a minimum identification criterion 
of either: three identified peptides in a sample replicate for example trial two AAE6 DMSO 
identified protein SDA1 homolog (SDAD1) with three peptides; one peptide in each 
sample replicate to be considered significant for example protein Retinitis pigmentosa 9 
protein (RP9) had one peptide identified in both trial one and trial two EPE6 DMSO 
samples; or one peptide in two different variant treatment replicates. By using this 
approach, I identified 25 different proteins in AAE6 and EPE6 combined, of which 13 were 
common between AAE6 and EPE6 with six proteins unique to EPE6 and another six 









Table 4 – Heat map of Peptide Method depicting potential candidates for AAE6-targeted 
proteins (greater than three peptides). Each column represents a single sample type and 
each row represents a protein (name of protein on right side). The gene name for each 
corresponding protein is in brackets beside the protein name. Bolded Acc# (Column 1) are 
common to EPE6-targeted proteins (Table 5). Numbers in each coloured box corresponds 
to the number of peptides identified. 
 
Table 5  – Heat map of Peptide Method depicting potential candidates for EPE6-targeted 
proteins (greater than three peptides). Each column represents a single sample type and 
each row represents a protein (name of protein on right side). The gene name for each 
corresponding protein is in brackets beside the protein name. Bolded Acc# (Column 1) are 
common to AAE6-targeted proteins (Table 4). Numbers in each coloured box corresponds 
to the number of peptides identified. 
 
We then screened for functions related to HPV-related tumourigenesis and immune 
suppression, obtaining a short-list of 7 proteins. Screening for HPV related functions 
involved identifying peer-reviewed literature for each variant interacting protein using 
Google Scholar, and PubMed databases. Each literature search consisted of using the 
protein name followed by each of the following: HPV, HPV16, HPV16 E6, cancer, or 
cervical cancer (e.g. MX2 HPV16 E6). Among the short-list of proteins, three were found 
Acc# Description CRAPome AAE6 DMSO  T1 AAE6 MG132 T1 AAE6 MG132 T2 AAE6 DMSO T2 Sum
Q8TDD1 ATP-dependent RNA helicase DDX54 OS=Homo sapiens GN=DDX54 PE=1 SV=2 49 / 411 3 3
P04637 Cellular tumor antigen p53 OS=Homo sapiens GN=TP53 PE=1 SV=4 52 / 411 1 1 2
Q9H444 Charged multivesicular body protein 4b OS=Homo sapiens GN=CHMP4B PE=1 SV=1 28 / 411 1 1 3 2 7
Q14669 E3 ubiquitin-protein ligase TRIP12 OS=Homo sapiens GN=TRIP12 PE=1 SV=1 29 / 411 3 1 4
Q14244 Ensconsin OS=Homo sapiens GN=MAP7 PE=1 SV=1 42 / 411 2 3 3 8
Q5T3I0 G patch domain-containing protein 4 OS=Homo sapiens GN=GPATCH4 PE=1 SV=2 37 / 411 3 3 6
Q9C086 INO80 complex subunit B OS=Homo sapiens GN=INO80B PE=1 SV=2 5 / 411 2 2 4
Q7Z5P9 Mucin-19 OS=Homo sapiens GN=MUC19 PE=1 SV=3 NA 1 1 1 3
Q8WTT2 Nucleolar complex protein 3 homolog OS=Homo sapiens GN=NOC3L PE=1 SV=1 42 / 411 1 1 2
Q13823 Nucleolar GTP-binding protein 2 OS=Homo sapiens GN=GNL2 PE=1 SV=1 45 / 411 11 6 17
Q9UMY1 Nucleolar protein 7 OS=Homo sapiens GN=NOL7 PE=1 SV=2 11 / 411 1 1 1 3
Q96GQ7 Probable ATP-dependent RNA helicase DDX27 OS=Homo sapiens GN=DDX27 PE=1 SV=2 41 / 411 9 6 15
Q9HC23 Prokineticin-2 OS=Homo sapiens GN=PROK2 PE=1 SV=2 1 / 411 3 3
Q9NVU7 Protein SDA1 homolog OS=Homo sapiens GN=SDAD1 PE=1 SV=3 23 / 411 1 1 4 3 9
O75676 Ribosomal protein S6 kinase alpha-4 OS=Homo sapiens GN=RPS6KA4 PE=1 SV=1 1 / 411 1 1 2
O95478 Ribosome biogenesis protein NSA2 homolog OS=Homo sapiens GN=NSA2 PE=1 SV=1 15 / 411 1 1 2 4
Q5JTH9 RRP12-like protein OS=Homo sapiens GN=RRP12 PE=1 SV=2 61 / 411 3 1 4
Q9NUQ6 SPATS2-like protein OS=Homo sapiens GN=SPATS2L PE=1 SV=2 20 / 411 8 4 12
Q05086 Ubiquitin-protein ligase E3A OS=Homo sapiens GN=UBE3A PE=1 SV=4 1 / 411 5 4 2 4 15
Acc# Description CRAPome EPE6 DMSO T1 EPE6 MG132 T1 EPE6 MG132 T2 EPE6 DMSO T2 Sum
Q8TDD1 ATP-dependent RNA helicase DDX54 OS=Homo sapiens GN=DDX54 PE=1 SV=2 49 / 411 5 5
Q4AC94 C2 domain-containing protein 3 OS=Homo sapiens GN=C2CD3 PE=1 SV=4 1 / 411 3 3
P04637 Cellular tumor antigen p53 OS=Homo sapiens GN=TP53 PE=1 SV=4 52 / 411 4 4
Q9H444 Charged multivesicular body protein 4b OS=Homo sapiens GN=CHMP4B PE=1 SV=1 28 / 411 5 5
Q14669 E3 ubiquitin-protein ligase TRIP12 OS=Homo sapiens GN=TRIP12 PE=1 SV=1 29 / 411 3 3
Q14244 Ensconsin OS=Homo sapiens GN=MAP7 PE=1 SV=1 42 / 411 2 3 2 7
Q5T3I0 G patch domain-containing protein 4 OS=Homo sapiens GN=GPATCH4 PE=1 SV=2 37 / 411 2 3 5
P20592 Interferon-induced GTP-binding protein Mx2 OS=Homo sapiens GN=MX2 PE=1 SV=1 1 / 411 4 1 5
Q13823 Nucleolar GTP-binding protein 2 OS=Homo sapiens GN=GNL2 PE=1 SV=1 45 / 411 1 2 1 4
Q9UMY1 Nucleolar protein 7 OS=Homo sapiens GN=NOL7 PE=1 SV=2 11 / 411 1 1 1 1 4
Q96GQ7 Probable ATP-dependent RNA helicase DDX27 OS=Homo sapiens GN=DDX27 PE=1 SV=2 41 / 411 7 1 8
Q9NVU7 Protein SDA1 homolog OS=Homo sapiens GN=SDAD1 PE=1 SV=3 23 / 411 1 5 2 8
Q8TA86 Retinitis pigmentosa 9 protein OS=Homo sapiens GN=RP9 PE=1 SV=2 52 / 411 1 1 2
O95478 Ribosome biogenesis protein NSA2 homolog OS=Homo sapiens GN=NSA2 PE=1 SV=1 15 / 411 3 1 4
P84101 Small EDRK-rich factor 2 OS=Homo sapiens GN=SERF2 PE=1 SV=1 33 / 411 2 3 5
Q9NUQ6 SPATS2-like protein OS=Homo sapiens GN=SPATS2L PE=1 SV=2 20 / 411 2 7 1 10
O75683 Surfeit locus protein 6 OS=Homo sapiens GN=SURF6 PE=1 SV=3 38 / 411 3 3
P11441 Ubiquitin-like protein 4A OS=Homo sapiens GN=UBL4A PE=1 SV=1 19 / 411 1 2 3





exclusively in AAE6: the INO80 complex subunit B (INO80B), the Prokineticin-2 
(PROK2) and Ribosomal protein S6 kinase alpha-4 (RPS6KA4), three were found in both 
AAE6 and EPE6: the E3 ubiquitin-protein ligase (TRIP12), the Nucleolar GTP-binding 
protein 2 (GNL2) and the charged multivesicular body protein 4b (CHMP4B), and 
interferon-induced GTP-binding protein (Mx2) was found only in EPE6 samples. By using 
several databases including Reactome (Fabregat et al. 2018), and, BioGrid (Oughtred et al. 
2019) we were able to identify potential effects that E6 variants have on various host 
cellular proteins.  
The nuclear INO80 complex subunit B (INO80B) is part of the ATP-dependent 
INO80 remodeling complex consisting of 12 proteins. It has key functions in transcription 
regulation, DNA replication and repair, telomere maintenance and chromosome 
segregation (Min et al. 2013; Seeber et al. 2013). Researchers observed higher than normal 
expression of INO80 in cervical cancer epithelial cells (Hu et al. 2016). By increasing 
INO80 expression, the homeobox protein Nanog became overexpressed, resulting in 
tumourigenesis promotion (Hu et al., 2016). In a previous study (Lee et al. 2014), 
researchers uncovered the necessity of INO80 in DNA replication fork progression. DNA 
replication progression by INO80 was accomplished through interaction with tumor 
suppressor BRCA1-associated protein-1 (BAP1) (Lee et al. 2014). Interestingly, the 
absence of BAP1 in a variety of cancer cell types resulted in destabilization and 
downregulation of INO80. (Lee et al. 2014; Hu et al. 2016). HPV16 E6 is known to interact 
(Table 1) with another protein involved in chromatin remodeling, Tip60, a component of 
the TRRAP/Tip 60 complex (Jha et al. 2010). In addition, E6 interacts with Myc which can 





reports indicate a link between Myc and INO80B. Indeed, among other proteins identified 
by the peptide method (Table 4-5), INO80B interacts with GNL2, RRP12 and RP9 based 
on Co-IP data (Cloutier et al. 2017; Kuroda et al. 2004), while proximity label-MS showed 
that Myc interacts with GNL2 and RRP12 (Kalkat et al. 2018). INO80B and RRP12 were 
present only in the AAE6 sample, GNL2 was found in both AAE6 and EPE6, whereas RP9 
was unique to EPE6. Hence, even if EPE6 does not immunoprecipitate INO80B, EPE6 
may alter INO80B functions indirectly.  
Reactome analysis of INO80B yielded 8 pathways and for each of them are 
mentioned the protein present in the peptides method table that are involved in the same 
pathways: DNA Damage Recognition in GG-NER, Global Genome Nucleotide Excision 
Repair (GG-NER), UCH proteinases, Nucleotide Excision Repair, Deubiquitination (P53), 
DNA Repair (P53), Post-translational protein modification (P53 and Muc19), Metabolism 
of proteins (P53 and Muc19). Since Reactome analysis of GNL2, RRP12, and RP9 did not 
return any pathways, the roles of their interaction with INO80B and the pathways involving 
these proteins remain unclear. However, further literature research on nucleolar GTP-
binding protein 2 (GNL2) revealed that the GNL2 protein can affect P53 levels and cell 
cycle regulator expression (Racevskis et al. 1996; Paridaen et al. 2011). GNL2 works 
similarly to nucleostemin (NS) by destabilizing P53 in zebrafish retinal cells (Paridaen et 
al. 2011). GNL2 is overexpressed in various cancers and promotes G1/S phase transition.  
GNL2 increases cyclin-dependent kinase inhibitor expression and alters the P53/p21 
pathway (Datta et al. 2015). Interactome study also indicates that in addition to INO80B, 
GNL2 also interacts with NSA2 (Huttlin et al. 2015) and GPATCH4 (Huttlin et al. 2017) 





indicates that INO80B interacts with the other main HPV16 oncoprotein, E7 (Rozenblatt-
Rosen et al. 2012).   
In addition to INO80B, two other proteins out of the seven of interest, RPS6KA4 
and PROK2, were found only in the AAE6 immunoprecipitated samples. RPS6KA4 
regulates a variety of cellular functions such as: “cellular proliferation, motility, and 
survival” (Anjum and Blenis 2008). This serine/threonine-protein kinase is activated by 
p38aMAPK and ERK1 (Pierrat et al. 1998). We previously identified increased signaling in 
the ERK1 pathway for AAE6 compared to EPE6, suggesting that ERK 1/2 plays a 
significant role in increasing H1F-1a levels in AAE6 cells. (Cuninghame et al. 2017). 
Consistent with this result, RPSKA4 was only detected in AAE6 samples in our current 
MS data. In fibroblasts, during mitogenic and stress stimuli, RPS6KA4 is activated by p38α 
or ERK1. In turn, RPS6KA4 phosphorylates the histone H3 leading to an increase in the 
promoter activity of certain cytokine and chemokines genes as well as an increase in the 
recruitment of NF-kB to its target promoters (Soloaga et al. 2003, Saccani et al. 2002). In 
addition, RPSK6A4 activates CREB causing activation of other anti-apoptotic proteins 
belonging to the Bcl-2 family of protein (Bfl-1/A1 and plasminogen activator inhibitor 2 
(PAI-2)) (Park et al. 2005). None of the proteins in Table 5 were found in the Reactome 
pathway involving RPS6KA4 (Recycling pathway of L1, L1CAM interactions, Axon 
guidance, Developmental Biology) suggesting that these pathways are only altered by 
AAE6. 
Prokineticin-2 (PROK2) is a chemokine-like protein usually expressed by a 
component of the innate immune system such as macrophages influencing host defence 





Promotion of angiogenesis due to PROK2 was observed in vitro and in vivo (Mus 
musculus) which resulted in increased colon tumour mass (Kurebayashi et al. 2015). While 
PROK2 functions have not been fully characterized, Lauttia et al. 2014 observed an 
increased in PROK2 expression in human Merkel cell carcinomas caused by infection with 
Merkel cell polyomavirus. This expression was also correlated with a drastic increase of 
tumor infiltrating macrophages (Lauttia et al. 2014). So far little is known about PROK2’s 
effects on angiogenesis. However, the protein is known to sequester the promoter of the 
HIF-1 and to alter the extracellular matrix (LeCouter et al. 2001, LeCouter et al. 2003). 
PEOK2 is found in 7 Reactome pathways: peptide ligand-binding receptors; G alpha (q) 
signalling events; Class A/1 (Rhodopsin-like receptors); GPCR ligand binding; GPCR 
downstream signalling; signaling by GPCR and signal transduction. Except for the latest 
also matching P53, no proteins in tables 4 or 5 were associated to these pathways, 
suggesting that in a similar way as RPSK6K4A, binding of AAE6 to PROK2 could impact 
specific process not altered by EPE6. 
In addition to GNL2, two proteins among the seven selected, TRIP12 and 
CHMP4B, are common between AA and EP. The thyroid hormone receptor interacting 
protein 12 (TRIP12) is an E3 ubiquitin-protein ligase that shares similarities with E6AP. 
The protein contains the conserved HECT domain (Homologous to E6AP Carboxy 
Terminus) as well as multiple LxxLL (where x denotes any amino acid) motifs that 
correspond to the E6 binding site on E6AP (Vande Pol and Klingelhutz 2013; Zanier et al. 
2013; Larrieu et al. 2020). There are four motifs (LQALL AA position 402; LITLL AA 
position 485; LHFLL AA position 697; and LDQLL AA position 1862) present throughout 





and degradation of several proteins including P53 activator proteins ARF (p14 in humans) 
or Brg-1-associated factor 57 (BAF57) (Haupt et al. 1997; Collado and Serrano 2010; 
Keppler and Archer 2010) potentially doubling the effect of P53 inactivation by E6 as ARF 
acts upstream of E6AP-mediated P53 degradation. Interestingly, TRIP12-dependant ARF 
degradation is inactivated upon Myc or TRADD binding to TRIP12 (Chen et al. 2010, Chio 
et al. 2012). This means that E6 has the potential to block TRIP12’s interaction with Myc 
potentially allowing for degradation of ARF. In addition to Myc, TRIP12 also interacts 
with another known E6 binder, namely E6AP (Huttlin et al. 2015), but the consequence of 
this interaction is unknown. TRIP12 degradation of BAF57 could be inhibited when 
SMARCC1 is bound to TRIP12. BAF57 is a canonical component alongside BAF53 of the 
SWI/SNF chromatin remodeling complex (Martens and Winston 2003, Euskirchen et al., 
2012). Interestingly BAF53 is essential for the expression of E6 and E7 when the viral 
genome has been integrated inf the host cell (Lee et al., 2011), but BAF57’s requirement 
in this process is unknown. Based on Reactome, TRIP12 is involved in different pathways, 
and several are shared with some other cellular proteins targeted by the E6 proteins: antigen 
processing and ubiquitination/proteasome degradation (E6AP), class I MHC mediated 
antigen processing and presentation (E6AP), adaptive immune system (E6AP), immune 
system (P53, E6AP, MUC19, MX2).  
The charged multi-vesicular body protein 4B (CHMP4B) was identified as a 
potential binder to HPV16 E6 for both AA and EP variants. The protein is a subunit of the 
endosomal sorting complex required for transport (ESCRT)-III complex during which it is 
involved in cytokinetic membrane abscission and a potential prognostic marker (Hu et al. 





and its involvement with cell cycle progression (Hu et al. 2014). Co-IP experiments also 
indicated that CHMP4B interacts with the inhibitory P53 isoform Δ133P53α that can block 
the activity of wild type P53 (Horikawa et al., 2014). Other interesting interactors of 
CHMP4B are IRF-2 (Hubel et al., 2019), BRCA2 (Malik et al., 2016) or E-cadherin (Guo 
et al., 2014). It appears that head and neck squamous cell carcinomas appear to display an 
increase in CHMP4B gene expression regardless if HPV was present or not, indicating a 
potential difference in the mechanism of action by HPV depending on the cells infected 
(Gollin 2014). CHMP4B and the ESCRT-III are important in membrane fission processes, 
including the budding of enveloped viruses (Strack et al., 2003). CHMP4B is associated 
with different Reactome pathways, and only one of them is shared with another protein 
present in tables 4 and 5: endosomal sorting complex required for transport (ESCRT), late 
endosomal microautophagy, budding and maturation of HIV virion, macroautophagy, 
autophagy, late phase of HIV life cycle, HIV life cycle, HCMV late events, HIV infection, 
HCMV infection, membrane trafficking, infectious disease, vesicle-mediated transport, 
disease (Muc19).  
Our last protein of the interest is MX2, which is unique to EPE6. Proinflammatory 
signals are one of the hallmarks of cancer as cells could undergo necrosis recruiting 
inflammatory cells that in cancers can promote angiogenesis, proliferation, and 
invasiveness (Hanahan and Weinberg 2011). MX2 is a protein involved in innate immune 
response due to viral infections like human immunodeficiency virus (HIV). One of the 
main responsibilities of MX2 in HeLa cells is to permit G1/S cell cycle progression (King 
et al. 2004). In HPV16 positive cells (W12 cell line), treatment with type I interferon 





when viral DNA is integrated within host DNA, IFNa/b inducible genes like MX2 fail to 
inhibit E6 expression. Dysregulated E6 expression resulted in inhibition of IFNa/b 
inducible antiviral genes such as MX2 and activation of the TGF-b pathway (Pett et al. 
2006).  Based on Y2H experiments, MX2 interacts with the histone-lysine N-
methyltransferase EHMT2 (Rolland et al., 2014), which increases P53-dependant 
expression of pro-apoptotic genes (i.e. Bax and Puma) and is a known interactor of 
p300/CBP (Rada et al., 2017). MX2 is associated with several Reactome pathways: ISG15 
antiviral mechanism, antiviral mechanism by IFN-stimulated genes, IFNa/b signaling. IFN 
signaling is unique to the proteins in table 4. However, the immune system is shared with 
Muc19, TRIP12, P53 and E6AP, while cytokine signaling within the immune system also 
contains P53. 
The “Protein-Pathway Method” provided a broader approach to identification of 
potentially interesting HPV16 E6 interacting proteins. Although seemingly broader—not 
all proteins identified using the “Peptide Method” were present in the final protein-
pathway approach (Table 6-7) due to the fact that a final cleaning step was done with 
Reactome to eliminate any overlapping pathways also found non-specifically in the non-
transduced control PHFKs. The reasoning for this was that in a given pathway, not all 
proteins would be targeted by E6 and that some may “stick” to the capturing beads during 
the Co-IP process and as a result, be detected in control PHFKs. In total, 171 unique 
proteins were identified in AAE6 and EPE6 collectively via the protein-pathway approach. 
AAE6 samples identified 110 proteins, while EPE6 samples identified 81 proteins. Of the 
171 proteins identified, only 20 appeared in both AA and EP samples. Furthermore, when 





only three of proteins were identified namely the charged multivesicular body protein 4b 
(CHMP4B, Uniprot identifier: Q9H444), the cellular tumour antigen P53 (TP53, Uniprot 
identifier: P04637) and the ubiquitin-like protein 4A (UBL4A, Uniprot identifier: P11441).  
 
Table 6 – Heat map of Protein-Pathway Method showing AAE6-targeted proteins unique 
to PHFK-HA. Number of peptides are shown in each coloured box. Bolded Proteins are 






Table 7 – Heat map Protein-Pathway Method showing EPE6-targeted proteins unique to 
PHFK-HA proteins/pathways. Number of peptides are shown in each coloured box. Bolded 
Proteins are also targeted by AAE6 (Table 6). 
 
 
Table 8 – Proteins targeted by both AAE6 and EPE6 identified using the Protein-Pathway 
method.  
 
Protein Name AAE6 DMSO T1 AAE6 DMSO T2 AAE6 MG132 T1 AAE6 MG132 T2 EPE6 DMSO T1 EPE6 DMSO T2 EPE6 MG132 T1 EPE6 MG132 T2
BDP1 1 1 1
CAR11 1
CENPR 1 1 1
CHM4B 1 2 1 3 5
CX6B1 1
DVL2 1 1
EPC1 1 1 1
FIBA 1 1 1 1
HBB 1 1 1 1
IF172 1 1
LIN37 1 1 1
NFYA 1 1 1












Pathways targeted by AAE6 and EPE6 were independently analyzed using 
Reactome (Table 9 and 10). While the p-value was significant throughout for both sub-
lineages, the false discovery rate (FDR) was statistically significant in 18/25 pathways for 
the AA lineage only. Findings will be discussed in the light of all 25 most significant 
pathways for both sub-lineages since values are relative only to currently known pathways 
in the scientific literature.  
AAE6 was associated with 11 Notch1 signaling pathways (Table 9 Rows 1, 2, 3, 9, 
10, 11, 12, 13, 15, 16 and 22) with the identification of several interacting proteins: cyclin-
dependent kinase 8 (CDK8), histone acetyltransferase KAT2A, E3 ubiquitin-protein ligase 
RBX1 and two isoforms of the F-box/WD repeat-containing protein 7 FBW1B isoforms 1 
and 4. CDK8 phosphorylates Notch rendering it for ubiquitination and degradation through 
the proteasome. Consequently, mastermind-like protein 1 (MAML1) does not acetylate 
Notch, and its transcription is not enhanced by p300 (Popko-Scibor et al. 2011). RBX1 and 
FBW1B isoforms were found to participate in Wnt signaling (Table 9 Row 14), providing 
evidence that these two cancer pathways communicate with one another. Wnt/beta-catenin 
signaling plays a role in development and adult homeostasis. In the latter, it is mostly 
inactive which is controlled by several kinases such as glycogen synthase kinase 3 (GSK3), 
casein kinase 1 (CK1), axin and adenomatous polyposis coli (APC), a tumour suppressor 
gene often mutated in colon cancer (Verheyen & Gottardi 2010 and references therein). 
Interestingly, APC was found once with just one unique peptide, yet it also appeared in 
Wnt signaling pathway targeted by AAE6 (Table 9 Row 14). Other notable findings 
identified from AAE6 proteins using the protein-pathway method were binders belonging 





DNA glycosylase isoforms 3 and 6, TP53 regulates metabolic genes: P53, serine/threonine-
protein kinase mTOR (MTOR), thioredoxin (THIO), trinucleotide repeat-containing gene 
6C protein (TNR6C), cytochrome c oxidase subunit 6B1 (CX6B1) and 5'-AMP-activated 
protein kinase subunit gamma-2 (AAKG2). MUTYH germline mutations of the BER 
pathways cause MUTYH-associated polyposis (MAP), a disorder similar to familial 
adenomatous polyposis (FAP), caused by mutations in the APC gene (Mazzei et al., 2013). 
The TP53 regulates metabolic genes pathway also communicates with WNT signaling via 
Trinucleotide repeat-containing gene 6C protein (TNR6C). As such, AAE6-targeted 
cellular proteins derive from the axis of WNT and Notch1 signaling, as well as WNT 
signaling and TP53, regulates metabolic genes. The most striking candidates for this axis 
are RBX1, FBW1B, KAT2A, and CDK8 due to their presence in 8 to 11 pathways. The 
fact that the TP53 regulates metabolic genes pathway (Table 9 Row 8) is targeted by AAE6 
in this study may explain our finding that this E6 variant deregulates cellular metabolism 
through the Warburg effect (Richards et al. 2010, Cuninghame et al. 2017). The presence 
of AAE6 targeted proteins in the Defective base excision repair (BER) associated with 
MUTYH strengthens our previous findings that the AA (D2/D3) sub-lineage seems to 
integrate earlier into the host genome than EP (A1) as evidenced in wet lab studies (Jackson 
et al. 2014, 2016). Indeed, another group reported that BER is essential for the HIV 
provirus DNA to integrate into the host genome, making the analogy with transposable 
elements (Yoder et al. 2011), which have a lot in common with viruses (Jackson et al. 2020, 
in preparation). Finally, Forkhead box protein O1 (FOXO)-mediated transcription also 
overlaps between the two variants via nuclear transcription factor Y subunit alpha NFYA. 





differentiation, and metabolism in various scenarios, such as growth factor deprivation, 





Table 9 – Most significant pathways found in AAE6 targeted proteins using Reactome. Pathways in bold have a significant false detection rate 
(FDR). 









1. Loss of Function of FBXW7 in Cancer and 
NOTCH1 Signaling 
3/6 3.31E-05 0.012 P62877 E3 ubiquitin-protein ligase RBX1 
Q969H0-1 F-box/WD repeat-containing protein 7 FBXW7 isoform 1 
Q969H0-4 F-box/WD repeat-containing protein 7 FBXW7 isoform 4 
2. FBXW7 Mutants and NOTCH1 in Cancer 3/6 3.31E-05 0.012 
P62877 E3 ubiquitin-protein ligase RBX1 
Q969H0-1 F-box/WD repeat-containing protein 7 FBXW7 isoform 1 
Q969H0-4 F-box/WD repeat-containing protein 7 FBXW7 isoform 4 
3. NOTCH1 Intracellular Domain Regulates 
Transcription 5/48 1.30E-04 0.019 
P49336 Cyclin-dependent kinase 8 CDK8 
P62877 E3 ubiquitin-protein ligase RBX1 
Q969H0-1 F-box/WD repeat-containing protein 7 FBXW7 isoform 1 
Q969H0-4 F-box/WD repeat-containing protein 7 FBXW7 isoform 4 
Q92830 Histone acetyltransferase KAT2A 
4. Regulation of TP53 Expression 2/2 1.94E-04 0.019 P04637 Cellular tumour antigen P53 O75626 PR domain zinc finger protein 1 PRDM1 
5. Defective Base Excision Repair Associated 
with MUTYH 2/2 1.94E-04 0.019 
Q9UIF7-3 Adenine DNA glycosylase MUTYH isoform 3 
Q9UIF7-6 Adenine DNA glycosylase MUTYH isoform 6 
6. Pyrophosphate hydrolysis 2/2 1.94E-04 0.019 Q9H2U2 Inorganic pyrophosphatase 2, mitochondrial IPYR2 Q15181 Inorganic pyrophosphatase IPYR 
7. Defective MUTYH substrate processing 2/2 1.94E-04 0.019 Q9UIF7-3 Adenine DNA glycosylase MUTYH isoform 3 Q9UIF7-6 Adenine DNA glycosylase MUTYH isoform 6 
8. TP53 Regulates Metabolic Genes 6/88 2.70E-04 0.019 
P42345 Serine/threonine-protein kinase mTOR MTOR 
Q9UGJ0 5'-AMP-activated protein kinase subunit gamma-2 AAKG2 
P04637 Cellular tumour antigen P53 
P14854 Cytochrome c oxidase subunit 6B1 CX6B1 
P10599 Thioredoxin THIO 
Q9HCJ0 Trinucleotide repeat-containing gene 6C protein TNR6C 
9. Constitutive Signaling by NOTCH1 
HD+PEST Domain Mutants 5/59 3.34E-04 0.019 
P49336 Cyclin-dependent kinase 8 CDK8 
P62877 E3 ubiquitin-protein ligase RBX1 
Q969H0-1 F-box/WD repeat-containing protein 7 FBXW7 isoform 1 
Q969H0-4 F-box/WD repeat-containing protein 7 FBXW7 isoform 4 
Q92830 Histone acetyltransferase KAT2A 
10. Signaling by NOTCH1 HD+PEST 
Domain Mutants in Cancer 5/59 3.34E-04 0.019 
P49336 Cyclin-dependent kinase 8 CDK8 
P62877 E3 ubiquitin-protein ligase RBX1 
Q969H0-1 F-box/WD repeat-containing protein 7 FBXW7 isoform 1 
Q969H0-4 F-box/WD repeat-containing protein 7 FBXW7 isoform 4 
Q92830 Histone acetyltransferase KAT2A 
      
      














11. Signaling by NOTCH1 PEST Domain 
Mutants in Cancer 5/59 3.34E-04 0.019 
P49336 Cyclin-dependent kinase 8 CDK8 
P62877 E3 ubiquitin-protein ligase RBX1 
Q969H0-1 F-box/WD repeat-containing protein 7 FBXW7 isoform 1 
Q969H0-4 F-box/WD repeat-containing protein 7 FBXW7 isoform 4 
Q92830 Histone acetyltransferase KAT2A 
12. Constitutive Signaling by NOTCH1 PEST 
Domain Mutants 5/59 3.34E-04 0.019 
P49336 Cyclin-dependent kinase 8 CDK8 
P62877 E3 ubiquitin-protein ligase RBX1 
Q969H0-1 F-box/WD repeat-containing protein 7 FBXW7 isoform 1 
Q969H0-4 F-box/WD repeat-containing protein 7 FBXW7 isoform 4 
Q92830 Histone acetyltransferase KAT2A 
13. Signaling by NOTCH1 in Cancer 5/59 3.34E-04 0.019 
P49336 Cyclin-dependent kinase 8 CDK8 
P62877 E3 ubiquitin-protein ligase RBX1 
Q969H0-1 F-box/WD repeat-containing protein 7 FBXW7 isoform 1 
Q969H0-4 F-box/WD repeat-containing protein 7 FBXW7 isoform 4 
Q92830 Histone acetyltransferase KAT2A 
14. Signaling by WNT 10/299 8.48E-04 0.044 
P25054 Adenomatous polyposis coli protein APC  
Q13237 cGMP-dependent protein kinase 2 KGP2 
P09497 Clathrin light chain B CLCB 
P62877 E3 ubiquitin-protein ligase RBX1 
P56545 PC-terminal-binding protein 2 CTBP2 
Q9P219 Protein Daple DAPLE 
P35913 Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit beta PDE6B 
Q8N474 Secreted frizzled-related protein 1 SFRP1 
O14641 Segment polarity protein dishevelled homolog DVL2 
Q9HCJ0 Trinucleotide repeat-containing gene 6C protein TNR6C 
15. Signaling by NOTCH1 5/74 9.23E-04 0.045 
P49336 Cyclin-dependent kinase 8 CDK8 
P62877 E3 ubiquitin-protein ligase RBX1 
Q969H0-1 F-box/WD repeat-containing protein 7 FBXW7 isoform 1 
Q969H0-4 F-box/WD repeat-containing protein 7 FBXW7 isoform 4 
Q92830 Histone acetyltransferase KAT2A 
16. Signaling by NOTCH 8/205 0.0011 0.049 
P04637 Cellular tumour antigen P53 
P49336 Cyclin-dependent kinase 8 CDK8 
P62877 E3 ubiquitin-protein ligase RBX1 
Q969H0-1 F-box/WD repeat-containing protein 7 FBXW7 isoform 1 
Q969H0-4 F-box/WD repeat-containing protein 7 FBXW7 isoform 4 
Q92830 Histone acetyltransferase KAT2A 
Q14186 Transcription factor Dp-1 TFDP1 
Q9HCJ0 Trinucleotide repeat-containing gene 6C protein TNR6C 
17. Negative regulation of TCF-dependent 
signaling by DVL-interacting proteins 2/5 0.0012 0.049 
Q9P219 Protein Daple DAPLE 
O14641 Segment polarity protein dishevelled homolog DVL2 
18. Activation of NOXA and translocation to 
mitochondria 2/5 0.0012 0.049 
P04637 Cellular tumour antigen P53 














19. Diseases of Base Excision Repair 2/7 0.0023 0.087 Q9UIF7-3 Adenine DNA glycosylase MUTYH isoform 3 Q9UIF7-6 Adenine DNA glycosylase MUTYH isoform 6 
20. Insulin processing 3/27 0.0026 0.091 
P16870 Carboxypeptidase E CBPE 
Q12840 Kinesin heavy chain isoform 5A KIF5A 
P33176 Kinesin-1 heavy chain KINH 
21. Oxidative Stress Induced Senescence 5/94 0.0026 0.091 
P04637 Cellular tumour antigen P53 
P01100 Proto-oncogene c-Fos FOS 
P10599 Thioredoxin THIO 
Q14186 Transcription factor Dp-1 TFDP1 
Q9HCJ0 Trinucleotide repeat-containing gene 6C protein TNR6C 
22. Pre-NOTCH Transcription and Translation 4/62 0.0036 0.113 
P04637 Cellular tumour antigen P53 
Q92830 Histone acetyltransferase KAT2A 
Q14186 Transcription factor Dp-1 TFDP1 
Q9HCJ0 Trinucleotide repeat-containing gene 6C protein TNR6C 
23. Activation of PUMA and translocation to 
mitochondria 2/9 0.0038 0.113 
P04637 Cellular tumour antigen P53 
Q14186 Transcription factor Dp-1 TFDP1 
24. Transcriptional Regulation by TP53 10/367 0.0038 0.113 
Q9UGJ0 5'-AMP-activated protein kinase subunit gamma-2 AAKG2 
Q92851 Caspase-10 CASP10 
P04637 Cellular tumour antigen P53 
P14854 Cytochrome c oxidase subunit 6B1 CX6B1 
O75626 PR domain zinc finger protein 1 PRDM1 
P01100 Proto-oncogene c-Fos FOS 
P42345 Serine/threonine-protein kinase mTOR MTOR 
P10599 Thioredoxin THIO 
Q14186 Transcription factor Dp-1 TFDP1 
Q9HCJ0 Trinucleotide repeat-containing gene 6C protein TNR6C 
25. FOXO-mediated transcription 4/66 0.0045 0.124 
Q8N139 ATP-binding cassette sub-family A member 6 ABCA6 
Q969P5 F-box only protein 32 FBX32 
P23511 Nuclear transcription factor Y subunit alpha NFYA 





Up to 8 EPE6 interactors are part of homology directed repair (HDR) DNA damage 
pathways (Table 9 Rows 5,9,19, and 22): P53, THIO, proliferating cell nuclear antigen 
(PCNA), CX6B1, double-strand break repair protein MRE11, CDK9, geranylgeranyl 
transferase type-2 subunit alpha PGTA and DNA endonuclease RBBP8. PCNA also 
interacts with the adenine DNA glycosylase MUTYH pathway (Parker et al. 2001) linking 
the two E6 variants under study. While EPE6 does target different cancer pathways than 
AAE6 namely the Hippo, PIK3/AKT, MET and epidermal growth factor receptor pathways 
(Table 9 Rows 1,3,7,10,14, and 24), Hippo communicates with the Wnt pathway through 
segment polarity protein dishevelled homolog DVL-2 (EPE6’s Signaling by Hippo 
pathway and AAE6’s pathways Signaling by WNT and Negative regulation of TGF-
dependent signaling by DVL-interacting proteins). The most notable EPE6 target seems to 
be phosphatidylinositol 3-kinase regulatory subunit alpha PIK3R1 detected in 5 pathways 
related to PI3K, MET and EGFR (Table 9 Rows 3,7,10,14, and 24), which all communicate 
with each other. Wet lab studies are warranted for the above findings to finally establish 





Table 10 – Most significant pathways of EPE6 targeted proteins using Reactome. 









1. Signaling by Hippo 3/20 4.21E-04 0.144 
O14641 Segment polarity protein disheveled homolog DVL-2 
Q9UDY2 Tight junction protein ZO-2 
Q9GZV5 WW domain-containing transcription regulator protein 1 WWTR1 
2. Post-chaperonin tubulin folding pathway 3/23 6.31E-04 0.144 
Q13509 Tubulin beta-3 chain TUBB3 
O75347 Tubulin-specific chaperone A TBCA 
Q9BTW9 Tubulin-specific chaperone D TBCD 
3. Activated NTRK3 signals through PI3K 2/6 8.81E-04 0.144 
P35568 Insulin receptor substrate 1 IRS1 
P27986 Phosphatidylinositol 3-kinase regulatory subunit alpha PIK3R1 
4. RNA Polymerase III Transcription Initiation 
from Type 3 Promoter 3/28 0.0011 0.144 
Q16533 snRNA-activating protein complex subunit 1 SNAPC1 
Q5SXM2 snRNA-activating protein complex subunit 4 SNAPC4 
A6H8Y1 Transcription factor TFIIIB component B'' homolog BDP1 
5. HDR through Homologous Recombination 
(HRR) 4/66 0.0013 0.144 
Q99708 DNA endonuclease RBBP8 
Q07864 DNA polymerase epsilon catalytic subunit POLE 
P49959 Double strand break repair protein MRE11 
P12004 Proliferating cell nuclear antigen PCNA 
6. Erythrocytes take up oxygen and release 
carbon dioxide 2/8 0.0016 0.144 
P69905 Hemoglobin subunit alpha HBA1 
P68871 Hemoglobin subunit beta HBB 
7. PI3K/AKT activation 2/9 0.0020 0.144 
P35568 Insulin receptor substrate 1 IRS1 
P27986 Phosphatidylinositol 3-kinase regulatory subunit alpha PIK3R1 
8. RNA Polymerase III Transcription Initiation 3/36 0.0023 0.144 
Q16533 snRNA-activating protein complex subunit 1 SNAPC1 
Q5SXM2 snRNA-activating protein complex subunit 4 SNAPC4 
A6H8Y1 Transcription factor TFIIIB component B'' homolog BDP1 
9. HDR through MMEJ (alt-NHEJ) 2/10 0.0024 0.144 
Q99708 DNA endonuclease RBBP8 
P49959 Double strand break repair protein MRE11 
10. Signaling by MET 4/80 0.0027 0.144 
Q8N307 Mucin-20 MUC20 
P27986 Phosphatidylinositol 3-kinase regulatory subunit alpha PIK3R1 
Q6VN20 Ran-binding protein 10 RANBP10 
Q96B97 SH3 domain-containing kinase-binding protein 1 SH3KBP1 
      
      
      
      
      
      
      
      
      
      
      














11. Metabolism of proteins 25/2012 0.0028 0.144 
O95786 Antiviral innate immune response receptor RIG-I DDX58 
P07550 Beta-2 adrenergic receptor ADRB2 
P04637 Cellular tumour antigen P53 
Q8IWV2 Contactin-4 CNTN4 
Q13618 Cullin-3 CUL3 
Q13217 DnaJ homolog subfamily C member 3 DNAJC3 
Q9Y297 F-box/WD repeat-containing protein 1A BTRC 
P02671 Fibrinogen alpha chain FGA 
Q92696 Geranylgeranyl transferase type-2 subunit alpha RABGGATA 
Q6ZVT0 Inactive polyglycylase TTLL10 
P05019 Insulin-like growth factor I IGF1 
P15088 Mast cell carboxypeptidase A CPA3 
Q8N307 Mucin-20 MUC20 
P23511 Nuclear transcription factor Y subunit alpha NFYA 
Q9UBK2 Peroxisome proliferator-activated receptor gamma coactivator 1-alpha PPARGC1A 
Q14435 Polypeptide N-acetylgalactosaminyltransferase 3 GLNT3 
P12004 Proliferating cell nuclear antigen PCNA 
Q9Y6M0 Testisin PRSS21 
P10599 Thioredoxin THIO 
Q9P031 Thyroid transcription factor 1-associated protein 26 CCDC59 
Q5JRA6 Transport and Golgi organization protein 1 homolog MIA3 
Q13509 Tubulin beta-3 chain TUBB3 
Q9Y4R7 Tubulin monoglycylase TTLL3 
O75347 Tubulin-specific chaperone A TBCA 
Q9BTW9 Tubulin-specific chaperone D TBCD 
12. RNA Polymerase III Abortive and Retractive 
Initiation 3/41 0.0033 0.144 
Q16533 snRNA-activating protein complex subunit 1 SNAPC1 
Q5SXM2 snRNA-activating protein complex subunit 4 SNAPC4 
A6H8Y1 Transcription factor TFIIIB component B'' homolog BDP1 
13. RNA Polymerase III Transcription 3/41 0.0033 0.144 
Q16533 snRNA-activating protein complex subunit 1 SNAPC1 
Q5SXM2 snRNA-activating protein complex subunit 4 SNAPC4 
A6H8Y1 Transcription factor TFIIIB component B'' homolog BDP1 
14. Erythropoietin activates Phosphoinositide-3-
kinase (PI3K) 2/12 0.0034 0.144 
P27986 Phosphatidylinositol 3-kinase regulatory subunit alpha PIK3R1 
P48736 Thyroid transcription factor 1-associated protein 26 CCDC59 
15. MET activates RAS signaling 2/12 0.0034 0.144 
Q8N307 Mucin-20 MUC20 
Q6VN20 Ran-binding protein 10 RANBP10 
16. Erythrocytes take up carbon dioxide and 
release oxygen 2/12 0.0034 0.144 
P69905 Hemoglobin subunit alpha HBA1 
P68871 Hemoglobin subunit beta HBB 
17. O2/CO2 exchange in erythrocytes 2/12 0.0034 0.144 
P69905 Hemoglobin subunit alpha HBA1 
P68871 Hemoglobin subunit beta HBB 
18. Carboxyterminal post-translational 
modifications of tubulin 
3/43 0.0037 0.145 
Q6ZVT0 Inactive polyglycylase TTLL10 
Q13509 Tubulin beta-3 chain TUBB3 














19. DNA Double-Strand Break Repair 5/148 0.0043 0.146 
P04637 Cellular tumour antigen P53 
Q99708 DNA endonuclease RBBP8 
Q07864 DNA polymerase epsilon catalytic subunit POLE 
P49959 Double strand break repair protein MRE11 
P12004 Proliferating cell nuclear antigen PCNA 
20. TP53 regulates transcription of several 
additional cell death genes whose specific roles 
in P53-dependent apoptosis remain uncertain 
2/14 0.0046 0.146 
P04637 Cellular tumour antigen P53 
Q92696 Geranylgeranyl transferase type-2 subunit alpha RABGGATA 
21. SEMA3A-Plexin repulsion signaling by 
inhibiting Integrin adhesion 
2/14 0.0046 0.146 
O75051 Plexin-A2 PLXNA2 
Q14563 Semaphorin-3A SEMA3 
22. Transcriptional Regulation by TP53 8/367 0.0047 0.146 
P04637 Cellular tumour antigen P53 
P50750 Cyclin-dependent kinase 9 CDK9 
P14854 Cytochrome c oxidase subunit 6B1 COX6B1 
Q99708 DNA endonuclease RBBP8 
P49959 Double strand break repair protein MRE11 
Q92696 Geranylgeranyl transferase type-2 subunit alpha RABGGATA 
P12004 Proliferating cell nuclear antigen PCNA 
P10599 Thioredoxin THIO 
23. Toll-like Receptor Cascades 5/156 0.0053 0.146 
Q9Y297 F-box/WD repeat-containing protein 1A BTRC 
P02671 Fibrinogen alpha chain FGA 
Q9NWZ3 Interleukin-1 receptor-associated kinase 4 IRAK4 
Q13233 Mitogen-activated protein kinase kinase kinase 1 MAP3K1 
Q9BT09 Protein canopy homolog 3 CNPY3 
24. Signaling by EGFR 3/51 0.0060 0.146 
O43184 Disintegrin and metalloproteinase domain-containing protein 12 ADAM12 
P27986 Phosphatidylinositol 3-kinase regulatory subunit alpha PIK3R1 
Q96B97 SH3 domain-containing kinase-binding protein 1 SH3KBP1 
25. CRMPs in Sema3A signaling 2/16 0.0060 0.146 
O75051 Plexin-A2 PLXNA2 






I have successfully developed a method to selectively pull-down HPV16 E6 
variants and their interacting partners. Using the peptide method, seven novel candidates 
may interact with E6 variants. Three proteins that potentially bind to AAE6 exclusively: 
INO80B, PROK2, and RPS6KA4. These proteins may provide insight into new 
mechanisms which E6 variants can affect chromosome remodelling, angiogenesis and 
dysregulated metabolism. One protein (MX2) potentially binds exclusively to EPE6 
providing evidence that AAE6 may evade a component of the innate immune response. 
Finally, there were 3 proteins identified that may interact with both AA and EP. These 
proteins unravel new mechanisms for how E6 may degrade P53, and cause cell cycle 
progression. Using the Protein-Pathway method, AAE6 was found to interact with the 
NOTCH signalling pathway along with several cross-talking pathways (TP53 Regulates 
Metabolic Genes, Wnt signalling and Hypoxia signalling). This method also identified that  
AAE6 may interact with BER associated with MUTYH giving evidence that AAE6 can 
integrate earlier within the host genome compared to EPE6.  
With my initial approach, Co-IP coupled to MALDI MS/MS, I successfully 
immunoprecipitated E6. However, the MS failed to identify the E6 protein itself as well as 
the classical known E6 interactors E6AP and P53. I therefore set out to optimize our Co-
IP protocol and utilize an MS approach providing a user-friendly output amenable for 
bioinformatics using freely accessible software tools. The optimizations made to the 
original Co-IP protocol allowed for more effective isolation of 16 E6 variant interacting 
proteins. Many of the optimizations made resulted in a protocol similar to other groups 





White). Each step of the protocol was optimized to isolate the maximum amount of E6 and 
interacting proteins in a MS compatible elution buffer. The elution of proteins from the 
beads was the step that needed to deviate from most of the literature protocols on E6 IP 
experiments as synthetic peptides did not succeed at releasing any antigens from the beads. 
It was interesting that most groups that used peptide elution methods needed to concentrate 
their samples using TCA precipitation. Our samples failed to be precipitated at most 
concentrations of TCA (10 % (w/v) – 100 % (w/v)). TCA precipitation resulted in no 
visible precipitation of proteins in any samples. This was most likely because our total 
eluted protein was below 0.016 mg of protein, the minimum mass of protein needed to see 
obvious protein precipitation (Ngo et al. 2015). Therefore, we needed to use an acidic 
buffer to elute proteins. This proved effective as we successfully minimized antibody 
leeching from the magnetic beads and eluted E6 (for AAE6 only) with its targeted proteins. 
Without MG132 treatment it is highly unlikely that we would see any evidence of P53 in 
eluted samples (Personal communication with Dr. White). The use of proteasome inhibitors 
only assisted to target sufficient quantities of P53 that we could visualize the protein in 
western blotting applications. In MS applications however, we found that we were able to 
see P53 in both samples at least once with MG132 treatment and once for AAE6 in DMSO 
treatment. Therefore, even though P53 appeared in both MG132 and DMSO treatments the 
use of a proteasome inhibitor increased the likelihood of identifying P53 (and other 
potential E6 targets) in MS. The final IP method is quick to prepare and has little variability 
in efficacy from using many premade reagents (MPER, cOmplete, HALT etc.) This method 
works well for the cell types we used and to generate 4 mg of protein extract and effectively 





method may be an effective starting point, but optimizations should be made to suit each 
researcher’s needs.  A complete comparison of the Co-IP optimization could not be done 
due to switching from MALDI MS to LC MS/MS. This was done because since the 
samples were quite complex and contained a large variety of proteins, we needed to use 
more sensitive equipment (Abersold and Mann 2003). By switching to LC MS/MS analysis 
our samples could be present in lower concentrations. The result of switching to LC 
MS/MS sample analysis was successful detection of E6 in AAE6 and consistent 
identification of known E6 interacting proteins. Using LC MS/MS we were able to generate 
confident and accurate results.  
 The process of filtering proteins poses a substantial limitation in bioinformatics as 
there are many ways to analyze MS datasets. Most groups filter datasets by removing 
proteins involved in negative controls, along with setting a minimum number of peptides 
required to be a valid result. The use of the protein-pathway method provided a more 
inclusive method for identifying potential E6 interacting proteins. Interestingly, however, 
the protein-pathway method also demonstrated that it is possible to manipulate datasets in 
a variety of ways. For instance, the input name for identified proteins was crucial. While 
using UniProt Identifiers allowed for obtaining the results seen in this thesis we obtained 
drastically different results when inputting the dataset into Reactome versus KEGG. We 
settled for the latter since this tool seemed the more recent. It is therefore necessary to state 
what format studies import their datasets for bioinformatic analysis because this can create 
issues in the replicability of results in the future.  
This thesis aimed to develop a method to successfully pull-down and identify E6 





culminating in a method similar to previous pull-downs by other research groups. I 
successfully identified AAE6 using this pull-down method and was able to identify several 
potential interactors that may help unravel new mechanisms utilized by HPV16 E6 to 
promote tumourigenesis. Further wet lab work is necessary to identify and unravel the 
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6 Supplemental Data 
Figures 
 
Figure S1 – Pre-PCR purification of late-passage AAE6, EPE6 as well as PHFK-HA and 
no template by touchdown PCR. Two prominent bands at approximately 446 bp can be 
seen in only the AAE6 and EPE6 samples indicating a successful amplification of viral 
DNA for sequencing. Lanes on the far left and right sides are DNA ladders used to identify 
sample sizes.  
 
 
Figure S2 – Post-PCR purification of late-passage AAE6, EPE6 as well as PHFK-HA and 
no template. AAE6 and EPE6 bands remain and the bands present in pre-purification 
(Figure S1) samples are removed. Lanes on the far left and right sides are DNA ladders 






Figure S3 – Initial workflow for processing of mass spectrometry spectra files by HSMPF. All parts of the workflow were completed in Proteome 
Discoverer Version: 2.4.0.292. Workflow was done prior to analysis of data to ensure all files were in the correct format.  
 
Figure S4 – Final workflow for processing data in Proteome Discoverer Version 2.4.0.292 at HSMPF. Major components of each workflow 






Table S1 – Results from literature search for articles that performed Co-IP experiments targeting E6 or another HPV 
protein 




















Subbiah V. K., Massimi P., boon S. S., 
Myers M. M., Sharek L., Garcis-Mata R., 
Banks L. 2012. The Invasive Capacity of 
HPV Transformed Cells Requires the hDlg-
Dependent Enhancement of SGEF/RhoG 
Activity. PLoS Pathogens 8(2): e1002543.
HEPES Buffer (50 mM 
HEPES [pH 7.0], 500mM 
NaCl, 0.1% NP-40)
Yes (ND) Yes (ND) No 20 min on ice 7X10^5 HEK 293 ND N Y 3 @ 4C
3 washes with Lysis 
buffer
ND N N N Y (HPV18)
Bentley P., Tan M. J. M., McBride A. A., 
White E. A., Howley P. M. 2018. The 
SMC5/6 complex interacts with the 
papillomavirus E2 protein and influences 
maintenance of viral episomal DNA. 
Journal of Virology 92(15): e00356-18.
Tris-HCl (50mM Tris-HCl 
[pH 7.5], 150mM NaCl, 
0.5% NP-40, 1mM EDTA)
Yes (ND) No No ND
90% confluence in 4 
15cm dishes




Meyers J. M., Uberoi A., Grace M., 
Lambert P. F., Munger K. 2017. 
Cutaneous HPV8 and MmuPV1 E6 
proteins target the NOTCH and TGF-ß 
tumor suppressors to inhibit 
differentiation and sustain keratinocyte 
proliferation. PLoS Pathogens 13(1): 
e1006171. 
Tris-HCl (50mM Tris-HCl 
[pH 8.0], 120mM NaCl, 1% 
NP-40)
No No No ND ND U20S and HCT116 ND N Y ND ND ND N N N
Y (HPV -8, -
16)
J. Meyers PhD Dissertation 2017
Tris-HCl (50mM Tris-HCl 
[pH 8.0], 120mM NaCl, 1% 
NP-40)
No No No ND ND Unknown ND N Y ND ND ND N N Y Y
Grace M. and Munger K. 2017. 
Proteomic analysis of the gamma human 
papillomavirus type 197 E6 and E7 
associated cellular proteins. Virology 
500(2017): 71-81.
Tris-HCl (50mM Tris-HCl 
[pH 8], 150mM NaCl, 0.5% 
NP-40, 0.5mM EDTA)
Yes (Complete EDTA-free 
protease inhibitor per 50mL)
No No ND
4 X 15 cm dishes 
after 24h  growth 
with 8 million cells 
seeded 
HCT116 4 mL
Y (0.45µm spin 
filter)
Y 4-16h @ 4C
Several Ice Cold Lysis 
Buffer, then several 
washes in PBS (to get 
rid of detergent)
3 X 50mL of 
250µg/mL HA Peptide 
(Sigma: 12149) in PBS
Combined and 
precipitated in 20% TCA 
for 25 min on ice. 
Centrifuged at 20 000g 
for 25 min. Pellets 
washed once with 500µL 
10% TCA then 3 1 mL 







Jang M. K., Anderson D. E., van 
Doorslaer K., McBride A. A. 2015. A 
proteomic approach to discover and 
compare interacting partners of 
papillomavirus E2 proteins from diverse 
phylogenetic groups. Proteomics 15 (12):  
2038-2050.
HEPES Buffer (10mM [pH 
7.9], 10mM KCl, 1.5mM 
MgCl2, 0.2mM EDTA, 
0.5mM DTT)
Yes (cOmplete protease 
inhibitor cocktail, PMSF)
No No
30 min at 4C, 
20 stroke of 
Dounce 
Homogenizer
1X10^9 C33A ND N Y 16h @ 4C
Extensive washing 
Buffer (20mM HEPES 
[pH 7.9], 20% glycerol, 
150mM KCl, 0.2mM 
EDTA, 0.5mM DTT, 
0.1% NP-40, 1mM 
PMSF)








Martinez-Nöel G., Galligan J. T., Sowa 
M. E., Arndt V., Overton T. M., Harper J. 
W., Howley P. M. 2012. Identification 
and proteomic analysis of distinct 
UBE3A/E6AP protein complexes. 
Molecular and Cellular Biology 32(15): 
3095-3106.
Tris-HCl (50mM Tris-HCl 
[pH 7.5], 150mM NaCl, 
0.5% NP-40)
Yes (cOmplete protease 
inhibitor cocktail)





80%-90% confluent  
in 5 X 15 cm dishes 
T-Rex






Y 2h @ 4C
2 times with 10mL 
Lysis buffer. 2 times 
with 10mL PBS
3 X 50µL of 500µg/mL 





White E. A., Kramer R. E., Tan M. J. A., 
Hayes S. D., Harper J. W., Howley P. M. 
2012. Comprehensive analysis of host 
cellular interactions with human 
papillomavirus E6 proteins identifies 
new E6 Binding partners and reflects 
viral diversity. Journal of Virology 86(24): 
13174-13186. 
Tris-HCl (50mM Tris-HCl 
[pH 7.5], 150mM NaCl, 
0.5% NP-40, 1mM EDTA)
Yes (cOmplete protease 
inhibitor cocktail)
No No ND
90% confluent  in 4 




Y 16h @ 4C
5 times with lysis 
buffer. Exchange into 
PBS
eluted with SIGMA 
250µg/mL HA peptide 
at RT






White E. A., Sowa M. E., Tan M. J. A., 
Jeudy S., Hayes S. D., Santha S., Münger 
K., Harper J. W., Howley P. M. 2012 
Systematic identification of interactions 
between host cell proteins and E7 
oncoproteins from diverse human 
papillomaviruses. PNAS 109(5): E260-
E267.
Tris-HCl (50mM Tris-HCl 
[pH 7.5], 150mM NaCl, 
0.5% NP-40)
Yes (cOmplete protease 
inhibitor cocktail)





4 hours before 
harvesting
ND ND N/Tert-1 ND N Y ND 3 times PBS
eluted with HA 
peptide at RT
TCA precipitation, wash 
with acetone.
Y (ND) N Y 
Brimer N., Lyons Vande Pol S. B. 2007. 
Association of E6AP (UBE3A) with 
human papillomavirus type 11 E6 
protein. Virology 358(2007): 303-310.
0.5X Tris-HCl (50mM Tris-
HCl [pH 7.5], 150mM NaCl, 
1% NP-40)
0.01% PMSF, 1µg/mL 
leupeptin/aprotinin
Y (50mM NaF, 
5mM NAPPI?, 
1mM NaVO3 
No ND 5X10^8 CV1 CV1, HA CAT, NIKS ND N Y ND
Wash 3 times with 
Lysis Buffer
3 X 2µg FLAG peptide 
in 0.25X NP-40 Lysis 
Buffer
Band excision Y N N (E6-AP)
Jeong K. W., Kim H. Z., Kim S., Choe J. 
2007. Human papillomavirus type 16 E6 
protein interacts with cystic fibrosis 
transmembrane regulator-associated 
ligand and promotes E6-associated 
protein-mediated ubiquitination and 
proteasomal degradation. Oncogene 
26(2017): 487-499.
Tris-HCl (50mM Tris-HCl 
[pH 7.5], 120mM NaCl, 
0.5% NP-40)
1mM PMSF, and protease 
inhibitor
Y (50mM NaF, 
200µM Na3VO4
No ND ND 293T ND N Y 3h @ 4C Lysis Buffer 3 times SDS Sample Buffer N/A N N Y
Jing M., Bohl J., Brimer N., Kinter M., 
Vande Pol S. B. 2007. Degradation of 
tyepsine phosphatase PTPN3 (PTPH1) by 
association with oncogenic human 
papillomavirus E6 proteins. Journal of 
Virology 81(5): 2231-2239.
0.5X Tris-HCl (50mM Tris-
HCl [pH 7.5], 150mM NaCl, 
1% NP-40)
Y (0.01% PMSF, 5mM EDTA, 
1µg/mL leupeptin/aprotinin)
Y (50mM NaF, 
5mM NAPPI?, 
1mM NaVO3 
No ND 1X10^7 CV1 ND N Y 30 min @ 4C
Wash 3 times with 1X 
Lysis Buffer, 2 more 
washes with 0.25X NP-
40
3 X 2µg FLAG peptide 
in 0.25X NP-40 Lysis 
Buffer





Table S2 – Common identified proteins targeted by AAE6 and EPE6 using 
the Peptide Method. Number in columns for AAE6 and EPE6 trials 
correspond to the number of peptides identified.  
 
 
Table S3 – Common identified proteins targeted by AAE6 and EPE6 using 
the Protein-Pathway Method. Number in columns for AAE6 and EPE6 
trials correspond to the number of peptides identified during mass 
spectrometry. 
 
Acc# Description CRAPome AAE6 DMSO  T1 AAE6 MG132 T1 AAE6 MG132 T2 AAE6 DMSO T2 EPE6 DMSO T1 EPE6 MG132 T1 EPE6 MG132 T2 EPE6 DMSO T2
Q05086 Ubiquitin-protein ligase E3A OS=Homo sapiens GN=UBE3A PE=1 SV=4 1 / 411 5 4 2 4 5 4 2 2
Q9NUQ6 SPATS2-like protein OS=Homo sapiens GN=SPATS2L PE=1 SV=2 20 / 411 8 4 2 7 1
Q96GQ7 Probable ATP-dependent RNA helicase DDX27 OS=Homo sapiens GN=DDX27 PE=1 SV=2 41 / 411 9 6 7 1
Q9NVU7 Protein SDA1 homolog OS=Homo sapiens GN=SDAD1 PE=1 SV=3 23 / 411 1 1 4 3 1 5 2
Q14244 Ensconsin OS=Homo sapiens GN=MAP7 PE=1 SV=1 42 / 411 2 3 3 2 3 2
Q9H444 Charged multivesicular body protein 4b OS=Homo sapiens GN=CHMP4B PE=1 SV=1 28 / 411 1 1 3 2 5
Q5T3I0 G patch domain-containing protein 4 OS=Homo sapiens GN=GPATCH4 PE=1 SV=2 37 / 411 3 3 2 3
Q8TDD1 ATP-dependent RNA helicase DDX54 OS=Homo sapiens GN=DDX54 PE=1 SV=2 49 / 411 3 5
Q13823 Nucleolar GTP-binding protein 2 OS=Homo sapiens GN=GNL2 PE=1 SV=1 45 / 411 11 6 1 2 1
O95478 Ribosome biogenesis protein NSA2 homolog OS=Homo sapiens GN=NSA2 PE=1 SV=1 15 / 411 1 1 2 3 1
Q9UMY1 Nucleolar protein 7 OS=Homo sapiens GN=NOL7 PE=1 SV=2 11 / 411 1 1 1 1 1 1 1
P04637 Cellular tumor antigen p53 OS=Homo sapiens GN=TP53 PE=1 SV=4 52 / 411 1 1 4
Q14669 E3 ubiquitin-protein ligase TRIP12 OS=Homo sapiens GN=TRIP12 PE=1 SV=1 29 / 411 3 1 3
Accession Description AAE6 DMSO  T1 AAE6 MG132 T1 EPE6 DMSO T1 EPE6 MG132 T1 AAE6 MG132 T2 AAE6 DMSO T2 EPE6 MG132 T2 EPE6 DMSO T2
Q9BXL7 Caspase recruitment domain-containing protein 11 OS=Homo sapiens GN=CARD11 PE=1 SV=3 1 1
P04637 Cellular tumor antigen p53 OS=Homo sapiens GN=TP53 PE=1 SV=4 1 4 1
Q13352 Centromere protein R OS=Homo sapiens GN=ITGB3BP PE=1 SV=2 1 1 1
Q9H444 Charged multivesicular body protein 4b OS=Homo sapiens GN=CHMP4B PE=1 SV=1 1 1 3 2 5
P14854 Cytochrome c oxidase subunit 6B1 OS=Homo sapiens GN=COX6B1 PE=1 SV=2 1 1
Q9H2F5 Enhancer of polycomb homolog 1 OS=Homo sapiens GN=EPC1 PE=1 SV=1 1 1 1
P02671 Fibrinogen alpha chain OS=Homo sapiens GN=FGA PE=1 SV=2 1 1 1 1
P68871 Hemoglobin subunit beta OS=Homo sapiens GN=HBB PE=1 SV=2 1 1 1 1
Q6ZVT0 Inactive polyglycylase TTLL10 OS=Homo sapiens GN=TTLL10 PE=1 SV=2 1 1
Q9UG01 Intraflagellar transport protein 172 homolog OS=Homo sapiens GN=IFT172 PE=1 SV=2 1 1
P23511 Nuclear transcription factor Y subunit alpha OS=Homo sapiens GN=NFYA PE=1 SV=2 1 1 1
Q9BT09 Protein canopy homolog 3 OS=Homo sapiens GN=CNPY3 PE=1 SV=1 2 2 2 1
Q96GY3 Protein lin-37 homolog OS=Homo sapiens GN=LIN37 PE=1 SV=1 1 1 1
O14641 Segment polarity protein dishevelled homolog DVL-2 OS=Homo sapiens GN=DVL2 PE=1 SV=1 1 1
Q96B97 SH3 domain-containing kinase-binding protein 1 OS=Homo sapiens GN=SH3KBP1 PE=1 SV=2 1 1
Q9Y6M0 Testisin OS=Homo sapiens GN=PRSS21 PE=1 SV=1 1 1
P10599 Thioredoxin OS=Homo sapiens GN=TXN PE=1 SV=3 1 1 1 1
Q9P031 Thyroid transcription factor 1-associated protein 26 OS=Homo sapiens GN=CCDC59 PE=1 SV=2 1 1
A6H8Y1 Transcription factor TFIIIB component B'' homolog OS=Homo sapiens GN=BDP1 PE=1 SV=3 1 1 1
Q9Y4R7 Tubulin monoglycylase TTLL3 OS=Homo sapiens GN=TTLL3 PE=1 SV=2 1 1
